<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Deferasirox for managing iron overload in people with thalassaemia - Bollig, C - 2017 | Cochrane Library</title> <meta content="Deferasirox for managing iron overload in people with thalassaemia - Bollig, C - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007476.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Deferasirox for managing iron overload in people with thalassaemia - Bollig, C - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007476.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007476.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Deferasirox for managing iron overload in people with thalassaemia" name="citation_title"/> <meta content="Claudia Bollig" name="citation_author"/> <meta content="Medical Center – Univ. of Freiburg, Faculty of Medicine, Univ. of Freiburg" name="citation_author_institution"/> <meta content="Lisa K Schell" name="citation_author"/> <meta content="Gerta Rücker" name="citation_author"/> <meta content="Faculty of Medicine and Medical Center – University of Freiburg" name="citation_author_institution"/> <meta content="Roman Allert" name="citation_author"/> <meta content="University Hospital Frankfurt, Goethe University" name="citation_author_institution"/> <meta content="Edith Motschall" name="citation_author"/> <meta content="Medical Center ‐ University of Freiburg, Faculty of Medicine, University of Freiburg" name="citation_author_institution"/> <meta content="Charlotte M Niemeyer" name="citation_author"/> <meta content="University Medical Center Freiburg" name="citation_author_institution"/> <meta content="Dirk Bassler" name="citation_author"/> <meta content="University Hospital Zurich and University of Zurich" name="citation_author_institution"/> <meta content="Joerg J Meerpohl" name="citation_author"/> <meta content="Medical Center – Univ. of Freiburg, Faculty of Medicine, Univ. of Freiburg" name="citation_author_institution"/> <meta content="meerpohl@cochrane.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD007476.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/08/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007476.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007476.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007476.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Benzoates [administration &amp; dosage, adverse effects, *therapeutic use]; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Deferiprone; Deferoxamine [administration &amp; dosage, therapeutic use]; Erythrocyte Transfusion [adverse effects]; Ferritins [blood]; Iron Chelating Agents [administration &amp; dosage, adverse effects, *therapeutic use]; Iron Overload [blood, *drug therapy, etiology]; Patient Satisfaction; Pyridones [administration &amp; dosage, therapeutic use]; Randomized Controlled Trials as Topic; Thalassemia [*complications, mortality, therapy]; Triazoles [administration &amp; dosage, adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007476.pub3&amp;doi=10.1002/14651858.CD007476.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="KUoIaN9D";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007476\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007476\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007476\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007476\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007476.pub3",title:"Deferasirox for managing iron overload in people with thalassaemia",firstPublishedDate:"Aug 15, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007476.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007476.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007476.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007476.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007476.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007476.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007476.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007476.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007476.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007476.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3570 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007476.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-sec-0140"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-sec-0134"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/appendices#CD007476-sec-0145"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/table_n/CD007476StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/table_n/CD007476StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Deferasirox for managing iron overload in people with thalassaemia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/information#CD007476-cr-0002">Claudia Bollig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/information#CD007476-cr-0003">Lisa K Schell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/information#CD007476-cr-0004">Gerta Rücker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/information#CD007476-cr-0005">Roman Allert</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/information#CD007476-cr-0006">Edith Motschall</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/information#CD007476-cr-0007">Charlotte M Niemeyer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/information#CD007476-cr-0008">Dirk Bassler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007476.pub3/information#CD007476-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Joerg J Meerpohl</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/information/en#CD007476-sec-0151">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 August 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007476.pub3">https://doi.org/10.1002/14651858.CD007476.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007476-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007476-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007476-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007476-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007476-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007476-abs-0001" lang="en"> <section id="CD007476-sec-0001"> <h3 class="title" id="CD007476-sec-0001">Background</h3> <p>Thalassaemia is a hereditary anaemia due to ineffective erythropoiesis. In particular, people with thalassaemia major develop secondary iron overload resulting from regular red blood cell transfusions. Iron chelation therapy is needed to prevent long‐term complications. </p> <p>Both deferoxamine and deferiprone are effective; however, a review of the effectiveness and safety of the newer oral chelator deferasirox in people with thalassaemia is needed. </p> </section> <section id="CD007476-sec-0002"> <h3 class="title" id="CD007476-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of oral deferasirox in people with thalassaemia and iron overload. </p> </section> <section id="CD007476-sec-0003"> <h3 class="title" id="CD007476-sec-0003">Search methods</h3> <p>We searched the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register: 12 August 2016. </p> <p>We also searched MEDLINE, Embase, the Cochrane Library, Biosis Previews, Web of Science Core Collection and three trial registries: ClinicalTrials.gov; the WHO International Clinical Trials Registry Platform; and the Internet Portal of the German Clinical Trials Register: 06 and 07 August 2015. </p> </section> <section id="CD007476-sec-0004"> <h3 class="title" id="CD007476-sec-0004">Selection criteria</h3> <p>Randomised controlled studies comparing deferasirox with no therapy or placebo or with another iron‐chelating treatment. </p> </section> <section id="CD007476-sec-0005"> <h3 class="title" id="CD007476-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed risk of bias and extracted data. We contacted study authors for additional information. </p> </section> <section id="CD007476-sec-0006"> <h3 class="title" id="CD007476-sec-0006">Main results</h3> <p>Sixteen studies involving 1807 randomised participants (range 23 to 586 participants) were included. Twelve two‐arm studies compared deferasirox to placebo (two studies) or deferoxamine (seven studies) or deferiprone (one study) or the combination of deferasirox and deferoxamine to deferoxamine alone (one study). One study compared the combination of deferasirox and deferiprone to deferiprone in combination with deferoxamine. Three three‐arm studies compared deferasirox to deferoxamine and deferiprone (two studies) or the combination of deferasirox and deferiprone to deferiprone and deferasirox monotherapy respectively (one study). One four‐arm study compared two different doses of deferasirox to matching placebo groups. </p> <p>The two studies (a pharmacokinetic and a dose‐escalation study) comparing deferasirox to placebo (n = 47) in people with transfusion‐dependent thalassaemia showed that deferasirox leads to net iron excretion. In these studies, safety was acceptable and further investigation in phase II and phase III studies was warranted. </p> <p>Nine studies (1251 participants) provided data for deferasirox versus standard treatment with deferoxamine. Data suggest that a similar efficacy can be achieved depending on the ratio of doses of deferoxamine and deferasirox being compared. In the phase III study, similar or superior efficacy for the intermediate markers ferritin and liver iron concentration (LIC) could only be achieved in the highly iron‐overloaded subgroup at a mean ratio of 1 mg of deferasirox to 1.8 mg of deferoxamine corresponding to a mean dose of 28.2 mg per day and 51.6 mg per day respectively. The pooled effects across the different dosing ratios are: serum ferritin, mean difference (MD) 454.42 ng/mL (95% confidence interval (CI) 337.13 to 571.71) (moderate quality evidence); LIC evaluated by biopsy or SQUID, MD 2.37 mg Fe/g dry weight (95% CI 1.68 to 3.07) (moderate quality evidence) and responder analysis, LIC 1 to &lt; 7 mg Fe/g dry weight, risk ratio (RR) 0.80 (95% CI 0.69 to 0.92) (moderate quality evidence). The substantial heterogeneity observed could be explained by the different dosing ratios. Data on mortality (low quality evidence) and on safety at the presumably required doses for effective chelation therapy are limited. Patient satisfaction was better with deferasirox among those who had previously received deferoxamine treatment, RR 2.20 (95% CI 1.89 to 2.57) (moderate quality evidence). The rate of discontinuations was similar for both drugs (low quality evidence). </p> <p>For the remaining comparisons in people with transfusion‐dependent thalassaemia, the quality of the evidence for outcomes assessed was low to very low, mainly due to the very small number of participants included. Four studies (205 participants) compared deferasirox to deferiprone; one of which (41 participants) revealed a higher number of participants experiencing arthralgia in the deferiprone group, but due to the large number of different types of adverse events reported and compared this result is uncertain. One study (96 participants) compared deferasirox combined with deferiprone to deferiprone with deferoxamine. Participants treated with the combination of the oral iron chelators had a higher adherence compared to those treated with deferiprone and deferoxamine, but no participants discontinued the study. In the comparisons of deferasirox versus combined deferasirox and deferiprone and that of deferiprone versus combined deferasirox and deferiprone (one study, 40 participants), and deferasirox and deferoxamine versus deferoxamine alone (one study, 94 participants), only a few patient‐relevant outcomes were reported and no significant differences were observed. </p> <p>One study (166 participants) included people with non‐transfusion dependent thalassaemia and compared two different doses of deferasirox to placebo. Deferasirox treatment reduced serum ferritin, MD ‐306.74 ng/mL (95% CI ‐398.23 to ‐215.24) (moderate quality evidence) and LIC, MD ‐3.27 mg Fe/g dry weight (95% CI ‐4.44 to ‐2.09) (moderate quality evidence), while the number of participants experiencing adverse events and rate of discontinuations (low quality evidence) was similar in both groups. No participant died, but data on mortality were limited due to a follow‐up period of only one year (moderate quality evidence). </p> </section> <section id="CD007476-sec-0007"> <h3 class="title" id="CD007476-sec-0007">Authors' conclusions</h3> <p>Deferasirox offers an important treatment option for people with thalassaemia and secondary iron overload. Based on the available data, deferasirox does not seem to be superior to deferoxamine at the usually recommended ratio of 1 mg of deferasirox to 2 mg of deferoxamine. However, similar efficacy seems to be achievable depending on the dose and ratio of deferasirox compared to deferoxamine. Whether this will result in similar efficacy and will translate to similar benefits in the long term, as has been shown for deferoxamine, needs to be confirmed. Data from randomised controlled trials on rare toxicities and long‐term safety are still limited. However, after a detailed discussion of the potential benefits and risks, deferasirox could be offered as the first‐line option to individuals who show a strong preference for deferasirox, and may be a reasonable treatment option for people showing an intolerance or poor adherence to deferoxamine. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007476-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007476-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007476-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007476-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007476-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007476-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007476-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007476-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007476-abs-0002" lang="en"> <h3>Deferasirox for managing iron overload in people with thalassaemia</h3> <p><b>Background</b> </p> <p>Thalassaemia is a hereditary anaemia due to a defect in the production of haemoglobin. Regular red blood cell transfusions are needed, particularly for the severe form of the disease, thalassaemia major. This results in iron overload. Since the human body has no means of actively getting rid of excessive iron, drug treatment (iron‐chelating drugs) is needed. Several years ago, a newer oral iron chelator, deferasirox, was introduced. </p> <p><b>Review question</b> </p> <p>Does deferasirox offer advantages compared to placebo or to the other iron chelators deferoxamine or deferiprone in people with thalassaemia with regard to effectiveness and safety? </p> <p><b>Study characteristics</b> </p> <p>The evidence is current to 12 August 2016. This updated review includes 16 randomised controlled studies (1807 participants) containing 20 comparisons of deferasirox versus another treatment. </p> <p>In people with transfusion‐dependent thalassaemia, two studies compared deferasirox with placebo and nine studies (1251 participants) compared deferasirox with standard treatment of deferoxamine. Four studies (205 participants) compared deferasirox to deferiprone. One study each compared deferasirox and deferiprone respectively to deferasirox and deferiprone combination therapy (40 participants), deferasirox and deferoxamine combination therapy to deferoxamine alone (94 participants) and deferasirox and deferiprone combination therapy to deferiprone and deferoxamine combination therapy (96 participants). </p> <p>In people with non‐transfusion dependent thalassemia (individuals not requiring regular blood transfusions), one study (166 participants) compared deferasirox to placebo. The duration of the included studies ranged from 12 days to two years. </p> <p><b>Key results</b> </p> <p>Two studies comparing deferasirox with placebo in people with transfusion‐dependent thalassaemia showed that deferasirox was effective at removing iron. Nine other studies compared deferasirox with standard treatment of deferoxamine. Similar effectiveness seems possible, depending of the doses of the two drugs compared. It needs to be confirmed whether this leads to similar improvements in patient‐important outcomes in the long run. The safety of deferasirox was acceptable; however, rarer adverse events or long‐term side effects could not be adequately investigated due to the limited number of participants and the relatively short duration of the studies. Patient satisfaction was significantly better with deferasirox among those who had previously been treated with deferoxamine. The rate of discontinuations was similar for both drugs. Deferasirox may be an alternative for those individuals who do not tolerate, or have poor adherence with, deferoxamine. In people with a strong preference to deferasirox, potential benefits and risks should be discussed. </p> <p>One study (41 participants) reported that more individuals with transfusion‐dependent thalassaemia experienced joint pain when treated with deferiprone than with deferasirox, but due to the large number of different types of adverse events reported and compared, this result may be due to chance. One study revealed that adherence to treatment was higher when both oral iron chelators, deferasirox and deferiprone are used than the combination of deferiprone and deferoxamine, but no participant discontinued the study. We found no evidence for any differences comparing deferasirox or deferiprone alone to combined deferasirox and deferiprone treatment or deferasirox and deferoxamine combination to deferoxamine alone, but the numbers of people in the studies were small and available data were very limited. </p> <p>One study in people with non‐transfusion‐dependent thalassaemia found deferasirox was better at reducing serum ferritin and liver iron concentration compared to placebo. However, there is no evidence on the impact on patient‐important outcomes or long‐term safety data in this population. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of included studies comparing deferasirox to deferoxamine in people with transfusion‐dependent thalassaemia was moderate to low, mainly due fact that the investigators and participants knew which interventions had been assigned to which participants, the small number of participants included in the studies and the use of a surrogate markers (measures used in place of a hard clinical end point) instead of patient‐important outcomes. For the comparison of deferasirox to placebo in people with non‐transfusion‐dependent thalassaemia, the quality of the evidence was moderate to very low based on only one small study. For the other comparisons, the quality of the evidence was low to very low, mainly due to the inclusion of even fewer participants. Ideally, further randomised studies looking at patient‐important, long‐term outcomes and rarer adverse events, should be conducted. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007476-sec-0140" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007476-sec-0140"></div> <h3 class="title" id="CD007476-sec-0141">Implications for practice</h3> <section id="CD007476-sec-0141"> <p>Deferasirox offers an important treatment option for people with thalassaemia and secondary iron overload. Based on the available data, deferasirox does not seem to be superior to deferoxamine at the usually recommended ratio of 1 mg of deferasirox to 2 mg of deferoxamine. However, similar efficacy seems to be achievable depending on the dose and ratio of deferasirox compared to deferoxamine. Whether this will result in similar efficacy and will translate to similar benefits in the long term, as has been shown for deferoxamine, needs to be confirmed. Data from randomised controlled trials on rare toxicities and long‐term safety are still limited. However, after a detailed discussion of the potential benefits and risks, deferasirox could be offered as the first‐line option to individuals who show a strong preference for deferasirox, and may be a reasonable treatment option for people showing an intolerance or poor adherence to deferoxamine. </p> </section> <h3 class="title" id="CD007476-sec-0142">Implications for research</h3> <section id="CD007476-sec-0142"> <p>Although the efficacy of deferasirox to reduce iron overload has been shown, data for a comprehensive comparison with the standard treatment of deferoxamine are still insufficient. Therefore, patients should ideally be included in further, investigator‐initiated clinical trials independent from the producer Novartis assessing patient‐relevant outcomes and long‐term effects of deferasirox. However, given its broad availability, it is unlikely that these studies will ever be conducted. In addition, assessment of rarer AEs, as well as assessment of long‐term adherence, in particular with the new formulation, are important to pursue. Finally, it should be ensured that relevant outcomes are measured in a consistent way across studies to allow combination of data in a meta‐analysis. </p> <p>Since this review only included evidence from randomised studies and additional evidence is available from non‐randomised, uncontrolled studies, a systematic review also considering this observational evidence would most likely shed some additional light on this topic. Taking into account that there is a third chelator, deferiprone, available and approved in some countries for treatment of iron overload in people with thalassaemia, a network analysis comparing these three interventions would seem useful in the future, if more data are available. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007476-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007476-sec-0022"></div> <div class="table" id="CD007476-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Deferasirox compared to deferoxamine in people with transfusion‐dependent thalassemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Deferasirox compared to deferoxamine in people with transfusion‐dependent thalassemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : people with transfusion‐dependent thalassemia<br/> <b>Setting</b> : outpatient care<br/> <b>Intervention</b> : deferasirox<br/> <b>Comparison</b>: deferoxamine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferoxamine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality at any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.48<br/> (0.09 to 2.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1170<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1.000<br/> (1 to 18) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Responder analysis II (responder: LIC 1 to less than 7 mg Fe/g dw)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/> (0.69 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>553<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>664 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>531 per 1.000<br/> (458 to 611) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum ferritin (ng/mL): mean change from baseline and at end of study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 454.42 higher<br/> (337.13 higher to 571.71 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1002<br/> (6 RCTs) <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LIC (mg Fe/g dw) evaluated by biopsy or SQUID: mean change from baseline</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.37 higher<br/> (1.68 higher to 3.07 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>541<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Satisfaction with treatment (very satisfied or satisfied): participants previously treated with DFO<br/> assessed with: questionnaire<br/> follow up: mean 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.20<br/> (1.89 to 2.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>571<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.330 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1.000<br/> (1.000 to 1.000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adherence: discontinuations</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.95<br/> (0.60 to 1.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1211<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1.000<br/> (33 to 82) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AE: investigations ‐ isolated serum creatinine increase above ULN</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.57<br/> (1.88 to 3.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>657<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>137 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>353 per 1.000<br/> (258 to 482) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE</b> : adverse events; <b>CI</b> : confidence interval; <b>DFO</b> :deferiprone; <b>dw</b> : dry weight; <b>FE</b> : iron <b>LIC</b> : liver iron concentration; <b>MD</b> : mean difference; <b>RR</b> : risk ratio; <b>SQUID</b> : superconducting quantum interference device; <b>ULN</b>: upper limit of normal. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Serious risk of bias: studies that carry large weight for the overall effect estimate rated as high risk of bias due to lack of blinding and selective reporting.<br/> <sup>2</sup> Serious imprecision: wide confidence interval including both clinically relevant benefit as well as harm.<br/> <sup>3</sup> Serious inconsistency: differing ratio of drugs between subgroups of one study.<br/> <sup>4</sup> Upgrade due to dose‐response gradient: observed for both drugs. Effects therefore depending on ratio of drugs used in comparisons.<br/> <sup>5</sup> A sensitivity analysis without the results from four studies which were calculated according to <a href="./references#CD007476-bbs2-0131" title="WanX , WangW , LiuJ , TongT . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology2014;19(14):135. ">Wan 2014</a> showed similar results.<br/> <sup>6</sup> Serious imprecision: Wide confidence interval, including less discontinuations with deferoxamine treatment.<br/> <sup>7</sup> Serious indirectness: Surrogate of creatinine used for patient‐important outcome of kidney failure. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007476-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Deferasirox compared to deferiprone in people with transfusion‐dependent thalassemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Deferasirox compared to deferiprone in people with transfusion‐dependent thalassemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> :people with transfusion‐dependent thalassemia<br/> <b>Setting</b> : outpatient care<br/> <b>Intervention</b> : deferasirox<br/> <b>Comparison</b>: deferiprone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferiprone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality at any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>146<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Responder analysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum ferritin (ng/mL): mean change from baseline and at end of study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 229.99 ng/mL higher<br/> (403.14 lower to 863.11 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LIC (mg/g) evaluated by MRI R2*: mean change from baseline</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.8 mg/g lower<br/> (2.75 lower to 1.15 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Satisfaction</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adherence: discontinuations</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.16<br/> (0.01 to 2.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>179<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1.000<br/> (0 to 95) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>38<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>LIC</b> : liver iron concentration; <b>MD</b> : mean difference; <b>MRI</b> : magnetic resonance imaging; <b>NA</b> : not applicable <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Very serious imprecision: only very few number of included participants.<br/> <sup>2</sup> Serious risk of bias: selective reporting: Results from <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a> for 60 participants not reported.<br/> <sup>3</sup> Serious risk of bias: no blinding assumed, selective reporting: Results from <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a> for 60 participants not reported.<br/> <sup>4</sup> Very serious imprecision: very wide confidence interval including both relevant benefit as well as harm.<br/> <sup>5</sup> Serious imprecision: wide CIs including both benefit as well as harm.<br/> <sup>6</sup> Serious risk of bias: no blinding assumed. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007476-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Deferasirox alone compared to combined deferasirox and deferiprone in people with transfusion‐dependent thalassemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Deferasirox alone compared to combined deferasirox and deferiprone in people with transfusion‐dependent thalassaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : people with transfusion‐dependent thalassaemia<br/> <b>Setting</b> : outpatient care<br/> <b>Intervention</b> : deferasirox<br/> <b>Comparison</b>: deferasirox and deferiprone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox and deferiprone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality at any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Responder analysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum ferritin (ng/mL)</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LIC (mg Fe/g dry weight)</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Satisfaction with treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adherence</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: serum creatinine increase</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE</b> : adverse events; <b>CI</b> : confidence interval; <b>LIC</b> : liver iron concentration; <b>MD</b> : mean difference; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> One RCT (40 participants) contributed to this comparison, but no relevant outcome data to this table are available (<a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007476-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Combined deferasirox and deferiprone compared to deferiprone alone in people with transfusion‐dependent thalassemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Combined deferasirox and deferiprone com</b> p<b>ared to deferiprone alone in people with transfusion‐dependent thalassaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : people with transfusion‐dependent thalassemia<br/> <b>Setting</b> : outpatient care<br/> <b>Intervention</b> : deferasirox and deferiprone<br/> <b>Comparison</b>: deferiprone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox and deferiprone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality at any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Responder analysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum ferritin (ng/mL)</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LIC (mg Fe/g dry weight)</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Satisfaction with treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adherence</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: Serum creatinine increase</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE</b> : adverse events; <b>CI</b> : confidence interval; <b>LIC</b> : liver iron concentration; <b>MD</b> : mean difference; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> One RCT (40 participants) contributed to this comparison, but no relevant outcome data to this table are available (<a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007476-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Deferasirox and deferoxamine compared to deferoxamine in people with transfusion‐dependent thalassemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Deferasirox and deferoxamine compared to deferoxamine in people with transfusion‐dependent thalassemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : people with transfusion‐dependent thalassemia<br/> <b>Setting</b> :outpatient care<br/> <b>Intervention</b> : deferasirox and deferoxamine<br/> <b>Comparison</b>: deferoxamine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferoxamine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox and deferoxamine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality at any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>94<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Responder analysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum ferritin (ng/mL) ‐ mean at end of study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 87.84 ng/mL higher<br/> (612.23 lower to 787.91 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LIC</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Satisfaction with treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adherence: Discontinuations</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>94<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: serum creatinine increased</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum creatinine was measured in Molavi 2014, but no results were reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE</b> : adverse events; <b>CI</b> : confidence interval; <b>LIC</b> : liver iron concentration; <b>MD</b> : mean difference; <b>NA</b> : not applicable; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Very serious imprecision: only very few participants included.<br/> <sup>2</sup> Serious risk of bias: assumed lack of blinding.<br/> <sup>3</sup> Very serious imprecision: very wide confidence interval including both benefit as well as harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007476-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Deferasirox and deferiprone compared to deferiprone and deferoxamine in people with transfusion‐dependent thalassemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Deferasirox and deferiprone compared to deferiprone and deferoxamine in people with transfusion‐dependent thalassemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : people with transfusion‐dependent thalassemia<br/> <b>Setting</b> : outpatient care<br/> <b>Intervention</b> : deferasirox and deferiprone<br/> <b>Comparison</b>: deferiprone and deferoxamine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferiprone and deferoxamine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox and deferiprone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality at any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"All the included patients continued till the end of study with no patients were lost follow‐up." (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Responder analysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum ferritin (ng/mL): mean change from baseline</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 315.9 ng/mL lower<br/> (1046.26 lower to 414.46 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LIC evaluated by MRI R2*: mean change from baseline</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.62 mg/g lower<br/> (2.25 lower to 1.01 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Satisfaction</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Compared to baseline, patient‐reported satisfaction associated with ICT was significantly higher in group B [DFX and DFP] compared to group A [DFP and DFO] (p&lt;0.01)" (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adherence: Discontinuations</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Drug‐related AE: serum creatinine increased (≥ 33%) above baseline in 2 consecutive occasions </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.00<br/> (0.32 to 27.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1.000<br/> (7 to 580) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE</b> : adverse events; <b>CI</b> : confidence interval; <b>LIC</b> : liver iron concentration; <b>MD</b> : mean difference; <b>MRI</b> : magnetic resonance imaging; <b>NA</b> : not applicable; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Very serious imprecision: very few participants included.<br/> <sup>2</sup> Serious risk of bias: no blinding, selective reporting: no data for 18 months follow‐up.<br/> <sup>3</sup> Very serious imprecision: very wide confidence interval including both benefit as well as harm.<br/> <sup>4</sup> Serious imprecision: wide confidence interval including both benefit as well as harm.<br/> <sup>5</sup> Serious indirectness: surrogate of creatinine used for patient‐important outcome of kidney failure. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007476-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Deferasirox compared to placebo in people with non‐transfusion‐dependent thalassemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Deferasirox compared to placebo in people with non‐transfusion‐dependent thalassemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : people with non‐transfusion‐dependent thalassemia<br/> <b>Setting</b> : outpatient care<br/> <b>Intervention</b> : deferasirox<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality at any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>148<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"No deaths occurred during the study in any group" (<a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Responder analysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum ferritin (ng/mL): mean change from baseline</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 306.74 ng/mL lower<br/> (398.23 lower to 215.24 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LIC (mg Fe/g dry weight) evaluated by MRI R2: least squares mean change from baseline</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.27 mg Fe/g dry weight lower<br/> (4.44 lower to 2.09 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Satisfaction with treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adherence: Discontinuations</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.32<br/> (0.50 to 3.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>166<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1.000<br/> (45 to 314) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AE: abnormal serum creatinine (post‐baseline)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.59<br/> (0.19 to 68.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>166<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE</b> : adverse events; <b>CI</b> : confidence interval; <b>LIC</b> : liver iron concentration; <b>MD</b> : mean difference; <b>NA</b> : not applicable; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Serious imprecision: only few patients included.<br/> <sup>2</sup> Very serious imprecision: very wide confidence interval, including both benefit as well as harm.<br/> <sup>3</sup> Serious indirectness: surrogate of creatinine used for patient‐important outcome of kidney failure. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007476-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007476-sec-0023"></div> <section id="CD007476-sec-0024"> <h3 class="title" id="CD007476-sec-0024">Description of the condition</h3> <p>Thalassaemia, first described by Cooley and Lee in 1925 (<a href="./references#CD007476-bbs2-0067" title="CooleyTB , LeeP . A series of cases of splenomegaly in children with anemia and peculiar bone changes. Transactions of the American Pediatric Society1925;37:29‐30. ">Cooley 1925</a>), is a hereditary anaemia resulting from a defect in haemoglobin production (<a href="./references#CD007476-bbs2-0134" title="WeatherallDJ , CleggJB . The Thalassemia Syndromes. 4th Edition. Oxford: Blackwell Sciences Ltd., 2000. ">Weatherall 2000</a>). The disruption in the synthesis of either the α‐ or β‐chains of haemoglobin, classified in α‐ and β‐thalassaemia, leads to an ineffective erythropoiesis (i.e. the process by which red blood cells are produced) (<a href="./references#CD007476-bbs2-0123" title="RundD , RachmilewitzE . Beta‐thalassemia. New England Journal of Medicine2005;353(11):1135‐46. ">Rund 2005</a>). The worldwide birth rate for symptomatic thalassaemia is about 0.44 per 1000 births (<a href="./references#CD007476-bbs2-0053" title="AngastiniotisM , ModellB . Global epidemiology of hemoglobin disorders. Annals of the New York Academy of Sciences1998;850:251‐69. ">Angastiniotis 1998</a>) summing up to more than 40,000 newborns per year (<a href="./references#CD007476-bbs2-0108" title="ModellB , DarlisonM . Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization2008;86(6):480‐7. ">Modell 2008</a>). An estimated number of one to two million people with thalassaemia major, the severe form of the condition, need regular blood transfusions worldwide (<a href="./references#CD007476-bbs2-0108" title="ModellB , DarlisonM . Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization2008;86(6):480‐7. ">Modell 2008</a>; <a href="./references#CD007476-bbs2-0134" title="WeatherallDJ , CleggJB . The Thalassemia Syndromes. 4th Edition. Oxford: Blackwell Sciences Ltd., 2000. ">Weatherall 2000</a>) of which only approximately 100,000 are treated as required (<a href="./references#CD007476-bbs2-0108" title="ModellB , DarlisonM . Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization2008;86(6):480‐7. ">Modell 2008</a>). The high frequency of thalassaemia genes can be explained by a protective effect of thalassaemia trait against malaria (<a href="./references#CD007476-bbs2-0122" title="RicherJ , ChudleyAE . The hemoglobinopathies and malaria. Clinical Genetics2005;68(4):332‐6. ">Richer 2005</a>; <a href="./references#CD007476-bbs2-0133" title="WeatherallDJ . Thalassemia in the next millennium. Keynote address. Annals of the New York Academy of Sciences1998; Vol. 850:1‐9. ">Weatherall 1998</a>). </p> <p>Due to various mutations in the different genes for the α‐ and β‐chain genes and other modifying factors, there is a broad spectrum of clinical symptoms ranging from intrauterine death through to severe anaemia with the need for regular red blood cell transfusions and to asymptomatic anaemia (<a href="./references#CD007476-bbs2-0114" title="OlivieriNF . The beta‐thalassemias. New England Journal of Medicine1999;341(2):99‐109. ">Olivieri 1999</a>). Diagnosis is usually confirmed by either using electrophoretic techniques or molecular analysis. According to the clinical severity, the β‐thalassaemia syndromes can be classified into thalassaemia major, thalassaemia intermedia and thalassaemia minor. </p> <p>Whereas carriers with thalassaemia minor are often asymptomatic, those with thalassaemia intermedia may need occasional red blood cell transfusions (<a href="./references#CD007476-bbs2-0118" title="PetersM , HeijboerH , SmiersF , GiordanoPC . Diagnosis and management of thalassaemia. BMJ2012;25(344):e228. ">Peters 2013</a>). To achieve sufficiently high haemoglobin levels for adequate growth and development, children with thalassaemia major usually are transfusion‐dependent, starting within their first year of life. Several studies have shown that a haemoglobin level above 9 to 10 g/dL is required to successfully suppress ineffective erythropoiesis and to prevent hepatosplenomegaly, as well as bone deformities due to extra‐medullary hematopoiesis (<a href="./references#CD007476-bbs2-0114" title="OlivieriNF . The beta‐thalassemias. New England Journal of Medicine1999;341(2):99‐109. ">Olivieri 1999</a>; <a href="./references#CD007476-bbs2-0123" title="RundD , RachmilewitzE . Beta‐thalassemia. New England Journal of Medicine2005;353(11):1135‐46. ">Rund 2005</a>; <a href="./references#CD007476-bbs2-0134" title="WeatherallDJ , CleggJB . The Thalassemia Syndromes. 4th Edition. Oxford: Blackwell Sciences Ltd., 2000. ">Weatherall 2000</a>). </p> <p>Iron overload in people with thalassaemia is mainly the result of the additional iron load of up to 10 g per year by regular blood transfusions (<a href="./references#CD007476-bbs2-0099" title="KushnerJP , PorterJP , OlivieriNF . Secondary iron overload. Hematology / the Education Program of the American Society of Hematology2001;1:47‐61. [DOI: 10.1182/asheducation‐2001.1.47] ">Kushner 2001</a>). Particularly in people with thalassaemia intermedia, iron overload is also due to increased intestinal iron absorption (<a href="./references#CD007476-bbs2-0125" title="TaherA , Isma'eelH , CappelliniMD . Thalassemia intermedia: revisited. Blood Cells, Molecules &amp; Diseases2006;37(1):12‐20. ">Taher 2006</a>). Since the human body has no means of effectively excreting excess iron apart from gastrointestinal mucosal shedding, loss via sweat or through any bleeding (e.g. menstrual loss), iron chelation therapy is essential for these people. Without iron chelation therapy, iron‐mediated free radical damage causes liver fibrosis, endocrine failure and myocardial damage (<a href="./references#CD007476-bbs2-0056" title="Borgna‐PignattiC , CappelliniMD , DeStefanoP , DelVecchioGC , ForniGL , GamberiniMR , et al. Survival and complications in thalassemia. Annals of the New York Academy of Sciences2005;1054:40‐7. ">Borgna‐Pignatti 2005</a>). </p> </section> <section id="CD007476-sec-0025"> <h3 class="title" id="CD007476-sec-0025">Description of the intervention</h3> <p>Deferasirox (4‐(3,5‐bis‐(2‐hydroxyphenyl)‐(1,2,4)‐triazole‐1‐yl)benzoic acid) also known as CGP 72670, ICL670, Exjade<sup>®</sup>, Osveral<sup>®</sup>, Desirox<sup>®</sup>, Defrijet<sup>®</sup>, Asunra<sup>®</sup>, Desifer<sup>®</sup> or Jadenu™ is an oral chelator available for routine use. It is approved for the treatment of secondary iron overload by the US Food and Drug Administration (FDA) (<a href="./references#CD007476-bbs2-0077" title="Food , Drug Administration(FDA) . USA . Exjade. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021882s010lbl.pdf (accessed 02 September 2011). ">FDA 2005</a>) and the European Medicines Agency (EMA) (<a href="./references#CD007476-bbs2-0075" title="European Medicines Agency, London , UK . Exjade: European Public Assessment Report: Summary of Product Characteristics. www.emea.europa.eu/humandocs/Humans/EPAR/exjade/exjade.htm (accessed 14 February 2008). ">EMEA 2007</a>). </p> <p>Adverse effects (AEs) known from experiences in people with thalassaemia include gastrointestinal disturbances (nausea, stomach pain or diarrhoea) that have generally been mild and a diffuse rash being more common at higher doses (<a href="./references#CD007476-bbs2-0059" title="CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. ">Cappellini 2006</a>). More rarely, fever, headache and cough have been encountered. The main AE with the use of deferasirox seems to be a mild to moderate elevation of the creatinine level in approximately a third of individuals. Elevations of liver enzyme levels have also been described with a lower incidence (5.6%) (<a href="./references#CD007476-bbs2-0059" title="CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. ">Cappellini 2006</a>). As with standard therapy (deferoxamine), hearing loss and ocular disturbances including cataracts and retinal disorders have been reported with a very low incidence (less than 1%). </p> <p>With wider use outside of clinical studies, other more severe AEs have been reported, such as cytopenias, Fanconi syndrome and renal failure (<a href="./references#CD007476-bbs2-0087" title="GrangeS , BertrandDM , GuerrotD , EasF , GodinM . Acute renal failure and Fanconi syndrome due to deferasirox. Nephrology, dialysis, transplantation2010;25(7):2376‐8. [PUBMED: 20466673] ">Grange 2010</a>; <a href="./references#CD007476-bbs2-0120" title="RafatC , FakhouriF , RibeilJA , DelarueR , LeQuintrecM . Fanconi syndrome due to deferasirox. American Journal of Kidney Diseases2009;54(5):931‐4. [PUBMED: 19493602] ">Rafat 2009</a>; <a href="./references#CD007476-bbs2-0138" title="YewCT , TalaulikarGS , FalkMC , ClaytonP , D'RozarioJ , BrownM . Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short‐term dialysis. Nephrology (Carlton, Vic.)2010;15(3):377. [PUBMED: 20470310] ">Yew 2010</a>), liver failure and gastrointestinal bleeding, which resulted in a boxed warning by the FDA (<a href="./references#CD007476-bbs2-0079" title="USFood , DrugAdministraton . Exjade (Deferasirox): Boxed Warning. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm200850.htm (accessed 02 September 2011). ">FDA Boxed Warning 2010</a>). </p> <p>Deferoxamine (DFO, Desferal<sup>®</sup>), a further iron chelator, which was reviewed in detail in a Cochrane Review (<a href="./references#CD007476-bbs2-0080" title="FisherSA , BrunskillS , DoreeC , GoodingS , ChowdhuryO , RobertsDJ . Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion‐dependent thalassaemia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD004450.pub2] ">Fisher 2013a</a>), has been the treatment of choice for iron overload for the last 40 years. Due to its long availability it is the only chelating agent for which a profound effect on the long‐term survival of a large cohort of people with thalassaemia has been shown (<a href="./references#CD007476-bbs2-0055" title="Borgna‐PignattiC , RugolottoS , DeStefanoP , ZhaoH , CappelliniMD , DelVecchioGC , et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica2004;89(10):1187‐93. ">Borgna‐Pignatti 2004</a>; <a href="./references#CD007476-bbs2-0057" title="BrittenhamGM , GriffithPM , NienhuisAW , McLarenCE , YoungNS , TuckerEE , et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. New England Journal of Medicine1994;331(9):567‐73. ">Brittenham 1994</a>; <a href="./references#CD007476-bbs2-0083" title="GabuttiV , PigaA . Results of long‐term iron‐chelating therapy. Acta Haematologica1996;95(1):26‐36. ">Gabutti 1996</a>; <a href="./references#CD007476-bbs2-0139" title="ZurloMG , DeStefanoP , Borgna‐PignattiC , DiPalmaA , PigaA , MelevendiC , et al. Survival and causes of death in thalassaemia major. Lancet1989;2(8653):27‐30. ">Zurlo 1989</a>). To be clinically effective, deferoxamine has to be administered as a subcutaneous, or less often an intravenous, infusion over 8 to 12 hours, five to seven days per week. This regimen has been demonstrated to reduce the body iron load, prevent the onset of iron‐induced complications and even reverse some of the organ‐damage due to iron (<a href="./references#CD007476-bbs2-0071" title="DavisBA , O'SullivanC , JarrittPH , PorterJB . Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood2004;104(1):263‐9. [PUBMED: 15001468] ">Davis 2004</a>; <a href="./references#CD007476-bbs2-0111" title="OlivieriNF , NathanDG , MacMillanJH , WayneAS , LiuPP , McGeeA , et al. Survival in medically treated patients with homozygous beta‐thalassemia. New England Journal of Medicine1994;331(9):574‐8. ">Olivieri 1994</a>). But the arduous schedule of overnight subcutaneous infusions often leads to reduced adherence (<a href="./references#CD007476-bbs2-0058" title="CappelliniMD . Overcoming the challenge of patient compliance with iron chelation therapy. Seminars in Hematology2005;42(2 Suppl 1):S19‐21. ">Cappellini 2005a</a>; <a href="./references#CD007476-bbs2-0107" title="ModellB , KhanM , DarlisonM . Survival in beta‐thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet2000;355(9220):2051‐2. ">Modell 2000</a>; <a href="./references#CD007476-bbs2-0112" title="OlivieriNF , BrittenhamGM . Iron‐chelating therapy and the treatment of thalassemia. Blood1997;89(3):739‐61. ">Olivieri 1997</a>). Another problem concerns the toxicity of deferoxamine, particularly at higher doses. Toxicities beside local skin reactions include ophthalmologic (optic neuropathy, retinal pigmentation) and hearing problems (high frequency sensorineural hearing loss). Rare AEs, such as growth retardation, renal impairment (<a href="./references#CD007476-bbs2-0098" title="KorenG , Kochavi‐AtiyaY , BenturY , OlivieriNF . The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. International Journal of Hematology1991;54(5):371‐5. ">Koren 1991</a>), anaphylactic reactions and pulmonary fibrosis (<a href="./references#CD007476-bbs2-0082" title="FreedmanMH , GrisaruD , OlivieriN , MacLuskyI , ThornerPS . Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. American Journal of Diseases of Children1990;144(5):565‐9. ">Freedman 1990</a>) have been reported. The high cost of deferoxamine (approximately USD 10,000 per year) (<a href="./references#CD007476-bbs2-0072" title="DeleaTE , HagiwaraM , ThomasSK , BaladiJF , PhatakPD , CoatesTD . Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. American Journal of Hematology2008;83(4):263‐70. ">Delea 2008</a>) and the consumables required (e.g. balloon infusers, which imply additional costs) as well as its complicated mode of administration limit its use in low‐and middle‐income countries. </p> <p>Oral preparations have been highly sought after for many years. In 1987 two studies showed that the orally active iron chelator deferiprone (1,2 dimethyl‐3‐hydroxypyrid‐4‐1, also known as L1, CP20, Ferriprox<sup>®</sup> or Kelfer) could achieve effective short‐term iron chelation (<a href="./references#CD007476-bbs2-0096" title="KontoghiorghesGJ , AldouriMA , HoffbrandAV , BarrJ , WonkeB , KourouclarisT , et al. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one. BMJ (Clinical Research Edition)1987;295(6612):1509‐12. ">Kontoghiorghes 1987a</a>; <a href="./references#CD007476-bbs2-0097" title="KontoghiorghesGJ , AldouriMA , SheppardL , HoffbrandAV . 1,2‐Dimethyl‐3‐hydroxypyrid‐4‐one, an orally active chelator for treatment of iron overload. Lancet1987;1(8545):1294‐95. ">Kontoghiorghes 1987b</a>). However, doubts on the efficacy to reduce liver iron and prevent liver damage arose due to individuals with progression to overt liver fibrosis (<a href="./references#CD007476-bbs2-0113" title="OlivieriNF , BrittenhamGM , McLarenCE , TempletonDM , CameronRG , McClellandRA , et al. Long‐term safety and effectiveness of iron‐chelation therapy with deferiprone for thalassemia major. New England Journal of Medicine1998;339(7):417‐23. ">Olivieri 1998</a>). However, the hypothesis of direct liver toxicity of deferiprone could not be confirmed (<a href="./references#CD007476-bbs2-0132" title="WanlessIR , SweeneyG , DhillonAP , GuidoM , PigaA , GalanelloR , et al. Lack of progressive hepatic fibrosis during long‐term therapy with deferiprone in subjects with transfusion‐dependent beta‐thalassemia. Blood2002;100(5):1566‐9. ">Wanless 2002</a>; <a href="./references#CD007476-bbs2-0137" title="WuSF , PengCT , WuKH , TsaiCH . Liver fibrosis and iron levels during long‐term deferiprone treatment of thalassemia major patients. Hemoglobin2006;30(2):215‐8. ">Wu 2006</a>). In the meantime, several studies have shown the efficacy of deferiprone for iron chelation (<a href="./references#CD007476-bbs2-0064" title="CeciA , BaiardiP , FelisiM , CappelliniMD , CarnelliV , DeSanctisV , et al. The safety and effectiveness of deferiprone in a large‐scale, 3‐year study in Italian patients. British Journal of Haematology2002;118(1):330‐6. ">Ceci 2002</a>; <a href="./references#CD007476-bbs2-0102" title="MaggioA , D'AmicoG , MorabitoA , CapraM , CiaccioC , CianciulliP , et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells, Molecules and Diseases2002;28(2):196‐208. ">Maggio 2002</a>) and in particular its benefit on cardiac iron and cardiac morbidity (<a href="./references#CD007476-bbs2-0117" title="PengCT , TsaiCH , WuKH . Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. Hemoglobin2008;32(1‐2):49‐62. ">Peng 2008</a>). Adverse effects include gastrointestinal disturbances, arthropathy, neutropenia and agranulocytosis (<a href="./references#CD007476-bbs2-0093" title="HoffbrandAV , BartlettAN , VeysPA , O'ConnorNT , KontoghiorghesGJ . Agranulocytosis and thrombocytopenia in patient with Blackfan‐Diamond anaemia during oral chelator trial. Lancet1989;2(8660):457. ">Hoffbrand 1989</a>). Studies on combination therapy of deferoxamine and deferiprone have been performed, most of which showed additive rather than synergistic effects (<a href="./references#CD007476-bbs2-0076" title="FarmakiK , AngelopoulosN , AnagnostopoulosG , GotsisE , RombopoulosG , TolisG . Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta‐thalassaemia major. British Journal of Haematology2006;134(4):438‐44. ">Farmaki 2006</a>; <a href="./references#CD007476-bbs2-0084" title="GalanelloR , KattamisA , PigaA , FischerR , LeoniG , LadisV , et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica2006;91(9):1241‐3. ">Galanello 2006</a>; <a href="./references#CD007476-bbs2-0094" title="KattamisA , KassouC , BerdousiH , LadisV , PapassotiriouI , KattamisC . Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica2003;88(12):1423‐25. ">Kattamis 2003</a>; <a href="./references#CD007476-bbs2-0095" title="KolnagouA , EconomidesC , EracleousE , KontoghiorghesGJ . Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin2008;32(1‐2):41‐7. ">Kolnagou 2008</a>; <a href="./references#CD007476-bbs2-0115" title="OrigaR , BinaP , AgusA , CrobuG , DefraiaE , DessiC , et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica2005;90(10):1309‐14. ">Origa 2005</a>; <a href="./references#CD007476-bbs2-0128" title="TannerMA , GalanelloR , DessiC , SmithGC , WestwoodMA , AgusA , et al. A randomized, placebo‐controlled, double‐blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation2007;115(14):1876‐84. ">Tanner 2007</a>). An extensive Cochrane Review on the effectiveness of deferiprone in people with thalassaemia was updated in 2013 (<a href="./references#CD007476-bbs2-0081" title="FisherSA , BrunskillSJ , DoreeC , ChowdhuryO , GoodingS , RobertsDJ . Oral deferiprone for iron chelation in people with thalassemia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD004839.pub3] ">Fisher 2013b</a>). </p> </section> <section id="CD007476-sec-0026"> <h3 class="title" id="CD007476-sec-0026">How the intervention might work</h3> <p>Deferasirox is an oral iron chelator which is rapidly absorbed after administration and has a bioavailability of about 70%. Safety and tolerability were shown to be reasonable in a randomised dose escalation study in people with β‐thalassaemia in 2003 (<a href="./references#CD007476-bbs2-0109" title="Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. ">Nisbet‐Brown 2003</a>). The elimination half‐life of 8 to 16 hours allows a once daily administration after the tablets have been added to water or juice. A newer formulation approved in 2015 in the USA (Jadenu™) (<a href="./references#CD007476-bbs2-0110" title="Novartis . Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overload. https://www.novartis.com/news/media‐releases/novartis‐announces‐fda‐approval‐jadenutm‐simplify‐treatment‐administration. ">Novartis 2015</a>) and in 2016 in the European Union (Exjade<sup>®</sup> film‐coated tablets) (<a href="./references#CD007476-bbs2-0074" title="European Medicines Agency (EMA). Exjade: EPAR. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/000670/WC500033925.pdf (accessed 2 January 2017). ">EMA 2016</a>) allows people to swallow the tablets with water directly. Containing the same active ingredient with comparable pharmacokinetics, the formulation was approved based on safety and efficacy studies investigating the original tablet for suspension (<a href="./references#CD007476-bbs2-0065" title="ChalmersAW , ShammoJM . Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long‐term blood transfusions. Ther Clin Risk Manag.2016;12:201‐8. ">Chalmers 2016</a>). </p> <p>As deferasirox is a tridentate chelator, two molecules of deferasirox are needed to bind one molecule of iron. The excretion of the bound iron is mainly via faeces. </p> </section> <section id="CD007476-sec-0027"> <h3 class="title" id="CD007476-sec-0027">Why it is important to do this review</h3> <p>Deferoxamine necessitates serious commitment from the user and due to its AEs, deferiprone is only approved as second‐line therapy in some countries. Thus, much hope is being placed in the newer oral chelator deferasirox which apparently offers a promising line of treatment due to its iron chelation properties and safety and tolerability profile (<a href="./references#CD007476-bbs2-0060" title="CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. ">Cappellini 2007</a>). Therefore, an update of our previous Cochrane Review of the effectiveness and safety of deferasirox according to state of the art Cochrane standards is needed in the light of several studies being recently published (<a href="./references#CD007476-bbs2-0141" title="MeerpohlJJ , AntesG , RückerG , FleemanN , MotschallE , NiemeyerCM , BasslerD . Deferasirox for managing iron overload in people with thalassaemia. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD007476.pub2] ">Meerpohl 2012</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007476-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007476-sec-0028"></div> <p>To evaluate the effectiveness and safety of oral deferasirox for management of iron overload in people with thalassaemia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007476-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007476-sec-0029"></div> <section id="CD007476-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007476-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised controlled studies (RCTs) were considered for this review.</p> </section> <section id="CD007476-sec-0032"> <h4 class="title">Types of participants</h4> <p>People with thalassaemia regardless of age, type of thalassaemia (e.g. thalassaemia major, thalassaemia intermedia) and setting (e.g. country, primary or secondary care), who have developed iron overload (defined as ferritin levels of over 1000 ng/mL on at least two occasions in individuals with transfusion‐dependent thalassaemia and over 300 ng/mL in those with non‐transfusion‐dependent thalassaemia). People with thalassemia who have undergone stem cell transplantation (SCT) are excluded. </p> </section> <section id="CD007476-sec-0033"> <h4 class="title">Types of interventions</h4> <p>For oral deferasirox (all schedules and doses) the following comparisons were considered:</p> <p> <ol id="CD007476-list-0001"> <li> <p>deferasirox compared with no therapy or placebo in people with transfusion‐dependent thalassaemia; </p> </li> <li> <p>deferasirox compared with no therapy or placebo in people with non‐transfusion‐dependent thalassaemia; </p> </li> <li> <p>deferasirox compared with another iron‐chelating treatment (i.e. deferoxamine or deferiprone or any combination thereof) in people with transfusion‐dependent thalassaemia; </p> </li> <li> <p>deferasirox compared with another iron‐chelating treatment (i.e. deferoxamine or deferiprone or any combination thereof) in people with non‐transfusion‐dependent thalassaemia. </p> </li> </ol> </p> <p>However, the necessity of chelation therapy in iron‐overloaded people is well‐established and, if at all, only short‐term (e.g. pharmacokinetic studies) would be ethically justifiable. Longer‐term studies with no therapy or placebo in people with transfusion‐dependent thalassemia would not suffice the paradigm of equipoise. </p> </section> <section id="CD007476-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD007476-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD007476-list-0002"> <li> <p>Overall mortality measured at any point in time</p> </li> </ol> </p> </section> <section id="CD007476-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD007476-list-0003"> <li> <p>Reduced end‐organ damage due to iron deposition</p> <ol id="CD007476-list-0004"> <li> <p>cardiac failure (necessitating medical treatment)</p> </li> <li> <p>endocrine disease (necessitating substitution hormone therapy or treatment of diabetes)</p> </li> <li> <p>histological evidence of hepatic fibrosis</p> </li> <li> <p>pathological surrogate markers of end‐organ damage (i.e. elevated liver enzymes, elevated fasting glucose or pathological oral glucose tolerance test (OGTT), pathological measures (e.g. ejection fraction in echocardiography) </p> </li> </ol> </li> <li> <p>Measures of iron overload</p> <ol id="CD007476-list-0005"> <li> <p>serum ferritin (ng/mL)</p> </li> <li> <p>iron levels in biopsies of liver and other tissue (mg/g liver dry weight)</p> </li> <li> <p>tissue iron assessment by superconducting quantum interference device (SQUID) (mg/g liver wet weight) </p> </li> <li> <p>tissue iron assessment by magnetic resonance imaging (MRI) (ms)</p> </li> <li> <p>responder analysis (deletion of body iron, depending on study definition)</p> </li> </ol> </li> <li> <p>Measures of iron excretion (urine and faeces) over 24 hours (mg/kg/day)</p> </li> <li> <p>Any AEs</p> <ol id="CD007476-list-0006"> <li> <p>raised levels of creatinine or kidney failure (above upper normal limit or rise of more than 20% above baseline level) </p> </li> <li> <p>skin rash</p> </li> <li> <p>gastrointestinal disturbances</p> </li> <li> <p>neutropenia or agranulocytosis (absolute neutrophil count (ANC) less than 1000/µl or less than 500/µL) </p> </li> <li> <p>raised levels of liver enzymes (above upper normal limit or rise of more than 20% above baseline level) or progression to liver fibrosis </p> </li> <li> <p>hearing loss</p> </li> <li> <p>eye problems (e.g. retinal toxicity)</p> </li> <li> <p>unanticipated AEs as reported in the primary studies</p> </li> </ol> </li> <li> <p>Participant satisfaction (measured e.g. by a validated questionnaire) and adherence to chelation treatment (measured by the number of people in each arm that show adequate level of adherence to treatment (intake or application of iron chelator on five or more days per week)) </p> </li> <li> <p>Cost of intervention per year</p> </li> </ol> </p> <p>Data from outcomes not defined a priori but which have arisen from the review were also collected, if the outcome was considered to be of clinical relevance. </p> <p>Data were extracted at longest follow‐up.</p> </section> </section> </section> <section id="CD007476-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>No language restriction was applied.</p> <section id="CD007476-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched for relevant studies in the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register using the terms: (thalassaemia OR haemoglobinopathies general) AND ICL670(A). </p> <p>The Haemoglobinopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library) and quarterly searches of MEDLINE. Unpublished work is identified by searching the abstract books of five major conferences: the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; the Caribbean Health Research Council Meetings; and the National Sickle Cell Disease Program Annual Meeting. For full details of all searching activities for the register, please see the relevant section of the Cochrane Cystic Fibrosis and Genetic Disorders Group's <a href="http://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of most recent search of the Group's Haemoglobinopathies Trials Register: 12 August 2016. </p> <p>We also searched:</p> <p> <ul id="CD007476-list-0007"> <li> <p>Cochrane Database of Systematic Reviews (2015, Issue 8); Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 7); Database of Abstracts of Reviews of Effect (DARE; 2015, Issue 2); Health Technology Assessment Database (2015, Issue 3); NHS Economic Evaluation Database (2015, Issue 2); Cochrane Methodology Register (2012, Issue 3) in the Cochrane Library <a href="http://www.thecochranelibrary.com" target="_blank">www.thecochranelibrary.com</a> (searched 6 August 2015); </p> </li> <li> <p>MEDLINE OvidSP (2010 to July Week 5 2015);</p> </li> <li> <p>MEDLINE OvidSP in Process and Other Non‐Indexed Citations (searched 05 August 2015);</p> </li> <li> <p>MEDLINE OvidSP Daily Update (searched 05 August 2015)</p> </li> <li> <p>Embase OvidSP (2010 to 05 August 2015);</p> </li> <li> <p>PubMed <a href="http://www.pubmed.com" target="_blank">www.pubmed.com</a> [limited to MEDLINE subset "supplied by publisher"] (1946 to 06 August 2015); </p> </li> <li> <p>Web of Science Core Collection via Thomson Reuters (2010 to 04 August 2015);</p> </li> <li> <p>Biosis Previews via Thomson Reuters (2010 to 04 August 2015);</p> </li> <li> <p>Google <a href="http://www.google.com" target="_blank">www.google.com</a> – searched for "Osferal" and also "Osveral" (searched 07 January 2016) </p> </li> </ul> </p> <p>An RCT filter was used for searches in MEDLINE, Embase, Biosis Previews and Web of Science Core Collection. In MEDLINE, we used the "Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity‐maximizing version (2008 revision); Ovid format" (<a href="./references#CD007476-bbs2-0100" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies.. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. ">Lefebvre 2011</a>), but we replaced "randomized" with "randomi#ed". For Embase, Biosis Previews and Web of Science Core Collection, we devised the search for RCTs and used textwords from the Cochrane RCT Filter we used for the MEDLINE search. For details of the search strategies see <a href="./appendices#CD007476-sec-0146">Appendix 1</a>. </p> <p>Regarding the search with Google, we screened the first 50 results of both searches. Every link which was suspected to obtain a relevant study was looked at. </p> <p>Since research into deferasirox treatment is ongoing, we searched the following trial registers for all years available in all possible fields using the basic search function (using separately the following keyword terms: "deferasirox", "ICL670", "ICL 670", "exjade", "desirox" and "jadenu"): </p> <p> <ol id="CD007476-list-0008"> <li> <p>ClinicalTrials.gov: <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> (searched 07 August 2015); </p> </li> <li> <p>ICTRP: <a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a> (searched 07 August 2015); </p> </li> <li> <p>German Clinical Trial Register: <a href="http://www.drks.de" target="_blank">www.drks.de</a> (searched 07 August 2015). </p> </li> </ol> </p> <p>For the previous version of this review, several databases and ongoing trials registers were searched from 24th June to 1st July 2010. Please see <a href="./appendices#CD007476-sec-0147">Appendix 2</a> for full details. </p> </section> <section id="CD007476-sec-0039"> <h4 class="title">Searching other resources</h4> <p>Additionally, reference lists of all identified primary papers were screened to identify other potentially relevant citations. </p> <p>Contact was made with selected experts in the field as well as the manufacturer of deferasirox (Novartis) to request information on any unpublished studies that involved deferasirox. </p> </section> </section> <section id="CD007476-sec-0040"> <h3 class="title" id="CD007476-sec-0040">Data collection and analysis</h3> <section id="CD007476-sec-0041"> <h4 class="title">Selection of studies</h4> <p>One author (JM; for the update: CB or LS) screened all titles and abstracts of papers identified by the search strategies for relevance. We only excluded citations which were clearly irrelevant at this stage. We obtained full copies of all potentially relevant papers. At this stage two review authors (JM and DB; for the update: CB and RA or LS and JM) independently screened the full papers, identified relevant studies and assessed eligibility of studies for inclusion. We resolved any disagreement on the eligibility of studies through discussion and consensus or if necessary through a third party (GA; for the update: JM). We excluded all irrelevant records and recorded details of the studies and the reasons for exclusion. </p> </section> <section id="CD007476-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>In addition to details relating to the risk of bias of the included studies, we extracted two sets of data. </p> <p> <ol id="CD007476-list-0009"> <li> <p>Study characteristics: place of publication; date of publication; population characteristics; setting; detailed nature of intervention; detailed nature of comparator; and detailed nature of outcomes. A key purpose of this data was to define unexpected clinical heterogeneity in included studies independently from the analysis of the results. </p> </li> <li> <p>Results of included studies with respect to each of the main outcomes indicated in the review question. We carefully recorded reasons why an included study did not contribute data on a particular outcome and considered the possibility of selective reporting of results on particular outcomes. </p> </li> </ol> </p> <p>Two review authors (JM, DB; for the update: CB and RA or LS and JM) independently undertook data extraction using a data extraction form developed by the authors (except for one Chinese study which was extracted by one Chinese reviewer only). The review authors resolved any disagreements by consensus or through discussion with a third review author (GA ; for the update: JM). Once we had resolved disagreements, we recorded the extracted data on the final data extraction form. One review author (JM; for the update: CB or LS) transcribed these into RevMan 5.3 (<a href="./references#CD007476-bbs2-0121" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). Another review author (DB; for the update: JM) verified all data entry for discrepancies. We extracted data primarily from full publications of studies; however, if additional abstracts or results records in clinicaltrials.gov were available, these data were also considered. When only abstracts were available, we extracted data therefrom as far as possible. </p> </section> <section id="CD007476-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JM, DB; for the update: CB, RA or LS, JM) assessed every study using a simple risk of bias form and following the domain‐based evaluation as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007476-bbs2-0091" title="HigginsJPT , AltmanDG , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). </p> <p>We assessed the following domains as having either a low, unclear, or high risk of bias: </p> <p> <ol id="CD007476-list-0010"> <li> <p>randomisation;</p> </li> <li> <p>concealment of allocation;</p> </li> <li> <p>blinding (of participants, personnel and outcome assessors);</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>other sources of bias.</p> </li> </ol> </p> <p>We reviewed the assessments and discussed any inconsistencies between the review authors in the interpretation of inclusion criteria and their significance to the selected studies. We resolved any disagreements through discussion with a third author (GA or JM). We did not automatically exclude any study as a result of a rating of 'unclear risk of bias' or a 'high risk of bias'. We presented the evaluation of the risk of bias in included studies in tabular form in the <a href="./full#CD007476-sec-0053">Results</a> section of the review. </p> </section> <section id="CD007476-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed extracted data using the most up‐to‐date version of the RevMan 5 software available at the time of analysis (<a href="./references#CD007476-bbs2-0121" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> <p>We planned to extract hazard ratios (HR) with their 95% confidence intervals (CI) for the time‐to‐event outcomes mortality and end‐organ damage. If reports did not provide HRs, we planned to use indirect estimation methods described by Parmar and Williamson to calculate them (<a href="./references#CD007476-bbs2-0116" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>; <a href="./references#CD007476-bbs2-0135" title="WilliamsonPR , SmithCT , HuttonJL , MarsonAG . Aggregate data meta‐analysis with time‐to‐event outcomes. Statistics in Medicine2002;21(22):3337‐51. ">Williamson 2002</a>). </p> <p>If we were unable to either extract these data from the study reports or receive the necessary information from the primary investigators, alternatively we used, where appropriate, the proportions of participants with the respective outcomes measured at certain time points (i.e. three months, six months, then six‐monthly intervals) to be able to calculate risk ratios (RR). We also extracted data from other time points if available. </p> <p>We expressed any results for binary outcomes as RR with 95% CIs as measures of uncertainty. Continuous outcomes were expressed as mean differences (MD) with 95% CIs as measures of uncertainty. </p> <p>Outcomes were not described as means and standard deviations (SD) in all studies, therefore, in order to enter and analyze as many data in RevMan as possible, we undertook further calculations wherever possible. If studies only reported median and range, CI or interquartile range, we estimated means and SDs as described by Wan (<a href="./references#CD007476-bbs2-0131" title="WanX , WangW , LiuJ , TongT . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology2014;19(14):135. ">Wan 2014</a>). If studies only reported standard error (SE) of the mean (SEM), we used the following calculation: SD = SEM*sqrt(n). If studies provided P values, n and mean, we calculated the SD with the calculator integrated in RevMan 5 (<a href="./references#CD007476-bbs2-0121" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). If studies provided Z values, we calculated the SD for the change from baseline. For heavily skewed data, analysis based on means is not appropriate. Although the study authors did not always explain the reasons, means were presented as geometric means (Gmeans) in some cases. We therefore analysed the data on a log scale and report these data as the ratio of Gmeans. </p> <p>Reporting of results was ambiguous in some studies, so we had to make the following assumptions. </p> <p> <ul id="CD007476-list-0011"> <li> <p>One study reported the percentage of participants with dose reductions and interruption and the values for adherence, but the number of participants included for each outcome was not clear (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). For our analysis we assumed that all those who had received the study drug were included. </p> </li> <li> <p>Where results of individual studies were displayed only graphically and we considered estimation to be reasonable, we estimated values visually from the graphs. </p> </li> <li> <p>We assumed that the values of means and SD in neutrophil, alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP) levels were confused in one study (<a href="./references#CD007476-bbs2-0010" title="MolaviMA , PoorST , MalesksabetM . Combined Desferrioxamine (Desferal) and Deferasirox in children. Advances in Biological Research2014;8(4):171‐5. ">Molavi 2014</a>) so we used corrected values for our meta‐analysis. </p> </li> <li> <p>A further study reported different P values for the same outcome "QoL (end of study‐baseline)" in the same journal publication (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>). We calculated the SD for change from baseline using the most conservative P values given. </p> </li> <li> <p>When the P value was reported as P &lt; 0.001, we used P = 0.001 for our calculation of SD. </p> </li> <li> <p>One study lost three participants across the term of the study (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). For calculating change from baseline, we included all 30 participants for our conservative analysis. </p> </li> <li> <p>Sometimes we realised discrepancies in results reported in journal publications and in abstracts or trial registers. In these cases, we usually extract results from full journal publications. </p> </li> <li> <p>For some outcomes, a possible perception of the comparison might be whether deferasirox is not inferior to standard treatment with deferoxamine. Therefore, for these outcomes a per protocol analysis might be chosen. </p> </li> </ul> </p> </section> <section id="CD007476-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>We found two three‐armed studies comparing the three different iron chelation monotherapies deferasirox, deferiprone and deferoxamine (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>; <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). To include the results in our meta‐analysis, we divided the number of participants in the deferasirox arms as suggested in chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007476-bbs2-0092" title="HigginsJPT , DeeksJJ , AltmanDG , editor(s) . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration, 201. ">Higgins 2011b</a>). </p> <p>One four‐arm study compared two different doses of deferasirox to equivalent placebos, but results of both placebo groups were not reported individually, so we split the placebo group for both comparisons (<a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>). </p> <p>We did not include any cross‐over studies in this review. However, for future updates, we plan to use the methods recommended by Elbourne for combining results from such studies (<a href="./references#CD007476-bbs2-0073" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). We will use the methods described by Curtin to combine results from parallel and cross‐over studies (<a href="./references#CD007476-bbs2-0068" title="CurtinF , AltmanDG , ElbourneD . Meta‐analysis combining parallel and cross‐over clinical trials. I: Continuous outcomes. Statistics in Medicine2002;21(15):2131‐44. ">Curtin 2002a</a>; <a href="./references#CD007476-bbs2-0069" title="CurtinF , ElbourneD , AltmanDG . Meta‐analysis combining parallel and cross‐over clinical trials. II: Binary outcomes. Statistics in Medicine2002;21(15):2145‐59. ">Curtin 2002b</a>; <a href="./references#CD007476-bbs2-0070" title="CurtinF , ElbourneD , AltmanDG . Meta‐analysis combining parallel and cross‐over clinical trials. III: The issue of carry‐over. Statistics in Medicine2002;21(15):2161‐73. ">Curtin 2002c</a>). </p> <p>The study investigators planned that the included phase III study would be a non‐inferiority study (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>). Therefore, they did not report efficacy outcomes based on an intention‐to‐treat (ITT) analysis. For our review, we used the data as presented, i.e. per protocol. </p> <p>We did not use any of the below mentioned strategies outlined by Witte (<a href="./references#CD007476-bbs2-0136" title="WitteS , VictorN . Some problems with the investigation of noninferiority in meta‐analysis. Methods of Information in Medicine2004;43(5):470‐4. ">Witte 2004</a>) in this version of the review, because only a few studies could be pooled per outcome. However, for future updates we will consider applying one of these strategies according to the data available. </p> <p> <ol id="CD007476-list-0012"> <li> <p>If all studies report only an ITT analysis (or all studies report only a per protocol analysis), we will perform a non‐inferiority meta‐analysis based on Witte's 'perfect case' proposal. </p> </li> <li> <p>If some studies report only an ITT analysis and others only a per protocol analysis (exclusively), we will perform meta‐regression with analysis type as a covariate. </p> </li> <li> <p>If some studies report only an ITT analysis and others only a per protocol analysis, whilst others report both, we will undertake a sensitivity analysis. </p> </li> <li> <p>If all studies give enough information to do both analyses, we will analyse data using a bivariate model. </p> </li> </ol> </p> <p>To interpret results according to a non‐inferiority scenario, we will use the following definitions. </p> <p>For time‐to‐event data, non‐inferiority is given, if the relative difference in HRs is less than 10%. For RRs, non‐inferiority is defined as a relative RR difference of less than 10% in treatment failures compared to standard therapy. For the continuous outcomes of "measures of iron overload and iron excretion" as well as "costs", a relative difference of less than 10% is considered equivalent. </p> </section> <section id="CD007476-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the original investigators to clarify some methodological issues and to request additional data from two studies during the development of the previous review version (<a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>; <a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>); however, to date, we have not received any additional data to that presented in the primary reports. For this version of the review, we contacted investigators of 11 studies (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>; <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>; <a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>; <a href="./references#CD007476-bbs2-0006" title="HabibianN . Comparison of therapeutic effect of osveral &amp; desferal in patients with thalassemia (bahonar hospital in karaj 2012‐13). Iranian Journal of Pediatrics2014;24(Suppl 2):S27. ">Habibian 2014</a>; <a href="./references#CD007476-bbs2-0045" title="HagagAA , HamamMA , TahaOA , HazaaSM . Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload. Infectious Disorders Drug Targets2015;15(2):98‐105. ">Hagag 2015</a>; <a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>; <a href="./references#CD007476-bbs2-0047" title="KakkarS , SobtiPPC , KalraA . Efficacy and safety of deferasirox in single vs divided dosage in Thalassemic children. Haematologica2015;100 Suppl 1 785:PB2010. ">Kakkar 2015</a>; <a href="./references#CD007476-bbs2-0009" title="MolaviMA , DoozandehH , NazemiA , EvaziR , MansooriF . Comparison of therapeutic response and complications of oral Osveral and injection Desfereal chelating agent in patient with thalassemia major. Asian Journal of Medical and Pharmaceutical Researches2013;3(3):93‐7. ">Molavi 2013</a>; <a href="./references#CD007476-bbs2-0010" title="MolaviMA , PoorST , MalesksabetM . Combined Desferrioxamine (Desferal) and Deferasirox in children. Advances in Biological Research2014;8(4):171‐5. ">Molavi 2014</a>; <a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>; <a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>) and the manufacturer of deferasirox regarding two studies (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>: <a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>). We could clarify some issues and the original investigator confirmed that our list of included studies is complete. However, additional data on investigator‐sponsored studies have to be requested via a data request platform in most cases. We plan to request available data via this platform for all manufacturer sponsored studies for a future update. </p> </section> <section id="CD007476-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>Where feasible, we considered clinical heterogeneity by presenting results of subgroups according to differences in dose of intervention and baseline measures of iron overload. We examined statistical heterogeneity in the results of studies using the I² and Chi² statistics (<a href="./references#CD007476-bbs2-0088" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. ">Higgins 2002</a>; <a href="./references#CD007476-bbs2-0089" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). </p> </section> <section id="CD007476-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We made a great effort to identify unpublished studies and minimise the impact of possible dissemination bias by using a comprehensive search strategy and contacting the manufacturer of deferasirox for the previous version. We did not use funnel plots to assess dissemination bias, since asymmetry is difficult to detect with a small number of studies (i.e. less than 10) and we could only include 16 studies overall in this review, with no more than eight studies per outcome. If in future we are able to include more than 10 studies for a given outcome in the review, we will use funnel plots to graphically assess the likelihood of dissemination bias. We took care in translating the results of the included studies into recommendations for action by involving all review authors in drawing conclusions. </p> </section> <section id="CD007476-sec-0049"> <h4 class="title">Data synthesis</h4> <p>While extracting data, we had to take the following decisions. Although we would have preferred to consistently present data separately for the different dose groups, we decided to pool safety data of the different dose groups from the Nisbet‐Brown study, since splitting the placebo group (N = 5) did not seem reasonable due to the small size (<a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>). Due to the huge amount of different AE types reported, we decided to pool AEs for the different dose groups for three studies rather than presenting the various subgroups for all AEs (as in the previous version of this review) (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>; <a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>; <a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>). </p> <p>We conducted meta‐analyses of pooled data from all contributing studies using a fixed‐effect model. We took heterogeneity of the pooled data into account by using subgroup analysis or the random‐effects model (or both) (see <a href="#CD007476-sec-0078">Effects of interventions</a> for specific details). </p> <section id="CD007476-sec-0050"> <h5 class="title"><i>'Summary of findings' tables</i> </h5> <p>We created 'Summary of findings' tables for each comparison apart from deferasirox versus placebo in people with transfusion‐dependent thalassemia, because abstaining from iron chelation treatment in this patient group is ethically not justified and therefore not patient‐relevant. </p> <p>The following outcomes were selected for presentation in the 'summary of findings' tables because we considered these outcomes most relevant for decision‐making given the limitations of the available evidence: </p> <p> <ol id="CD007476-list-0013"> <li> <p>overall mortality measured at any point in time;</p> </li> <li> <p>responder analysis (deletion of body iron, depending on study definition);</p> </li> <li> <p>serum ferritin (ng/mL);</p> </li> <li> <p>iron levels in liver measured by biopsies (mg/g liver dry weight) or SQUID (mg/g liver wet weight) or MRI (ms); </p> </li> <li> <p>adherence to chelation treatment (measured by the number of people in each arm that show adequate level of adherence to treatment (intake or application of iron chelator on five or more days per week, or number of patients who discontinued as form of adherence)); </p> </li> <li> <p>participant satisfaction (measured e.g. by a validated questionnaire);</p> </li> <li> <p>AEs: raised levels of creatinine or kidney failure (above upper normal limit or rise of more than 20% above baseline level). </p> </li> </ol> </p> <p>We used the five Grading of Recommendations Assessment, Development and Evaluation (<a href="./references#CD007476-bbs2-0085" title="GuyattGH , OxmanAD , VistG , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">GRADE</a>) considerations (risk of bias, inconsistency, indirectness, imprecision and publication bias) to assess the quality of the body of evidence as it relates to the studies that contributed data to the meta‐analyses as described in chapters 11 and 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007476-bbs2-0090" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We used footnotes to justify all decisions to down‐ or upgrade the quality of evidence and we made comments to aid readers’ understanding of the review where necessary. We generated 'Summary of findings' tables using the Gradepro software (<a href="./references#CD007476-bbs2-0086" title="GRADE Working Group, McMaster University. GRADEpro GDTool. Hamilton (ON): GRADE Working Group, McMaster University, (accessed prior to 22 August 2016). ">GRADEpro GDT 2015</a>). </p> </section> </section> <section id="CD007476-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If data were available, we presented subgroups according to baseline measures of iron overload or doses of intervention as they were reported in the studies. If relevant, other subgroup analysis as defined in study publications are presented. Due to the amount of reported adverse events, we merged AEs for different subgroups. For future updates of this review, we will assess clinical heterogeneity, if possible, in addition by examining differences due to: </p> <p> <ul id="CD007476-list-0014"> <li> <p>age of participants (e.g. zero to two years, three to five years, 6 to 11 years; 12 to 17 years, 18 years or older); </p> </li> <li> <p>age at commencement of the intervention (e.g. zero to two years, three to five years, 6 to 11 years, 12 to 17 years, 18 years or older). </p> </li> </ul> </p> <p>Additional subgroup analyses are planned for different:</p> <p> <ul id="CD007476-list-0015"> <li> <p>subtypes of thalassaemia (e.g. thalassaemia major, thalassaemia intermedia, haemoglobin E thalassaemia) where applicable. </p> </li> </ul> </p> </section> <section id="CD007476-sec-0052"> <h4 class="title">Sensitivity analysis</h4> <p>We were only able to include a maximum of nine published studies for each of our comparisons and no additional unpublished studies nor studies with a low risk of bias were identified. Due to missing data regarding SD, we did some calculations according to Wan and undertook sensitivity analysis (<a href="./references#CD007476-bbs2-0131" title="WanX , WangW , LiuJ , TongT . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology2014;19(14):135. ">Wan 2014</a>). For future updates of this review, we plan to perform additional sensitivity analyses based on assessment of risk of bias (evaluating only studies of low risk of bias) and publication status (unpublished and published studies). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007476-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007476-sec-0053"></div> <section id="CD007476-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD007476-sec-0055"> <h4 class="title">Results of the search</h4> <section id="CD007476-sec-0056"> <h5 class="title">Updated searches</h5> <p>The updated searches for this current version of the review (last search ran in August 2016) identified 1211 citations, including 477 duplicates (<a href="#CD007476-fig-0001">Figure 1</a>). The title and abstract screening of the remaining 734 citations identified 71 as potentially eligible for this review. After screening of the full texts, eight new studies (described in 23 references) and a reference to a previously included study were included in the updated version of this review. Four additional studies (reported in five references) were identified through Google‐searches resulting overall in a total of 16 included studies. </p> <div class="figure" id="CD007476-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007476-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD007476-sec-0057"> <h5 class="title">Previous searches</h5> <p>For the previous version of this review, the last search was run in November 2011 (see <a href="#CD007476-fig-0001">Figure 1</a>). Altogether, 2171 citations, including 1195 duplicates, were identified. After title and abstract screening of the 976 unique citations, 687 citations could be excluded. A total of 289 full texts were screened and four RCTs (described in 33 references) were identified (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>; <a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>; <a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>; <a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>). </p> <p>The search of the three trial registers (last run on 30 June 2010) identified 49 unique references to studies. One ongoing RCT was identified, which has now been published and was therefore included in this updated review (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). </p> </section> </section> <section id="CD007476-sec-0058"> <h4 class="title">Included studies</h4> <p>Sixteen studies met the inclusion criteria (<a href="./references#CD007476-sec-0157" title="">Characteristics of included studies</a>) including 1807 randomised participants (range 23 to 586 per study). Twelve studies included two treatment arms comparing deferasirox to placebo (<a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>; <a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>) or deferoxamine (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>; <a href="./references#CD007476-bbs2-0006" title="HabibianN . Comparison of therapeutic effect of osveral &amp; desferal in patients with thalassemia (bahonar hospital in karaj 2012‐13). Iranian Journal of Pediatrics2014;24(Suppl 2):S27. ">Habibian 2014</a>; <a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>; <a href="./references#CD007476-bbs2-0009" title="MolaviMA , DoozandehH , NazemiA , EvaziR , MansooriF . Comparison of therapeutic response and complications of oral Osveral and injection Desfereal chelating agent in patient with thalassemia major. Asian Journal of Medical and Pharmaceutical Researches2013;3(3):93‐7. ">Molavi 2013</a>; <a href="./references#CD007476-bbs2-0012" title="PengP , LongLL , HuangZK , ZhangL , LiXH , FengX , et al. Comparison of deferasirox and deferoxamine treatment in iron‐overloaded patients: Liver iron concentration determined by quantitative MRI‐R2*. Chinese Journal of Radiology2013;47(1):55‐9. ">Peng 2013</a>; <a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>; <a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>;) or deferiprone (<a href="./references#CD007476-bbs2-0015" title="MattiM . Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013. SanjeevaGN , NijagunaN , MattiM , ChebbiPG . Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. Journal of of Evolution of Medical and Dental Sciences2015;4(24):4178‐85. [DOI: 10.14260/jemds/2015/601] ">Sanjeeva 2015</a>) or comparing the combination of deferasirox and deferoxamine to deferoxamine alone (<a href="./references#CD007476-bbs2-0010" title="MolaviMA , PoorST , MalesksabetM . Combined Desferrioxamine (Desferal) and Deferasirox in children. Advances in Biological Research2014;8(4):171‐5. ">Molavi 2014</a>). One study compared the combination of deferasirox and deferiprone to deferiprone in combination with deferoxamine (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>). Three studies included three treatment arms comparing deferasirox to deferoxamine and deferiprone (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>; <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>) or the combination of deferasirox and deferiprone to deferiprone and deferasirox monotherapy respectively (<a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). One study included four treatment arms, comparing two different doses of deferasirox to matching placebo groups (<a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>). One identified abstract is a report of a previously included study (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>). </p> <section id="CD007476-sec-0059"> <h5 class="title">1. Transfusion‐dependent thalassaemia: deferasirox versus placebo</h5> <p>The two relevant studies comparing deferasirox to placebo are short‐term studies examining mainly safety and pharmacokinetic outcomes while on deferasirox therapy (<a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>; <a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>). </p> <p>The first study was reported in one full article and one abstract (<a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>). Twenty‐four individuals were allocated to three groups: all groups received two single doses of deferasirox at an interval of at least seven weeks. Group 1 received single doses of 2.5 mg/kg and 20 mg/kg, Group 2 single doses of 5 mg/kg and 40 mg/kg and Group 3 single doses of 10 mg/kg and 80 mg/kg. In each treatment period, two of eight participants received placebo in such a way that a given participant did not receive placebo more than once. Usual deferoxamine and transfusion therapy was given in the interval between the two doses. This study by Galanello on deferasirox focused on safety, tolerability and pharmacokinetics. </p> <p>The second study was reported in one full article and two abstracts (<a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>). It was designed as a dose‐escalation study focusing on effectiveness and safety; treatment duration was 12 days. A total of 23 individuals were randomly assigned to placebo (n = 5), 10 mg/kg/day of deferasirox (n = 5), 20 mg/kg/day of deferasirox (n = 6) and 40 mg/kg/day of deferasirox (n = 7). Primary objectives included assessment of safety and tolerability (measured by adverse events and clinical laboratory monitoring), pharmacokinetics (measured as drug and drug‐iron complex), and cumulative net iron excretion (measured by faecal and urine output minus food input). </p> </section> <section id="CD007476-sec-0060"> <h5 class="title">2. Transfusion‐dependent thalassaemia: deferasirox versus deferoxamine</h5> <p>One of the seven studies comparing deferasirox to deferoxamine was reported in one full article and four abstracts (<a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>). This is a randomised open‐label phase II study including 71 people with β‐thalassaemia aged over 18 years from four centres in Italy. The primary objective was to determine the safety and tolerability of deferasirox at daily doses of 10 and 20 mg/kg in comparison with a standard dose of deferoxamine 40 mg/kg in individuals with transfusional haemosiderosis. Secondary objectives included evaluation of the effects of deferasirox on liver iron concentration (LIC), serum ferritin, serum iron, transferrin and transferrin saturation. The ITT principle was used for analyses. </p> <p>Results from the second study were reported in five full articles, 19 abstracts (and two responses to letters) (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>). This phase 3 open‐label randomised study was planned as a non‐inferiority study with a predefined delta of 15% (two‐sided 95% CI). There were 591 participants actually randomised, but five withdrew consent prior to any study medication; 586 participants were included in the study, of which 541 completed one year of therapy. After randomisation, stratified by three age groups, people were assigned to a treatment dose of either deferasirox or deferoxamine according to baseline LIC; the mean ratio of doses between deferasirox and deferoxamine varied from 1:5.5 to 1:1.8. The primary endpoint was maintenance or reduction of LIC. Secondary criteria for response included evaluation of the change in serum ferritin levels over time and evaluation of net body iron balance. </p> <p>A third study, a randomised, controlled study in Iran, was reported in one journal article (<a href="./references#CD007476-bbs2-0009" title="MolaviMA , DoozandehH , NazemiA , EvaziR , MansooriF . Comparison of therapeutic response and complications of oral Osveral and injection Desfereal chelating agent in patient with thalassemia major. Asian Journal of Medical and Pharmaceutical Researches2013;3(3):93‐7. ">Molavi 2013</a>). A total of 138 people with thalassaemia major and intermedia with serum ferritin more than 1000 ng/mL and older than two years were randomised to 20 mg/kg oral Osveral<sup>®</sup> (Iranian generic product of deferasirox) daily or 40 mg/kg to 50 mg/kg subcutaneous Desferal<sup>®</sup> (deferoxamine) for six nights a week. Due to the different administration routes, we assumed that no blinding took place. Primary outcome was serum ferritin, secondary outcomes were serum levels of ALT, AST, creatinine, haemoglobin and drug side effects (leukopenia, thrombocytopenia). </p> <p>A further study (reported in one full article in Chinese) compared deferasirox to deferoxamine and was a single‐centre RCT in China (blinding not mentioned) (<a href="./references#CD007476-bbs2-0012" title="PengP , LongLL , HuangZK , ZhangL , LiXH , FengX , et al. Comparison of deferasirox and deferoxamine treatment in iron‐overloaded patients: Liver iron concentration determined by quantitative MRI‐R2*. Chinese Journal of Radiology2013;47(1):55‐9. ">Peng 2013</a>). A total of 24 people with severe β‐thalassaemia were randomised to oral deferasirox 40 mg/kg daily or deferoxamine 50 mg/kg at least five days a week. During the 12 month follow up, serum ferritin and liver R2* were assessed. </p> <p>A larger multi‐centre, open‐label study was reported in two full articles and two abstracts (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). A total of 197 people with β‐thalassaemia major (aged 10 years and over) were randomised to 40 mg/kg/day oral deferasirox or deferoxamine 50 mg/kg/day to 60 mg/kg/day as subcutaneous infusion over eight to 12 hours, five to seven days a week. Regarding the primary outcome, change in myocardial T2* during one year follow‐up, the study was designed as a non‐inferiority study with a non‐inferiority margin of 90%. Secondary endpoints were change in left ventricular ejection fraction (LVEF), LIC and serum ferritin. Adverse events and adherence were also reported. Data from the one‐year extension phase were not included in this review due to the high number of individuals who did not continue with deferoxamine therapy after the core phase. </p> <p>A small study including 30 people with thalassaemia major was only reported in a conference abstract (<a href="./references#CD007476-bbs2-0006" title="HabibianN . Comparison of therapeutic effect of osveral &amp; desferal in patients with thalassemia (bahonar hospital in karaj 2012‐13). Iranian Journal of Pediatrics2014;24(Suppl 2):S27. ">Habibian 2014</a>). After 12 months, serum ferritin was measured. More information regarding dosing or other outcomes was not reported. </p> <p>One study, reported in a journal publication, investigated 60 individuals with thalassaemia major (<a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>). Participants were randomised to receive deferasirox (single oral daily dose of 20 to 40 mg/kg/day) or deferoxamine (20 to 50 mg/kg/day via a subcutaneous infusion over 8 to 10 hours, five days a week) for one year. Serum ferritin, ALT, AST, blood urea, serum creatinine, neutrophilic and platelet counts and some adverse events were reported. </p> </section> <section id="CD007476-sec-0061"> <h5 class="title">3. Transfusion‐dependent thalassaemia: deferasirox versus deferiprone</h5> <p>One single randomised study compared deferasirox 20 mg/kg/day to deferiprone 75 mg/kg/day divided in three doses (<a href="./references#CD007476-bbs2-0015" title="MattiM . Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013. SanjeevaGN , NijagunaN , MattiM , ChebbiPG . Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. Journal of of Evolution of Medical and Dental Sciences2015;4(24):4178‐85. [DOI: 10.14260/jemds/2015/601] ">Sanjeeva 2015</a>). The study included 41 regularly transfused children with ferritin over 1000 ng/mL who were not on chelation therapy previously. Serum ferritin level (primary outcome) and AEs (secondary outcomes) were assessed during a follow up of 12 months. The study was reported as a journal article and a doctoral thesis. </p> </section> <section id="CD007476-sec-0062"> <h5 class="title">4. Transfusion‐dependent thalassaemia: deferasirox and deferoxamine versus deferoxamine</h5> <p>The combination of deferasirox (20 mg/kg to 40 mg/kg) and deferoxamine (50 mg/kg, three times a week) was compared to deferoxamine monotherapy in one study, reported in one journal article (<a href="./references#CD007476-bbs2-0010" title="MolaviMA , PoorST , MalesksabetM . Combined Desferrioxamine (Desferal) and Deferasirox in children. Advances in Biological Research2014;8(4):171‐5. ">Molavi 2014</a>). A total of 100 people with thalassaemia major were randomised to one of the groups at a medical centre in Iran. Six participants were excluded after randomisation but before start of the study. Serum ferritin, liver enzymes, ALP, neutrophils, creatinine and haemoglobin were measured. </p> </section> <section id="CD007476-sec-0063"> <h5 class="title">5. Transfusion‐dependent thalassaemia: deferasirox and deferiprone versus deferiprone and deferoxamine </h5> <p>One randomised study included two treatment arms and compared two combination regimes: the first group received oral deferiprone 75 mg/kg/day divided into two doses and deferoxamine 40 mg/kg/day by subcutaneous infusion over 10 hours for six days a week, the second group received in addition to deferiprone (75 mg/kg/day) deferasirox 30 mg/kg/day for seven days a week (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>). The open‐label study was reported in one full article and two abstracts. A total of 96 people with thalassaemia major were randomised into two equal groups. Primary outcomes were change in serum ferritin, LIC and cardiac MRI, secondary outcomes were AEs, serious AEs (SAEs), participant's adherence, participant's satisfaction and health‐related quality of life. </p> </section> <section id="CD007476-sec-0064"> <h5 class="title">6. Transfusion‐dependent thalassaemia: deferasirox versus deferoxamine versus deferiprone</h5> <p>Two studies compared all three iron‐chelators against each other (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>; <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). </p> <p>The first study was published as one full article and one abstract (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>). The full study had a duration of eight years, but only the last two years were designed as a randomised controlled study. A total of 37 individuals who had not developed a thyreopathy under treatment with deferoxamine in the last six years were randomised to either deferasirox (n = 12), deferoxamine (n = 13) or deferiprone (n = 12) monotherapy. The number of participants with thyroid disease and serum ferritin after two years of follow‐up were reported. </p> <p>The other study comparing the three iron chelator monotherapies was reported in one full‐text and two abstracts (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). The aim of this study was to investigate the effects of vitamin C as an adjuvant therapy to iron chelation in a factorial study with six arms. Therefore, 180 people with iron‐overloaded thalassaemia major with serum ferritin from 1000 ng/mL to 2500 ng/mL and vitamin C deficiency were randomised in a 1:1:1 ratio to deferoxamine 40 mg/kg/day (five days a week), deferiprone 75 mg/kg/day or deferasirox 25 mg/kg/day. Participants were further equally randomised either to receive vitamin C supplementation (100 mg daily) or not. The primary efficacy endpoint was change of serum ferritin, LIC and cardiac MRI T2* during one year of follow‐up. The occurrence of any adverse effects was a secondary outcome measure. </p> </section> <section id="CD007476-sec-0065"> <h5 class="title">7. Transfusion‐dependent thalassaemia: deferasirox versus deferiprone versus deferasirox and deferiprone </h5> <p>In one study, 40 people were randomised to deferasirox 30 mg/kg/day to 40 mg/kg/day (n = 10), deferiprone (75 mg/kg/day to 100 mg/kg/day) (n = 10), or both drugs administered sequentially every alternate week (n = 20) (<a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). Cardiac and liver MRI, serum ferritin, complete blood count (CBC), liver enzymes and renal function tests were performed. Duration of follow‐up was not reported. The study was only reported as a conference abstract. </p> </section> <section id="CD007476-sec-0066"> <h5 class="title">8. Non‐transfusion‐dependent thalassaemia: deferasirox compared to placebo</h5> <p>One study included participants with non‐transfusion‐dependent thalassaemia with iron overload (<a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>). We identified no other RCT evaluating people with non‐transfusion‐dependent thalassaemia. A total of 166 individuals were randomised in a 2:1:2:1 ratio to starting doses of 5 or 10 mg/kg/day or matching placebos. The primary efficacy endpoint was the change in LIC during the 52‐week treatment duration. Secondary endpoints were change in serum ferritin, correlation of serum ferritin and LIC, AEs and adherence. The study lasted for one year and was published in two journal publications and six abstracts. </p> </section> </section> <section id="CD007476-sec-0067"> <h4 class="title">Excluded studies</h4> <section id="CD007476-sec-0068"> <h5 class="title">Updated searches</h5> <p>Several reports of the extension phases of studies were not included, since after completion of the core first year, cross‐over to deferasirox treatment took place during the extension phase (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>; <a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>). Therefore, data collected during the extension phase represent observational data on a large cohort of deferasirox‐treated individuals; there is no longer a comparison group and participants were not analysed according to their initially assigned group. Due to a high number of participants who did not continue in the deferoxamine treatment group after the core phase, the extension phase of the Pennell study was also excluded (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). </p> <p>Overall, the reasons for exclusion of 44 reports were:</p> <p> <ul id="CD007476-list-0016"> <li> <p>included people with disease other than thalassaemia (n = 3);</p> </li> <li> <p>included people with thalassaemia who had received curative stem cell transplantation (n = 5); </p> </li> <li> <p>review/other, no primary data containing articles (n = 3);</p> </li> <li> <p>intervention/comparison other than deferasirox (n = 2);</p> </li> <li> <p>pharmacokinetic studies (n = 2);</p> </li> <li> <p>non‐randomised data on participants with thalassaemia (n = 29)</p> </li> </ul> <ul class="plain" id="CD007476-list-0017"> <li> <ul id="CD007476-list-0018"> <li> <p>extension phases of core studies (n = 13)</p> </li> <li> <p>other non‐randomised data (n = 16).</p> </li> </ul> </li> </ul> </p> <section id="CD007476-sec-0069"> <h6 class="title">Previous searches:</h6> <p>256 references were excluded. Reasons for exclusion were:</p> <p> <ul id="CD007476-list-0019"> <li> <p>included people with disease other than thalassaemia</p> <ul id="CD007476-list-0020"> <li> <p>only sickle cell disease (n = 16)</p> </li> <li> <p>only myelodysplastic syndrome (n = 53)</p> </li> <li> <p>other condition (n = 9);</p> </li> </ul> </li> <li> <p>review article, editorial or comment (n = 49);</p> </li> <li> <p>intervention other than deferasirox (n = 2);</p> </li> <li> <p>cost‐effectiveness analysis (n = 8);</p> </li> <li> <p>non‐randomised data on people with thalassaemia (n = 119) (for selected references see <a href="./references#CD007476-sec-0158" title="">Characteristics of excluded studies</a>) </p> </li> </ul> <ul class="plain" id="CD007476-list-0021"> <li> <ul id="CD007476-list-0022"> <li> <p>EPIC study (n = 16)</p> </li> <li> <p>ESCALATOR study (n = 13)</p> </li> <li> <p>extension phases of core studies (n = 21)</p> </li> <li> <p>other non‐randomised data (n = 69).</p> </li> </ul> </li> </ul> </p> </section> </section> <section id="CD007476-sec-0070"> <h5 class="title">Studies awaiting classification and ongoing studies</h5> <p>Three studies identified through searches in electronic databases were classified as 'awaiting classification', because it was not clear if randomisation of participants really took place in two studies (<a href="./references#CD007476-bbs2-0045" title="HagagAA , HamamMA , TahaOA , HazaaSM . Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload. Infectious Disorders Drug Targets2015;15(2):98‐105. ">Hagag 2015</a>; <a href="./references#CD007476-bbs2-0043" title="AnsariS , Miri Ali AbadiG , AzarkeivanA . Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia major [abstract]. Haematologica2015;100 Suppl 1:595, Abstract no: E1484. [CENTRAL: 1098922; CRS: 5500135000001406] ">Ansari 2015</a>;) and the conference abstract of another study did not mention the number of included participants (<a href="./references#CD007476-bbs2-0047" title="KakkarS , SobtiPPC , KalraA . Efficacy and safety of deferasirox in single vs divided dosage in Thalassemic children. Haematologica2015;100 Suppl 1 785:PB2010. ">Kakkar 2015</a>). Authors of all studies were contacted for clarification; however, we have not yet received any further information. </p> <p>The searches in trial registers identified four ongoing studies (<a href="./references#CD007476-bbs2-0049" title="Sequential DFX‐DFP versus DFX or DFP multicentre randomised study. Ongoing study Date of first enrolment: 27/01/2010. ">Cutino 2009</a>; <a href="./references#CD007476-bbs2-0050" title="Efficacy and safety study to compare deferiprone versus deferasirox in paediatric patients. Ongoing study Date of first enrolment: 29/11/2012. ">DEEP‐2 2012</a>; <a href="./references#CD007476-bbs2-0051" title="Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film‐coated Tablet). Ongoing studyJuly 2014. ">NCT02125877</a>; <a href="./references#CD007476-bbs2-0052" title="Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2 ‐ &lt; 18 years old) With Iron Overload. Ongoing studySeptember 2015. ">NCT02435212</a>) as well as two unpublished completed studies (<a href="./references#CD007476-bbs2-0044" title="">EUCTR2010‐023217‐61‐GB</a>; <a href="./references#CD007476-bbs2-0048" title="">NCT02198508</a>). The Google search also revealed a registry entry of an RCT in the Iranian Registry of Clinical Trials, which met our inclusion criteria and was added as study awaiting classification <a href="./references#CD007476-bbs2-0046" title="">IRCT201110087677N1</a>). </p> <p>We contacted the investigators of unpublished completed studies (as far as contact addresses could be identified) to request information on study results. If these studies are published within two years of this update (as per the standard Cochrane updating guidelines), this will trigger an earlier update of this review. </p> </section> </section> </section> <section id="CD007476-sec-0071"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias for the 16 included studies in this review was classified as previously described (<a href="#CD007476-sec-0043">Assessment of risk of bias in included studies</a>). </p> <p>The three blinded studies comparing deferasirox to placebo were judged overall as having an 'unclear' risk of bias (<a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>; <a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>; <a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>). These assessments were mainly based on the inadequate reporting of several of the criteria that are considered to be important in the evaluation of methodological rigour in terms of study design and conduct. </p> <p>All other included studies were predominantly classified as having an overall 'high' risk of bias, mainly due selective reporting of secondary outcomes and lack of blinding. </p> <p>For further details see the risk of bias tables in <a href="./references#CD007476-sec-0157" title="">Characteristics of included studies</a>, the risk of bias graph (<a href="#CD007476-fig-0002">Figure 2</a>) and the risk of bias summary (<a href="#CD007476-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD007476-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007476-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD007476-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007476-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD007476-sec-0072"> <h4 class="title">Allocation</h4> <p>The methods to generate the allocation sequence were not described in 11 studies (<a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999;</a><a href="./references#CD007476-bbs2-0006" title="HabibianN . Comparison of therapeutic effect of osveral &amp; desferal in patients with thalassemia (bahonar hospital in karaj 2012‐13). Iranian Journal of Pediatrics2014;24(Suppl 2):S27. ">Habibian 2014</a>; <a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>; <a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>; <a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>; <a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>; <a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>; <a href="./references#CD007476-bbs2-0009" title="MolaviMA , DoozandehH , NazemiA , EvaziR , MansooriF . Comparison of therapeutic response and complications of oral Osveral and injection Desfereal chelating agent in patient with thalassemia major. Asian Journal of Medical and Pharmaceutical Researches2013;3(3):93‐7. ">Molavi 2013</a>; <a href="./references#CD007476-bbs2-0010" title="MolaviMA , PoorST , MalesksabetM . Combined Desferrioxamine (Desferal) and Deferasirox in children. Advances in Biological Research2014;8(4):171‐5. ">Molavi 2014</a>; <a href="./references#CD007476-bbs2-0012" title="PengP , LongLL , HuangZK , ZhangL , LiXH , FengX , et al. Comparison of deferasirox and deferoxamine treatment in iron‐overloaded patients: Liver iron concentration determined by quantitative MRI‐R2*. Chinese Journal of Radiology2013;47(1):55‐9. ">Peng 2013</a>; <a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>). Three studies used computer‐generated randomisation sequences and were therefore assessed as low risk of bias (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>; <a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>; <a href="./references#CD007476-bbs2-0015" title="MattiM . Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013. SanjeevaGN , NijagunaN , MattiM , ChebbiPG . Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. Journal of of Evolution of Medical and Dental Sciences2015;4(24):4178‐85. [DOI: 10.14260/jemds/2015/601] ">Sanjeeva 2015</a>). One study used a "validated system that generates an automated random assignment of numbers to treatment groups" (<a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>). One study described randomisation based on permuted blocks which was considered as low risk of bias (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). </p> <p>Since no details were given in the reports with regard to allocation concealment, it remains unclear whether allocation concealment was achieved in 12 studies (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>; <a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>; <a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>; <a href="./references#CD007476-bbs2-0006" title="HabibianN . Comparison of therapeutic effect of osveral &amp; desferal in patients with thalassemia (bahonar hospital in karaj 2012‐13). Iranian Journal of Pediatrics2014;24(Suppl 2):S27. ">Habibian 2014</a>; <a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>; <a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>; <a href="./references#CD007476-bbs2-0009" title="MolaviMA , DoozandehH , NazemiA , EvaziR , MansooriF . Comparison of therapeutic response and complications of oral Osveral and injection Desfereal chelating agent in patient with thalassemia major. Asian Journal of Medical and Pharmaceutical Researches2013;3(3):93‐7. ">Molavi 2013</a>; <a href="./references#CD007476-bbs2-0010" title="MolaviMA , PoorST , MalesksabetM . Combined Desferrioxamine (Desferal) and Deferasirox in children. Advances in Biological Research2014;8(4):171‐5. ">Molavi 2014</a>; <a href="./references#CD007476-bbs2-0012" title="PengP , LongLL , HuangZK , ZhangL , LiXH , FengX , et al. Comparison of deferasirox and deferoxamine treatment in iron‐overloaded patients: Liver iron concentration determined by quantitative MRI‐R2*. Chinese Journal of Radiology2013;47(1):55‐9. ">Peng 2013</a>; <a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a><a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>; <a href="./references#CD007476-bbs2-0015" title="MattiM . Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013. SanjeevaGN , NijagunaN , MattiM , ChebbiPG . Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. Journal of of Evolution of Medical and Dental Sciences2015;4(24):4178‐85. [DOI: 10.14260/jemds/2015/601] ">Sanjeeva 2015</a>). One study reported using sealed envelopes but it was unclear if these were opaque and numbered (<a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>). Three studies were assessed as low risk of bias regarding allocation concealment. One Elalfy study used opaque and numbered sealed envelopes (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>), a second ensured allocation concealment through assigning participants to treatment groups by telephone contact from the co‐ordinating centre (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>). In one study the investigator had to contact an interactive voice system to obtain the linked randomisation number (<a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>). </p> </section> <section id="CD007476-sec-0073"> <h4 class="title">Blinding</h4> <p>Blinding was done in the three placebo‐controlled studies (<a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>; <a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>; <a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>), although in the Taher study blinding with regard to the different doses used was not done (<a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>). </p> <p>The remaining 12 studies were open‐label, the reason being the obvious difference in application mode, deferasirox and deferiprone being orally taken, while deferoxamine needs to be applied subcutaneously over several hours and the different frequency of intake regarding both oral iron chelators. One study reported that "patients, physicians, laboratory staff and the epidemiologist who analysed the data were not aware of the intervention for each group" (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>). However, no placebo treatment was mentioned, so we assumed that no adequate blinding took place. </p> </section> <section id="CD007476-sec-0074"> <h4 class="title">Incomplete outcome data</h4> <p>Since the Cappellini and Pennell studies were planned as non‐inferiority studies, efficacy data were not consistently reported on an ITT basis (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>; <a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). In the Pennell study, the provided ITT analysis did not include all randomised participants (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). Two studies did not address how many participants reached the end of the study (<a href="./references#CD007476-bbs2-0006" title="HabibianN . Comparison of therapeutic effect of osveral &amp; desferal in patients with thalassemia (bahonar hospital in karaj 2012‐13). Iranian Journal of Pediatrics2014;24(Suppl 2):S27. ">Habibian 2014</a>; <a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). One study reported three dropouts due to AEs; a per protocol analysis was done for most of the outcomes, which was assessed as having a high risk of bias (<a href="./references#CD007476-bbs2-0015" title="MattiM . Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013. SanjeevaGN , NijagunaN , MattiM , ChebbiPG . Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. Journal of of Evolution of Medical and Dental Sciences2015;4(24):4178‐85. [DOI: 10.14260/jemds/2015/601] ">Sanjeeva 2015</a>). One of the Elalfy studies reported discontinuing participants in an abstract publication, whereas in a later full publication, all participants apparently reached the end of the study (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>). One study reported that "efficacy was assessed for the full analysis set (all randomised patients)" in the journal publication, but the data set on clinicaltrials.gov states a lower number of analysed participants (<a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>). The author confirmed that the change could only be calculated for participants with both a baseline and at least one post‐baseline value. The remaining nine studies fully reported or addressed adequately incomplete outcome data (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>; <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>; <a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>; <a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>; <a href="./references#CD007476-bbs2-0009" title="MolaviMA , DoozandehH , NazemiA , EvaziR , MansooriF . Comparison of therapeutic response and complications of oral Osveral and injection Desfereal chelating agent in patient with thalassemia major. Asian Journal of Medical and Pharmaceutical Researches2013;3(3):93‐7. ">Molavi 2013</a>; <a href="./references#CD007476-bbs2-0010" title="MolaviMA , PoorST , MalesksabetM . Combined Desferrioxamine (Desferal) and Deferasirox in children. Advances in Biological Research2014;8(4):171‐5. ">Molavi 2014</a>; <a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>; <a href="./references#CD007476-bbs2-0012" title="PengP , LongLL , HuangZK , ZhangL , LiXH , FengX , et al. Comparison of deferasirox and deferoxamine treatment in iron‐overloaded patients: Liver iron concentration determined by quantitative MRI‐R2*. Chinese Journal of Radiology2013;47(1):55‐9. ">Peng 2013</a>; <a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>). </p> </section> <section id="CD007476-sec-0075"> <h4 class="title">Selective reporting</h4> <p>Only one study was assessed as low risk of bias regarding selective reporting (<a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>). Data on a broad spectrum of AEs were usually collected. However, only limited AE data were reported, often only qualitatively. Commonly, laboratory parameters were apparently measured but not reported. However, end of study results for the primary outcome were reported in all studies. </p> <p>Evidence of publication bias could not be detected.</p> </section> <section id="CD007476-sec-0076"> <h4 class="title">Other potential sources of bias</h4> <p>Four studies were assessed as unclear, because no or limited information on baseline characteristics was provided (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>; <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>; <a href="./references#CD007476-bbs2-0006" title="HabibianN . Comparison of therapeutic effect of osveral &amp; desferal in patients with thalassemia (bahonar hospital in karaj 2012‐13). Iranian Journal of Pediatrics2014;24(Suppl 2):S27. ">Habibian 2014</a>; <a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). </p> <section id="CD007476-sec-0077"> <h5 class="title">Support and sponsorship</h5> <p>Six studies were conducted with support and involvement of the producer of deferasirox (Novartis) (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>; <a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>; <a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>; <a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>; <a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>; <a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>). Also, many authors of these studies were affiliated with Novartis. The relevance of these conflicts of interest is open to interpretation. Four studies declared to have no conflicts of interest (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>; <a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>; <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>; <a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>), whereas conflicts of interest were not reported at all in five other studies (<a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>; <a href="./references#CD007476-bbs2-0015" title="MattiM . Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013. SanjeevaGN , NijagunaN , MattiM , ChebbiPG . Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. Journal of of Evolution of Medical and Dental Sciences2015;4(24):4178‐85. [DOI: 10.14260/jemds/2015/601] ">Sanjeeva 2015</a>; <a href="./references#CD007476-bbs2-0009" title="MolaviMA , DoozandehH , NazemiA , EvaziR , MansooriF . Comparison of therapeutic response and complications of oral Osveral and injection Desfereal chelating agent in patient with thalassemia major. Asian Journal of Medical and Pharmaceutical Researches2013;3(3):93‐7. ">Molavi 2013</a>; <a href="./references#CD007476-bbs2-0010" title="MolaviMA , PoorST , MalesksabetM . Combined Desferrioxamine (Desferal) and Deferasirox in children. Advances in Biological Research2014;8(4):171‐5. ">Molavi 2014</a>; <a href="./references#CD007476-bbs2-0006" title="HabibianN . Comparison of therapeutic effect of osveral &amp; desferal in patients with thalassemia (bahonar hospital in karaj 2012‐13). Iranian Journal of Pediatrics2014;24(Suppl 2):S27. ">Habibian 2014</a> ). One study was funded by a public grant (<a href="./references#CD007476-bbs2-0012" title="PengP , LongLL , HuangZK , ZhangL , LiXH , FengX , et al. Comparison of deferasirox and deferoxamine treatment in iron‐overloaded patients: Liver iron concentration determined by quantitative MRI‐R2*. Chinese Journal of Radiology2013;47(1):55‐9. ">Peng 2013</a>). </p> </section> </section> </section> <section id="CD007476-sec-0078"> <h3 class="title" id="CD007476-sec-0078">Effects of interventions</h3> <p>See: <a href="./full#CD007476-tbl-0001"><b>Summary of findings for the main comparison</b> Deferasirox compared to deferoxamine in people with transfusion‐dependent thalassemia</a>; <a href="./full#CD007476-tbl-0002"><b>Summary of findings 2</b> Deferasirox compared to deferiprone in people with transfusion‐dependent thalassemia</a>; <a href="./full#CD007476-tbl-0003"><b>Summary of findings 3</b> Deferasirox alone compared to combined deferasirox and deferiprone in people with transfusion‐dependent thalassemia</a>; <a href="./full#CD007476-tbl-0004"><b>Summary of findings 4</b> Combined deferasirox and deferiprone compared to deferiprone alone in people with transfusion‐dependent thalassemia</a>; <a href="./full#CD007476-tbl-0005"><b>Summary of findings 5</b> Deferasirox and deferoxamine compared to deferoxamine in people with transfusion‐dependent thalassemia</a>; <a href="./full#CD007476-tbl-0006"><b>Summary of findings 6</b> Deferasirox and deferiprone compared to deferiprone and deferoxamine in people with transfusion‐dependent thalassemia</a>; <a href="./full#CD007476-tbl-0007"><b>Summary of findings 7</b> Deferasirox compared to placebo in people with non‐transfusion‐dependent thalassemia</a> </p> <section id="CD007476-sec-0079"> <h4 class="title">1. Transfusion‐dependent thalassaemia: deferasirox compared to placebo</h4> <p>Two studies compared deferasirox to placebo (<a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>; <a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>). Due to both its design and the presentation of results in the paper, data could not be extracted quantitatively from the Galanello study (<a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>). Regarding safety data, it was not clear whether participants contributed more than one episode to the count of one AE (such as headache) since safety parameters were assessed after each dose. So, a single participant could theoretically contribute more than one episode of an event such as headache. For this reason, we do not present these data in a forest plot. We have contacted the authors but have not yet been able to clarify all details. Therefore, we decided to report important information in a narrative manner as done by Galanello (<a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>). </p> <section id="CD007476-sec-0080"> <h5 class="title">Primary outcomes  </h5> <section id="CD007476-sec-0081"> <h6 class="title">1. Overall mortality measured at any point in time</h6> <p>No deaths were observed during these two short‐term studies (47 participants) (<a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>; <a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>) (<a href="./references#CD007476-fig-0004" title="">Analysis 1.1</a>). </p> </section> </section> <section id="CD007476-sec-0082"> <h5 class="title">Secondary outcomes  </h5> <section id="CD007476-sec-0083"> <h6 class="title">1. Reduced end‐organ damage due to iron deposition</h6> <p>No data on end‐organ damage were available from either study.</p> </section> <section id="CD007476-sec-0084"> <h6 class="title">2. Measures of iron overload</h6> <p>Efficacy was not a focus of the Galanello study and no consistent trend on serum iron and transferrin could be observed (as expected after single‐dose administration) (<a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>). Other measures of efficacy were not reported. </p> <p>For the Nisbet‐Brown study, ferritin levels were reported at baseline and end of study for each group (<a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>). However, since no SD was given for mean change of ferritin and since we were unable to obtain these data from the authors, the mean ferritin levels (µg/L) and SDs at baseline and end of study are presented here (as reported in the primary study): </p> <p> <div class="table" id="CD007476-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum ferritin (mean (SD) [µg/L])</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10 mg/day</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20 mg/day</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>40 mg/day</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4265 (3882)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2452 (869)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4753 (3168)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2644 (1320)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5215 (5430)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2344 (1606)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4872 (2511)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1756 (793)</p> </td> </tr> </tbody> </table> </div> </p> <p>We decided against estimating SDs because imputation from another study would require studies similar in design and conduct which are not available (due to the fact that we are dealing here with an early phase dose escalation study). We decided against use of post‐treatment values only, since there were large, clinically relevant differences between groups at baseline due to small sample size despite randomisation. </p> </section> <section id="CD007476-sec-0085"> <h6 class="title">3. Measures of iron excretion (urine and faeces) over 24 hours (mg/kg/day)</h6> <p>In the Galanello study, the authors note that the majority of iron is excreted in the faeces; however, data are only given for urinary iron excretion (<a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>). These data are presented as urinary iron excretion over 24‐hour intervals for each dose. To minimize the influence of outliers, medians and ranges are given (see table). </p> <p> <div class="table" id="CD007476-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Iron excretion over 24 hours: median (range) (mg/kg/24 hours)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 mg deferasirox</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 mg deferasirox</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 mg deferasirox</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg deferasirox</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mg deferasirox</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 mg deferasirox</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.017</p> <p>(0.006 ‐ 0.629)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.009</p> <p>(0.005 ‐ 0.031)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.010</p> <p>(0.006 ‐ 0.028)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.010</p> <p>(0.004 ‐ 0.014)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.016</p> <p>(0.006 ‐ 0.119)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.193</p> <p>(0.053 ‐ 0.508)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.391</p> <p>(0.121 ‐ 0.842)</p> </td> </tr> </tbody> </table> </div> </p> <p>Therefore, we were unable to extract these data to include them in the RevMan graphs. We are trying to obtain additional data on faecal iron excretion. </p> <p>The Nisbet‐Brown study measured net iron excretion (<a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>). Since the actual data were not given in the publications and we have not received these from the authors, we estimated the values from the figures of the paper and performed an analysis of variance for the three dose groups using the placebo group as reference (Software: R). The mean and SE (mg Fe/kg/day) are 0.03 (0.10) for placebo, 0.12 (0.14) for 10 mg/day deferasirox, 0.31 (0.14) for 20 mg/day and 0.47 (0.13) for 40 mg/day. </p> </section> <section id="CD007476-sec-0086"> <h6 class="title">4. Any adverse events</h6> <p>Galanello reported that "Adverse events were infrequent and of mild intensity. The most frequently reported adverse event was headache, with no association to the dose level (four participants at 2.5 mg/kg, one participant at 20 mg/kg, and one participant at placebo). Nausea and diarrhoea occurred in the 80‐mg/kg group only (three of eight participants, all from one centre), suggesting that these symptoms were either drug related or possibly related to the dense oral suspension administered. Single occurrences of influenza, joint pain, and vertigo were not dose associated and were not suspected to be drug related. No consistent effect on individual laboratory values was observed. In single cases, hematological, biochemical, and special kidney parameters were outside the normal range, including at baseline, but no correlation with treatment could be observed. Notable parameters outside the normal ranges (and order of magnitude) were as follows: bilirubin, alanine aminotransferase, and aspartate aminotransferase (up to 1.5‐ to 3‐fold increase); alkaline phosphatase (up to 1.5‐fold increase); and creatinine kinase (0.3‐ to 0.6‐fold decrease). A couple of creatinine values were just below the normal ranges (with the exception of a single value observed at screening, which was below the lower limit by a factor of 0.8). Abnormally low hematocrit, haemoglobin, and erythrocytes were frequent but had no association to the dose level, while other hematological parameters were abnormally high, such as platelet, eosinophils, lymphocytes, monocytes, and neutrophils, with an order of magnitude of 1.2 to 1.5. These findings are suspected to be caused by the underlying disease and by frequent blood sampling during the study. As expected in this study population, all patients had elevated ferritin values prior to the study, ranging from 1422 to 4780 ng/mL. No notable change in the levels of the trace elements was observed (zinc, copper, magnesium, and calcium). Among the special kidney function parameters, values of α‐glutathione‐S‐transferase and β2‐ microglobulin were in single instances above the range of the normal values by a factor of 2‐ to 5‐fold (including at baseline) and, in the extreme case, by a factor of more than 10‐ and 30‐fold, respectively, for each parameter. The urinalysis sometimes showed pH values up to 6.5 to 7, as well as traces of urine bilirubin, glucose, ketones, leukocytes, and protein." (<a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>). </p> <p>Some data reported by Nisbet‐Brown regarding AEs (23 participants) (<a href="./references#CD007476-fig-0005" title="">Analysis 1.2</a>) could be extracted (<a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>). Other safety and tolerability data are only available descriptively. </p> <p>"No clinically relevant changes in any safety variable were seen between ICL670 and placebo groups. Specifically, no relevant changes were reported in haematological variables, mean concentrations of serum calcium, phosphorus, magnesium, uric acid, creatinine, urea nitrogen, albumin, creatine kinase, triglycerides, or total cholesterol. No abnormalities of renal sediment were noted. Further, no relevant changes from baseline in electrocardiographic, audiometric, or ophthalmologic examinations were noted, with the exception of one patient in whom a myelinated fibre bundle or retinal infarct was seen after seven days of treatment with ICL670 at 20 mg kg<sup>–1</sup> day<sup>–1</sup>. This patient was reviewed by an independent ophthalmologist, and the change was thought to be secondary to his underlying diabetes mellitus. No significant changes between ICL670 and placebo were seen in copper or zinc concentrations in blood over the study period, indicating thus that ICL670 was highly selective for iron." (<a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>). </p> </section> <section id="CD007476-sec-0087"> <h6 class="title">5. Participant satisfaction and adherence</h6> <p>Only data on discontinuations due to serious adverse events could be extracted (<a href="./references#CD007476-fig-0006" title="">Analysis 1.3</a>). Nisbet‐Brown reported that nine participants in total discontinued treatment for serious AEs, eight of which where receiving deferasirox (24 participants) (<a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>) (<a href="./references#CD007476-fig-0006" title="">Analysis 1.3</a>). However, two participants did not complete a single treatment day and only three discontinuations due to rash were deemed to be drug‐related. </p> </section> <section id="CD007476-sec-0088"> <h6 class="title">6. Cost of intervention per year</h6> <p>No data on costs of intervention were available from either study (<a href="./references#CD007476-bbs2-0005" title="GalanelloR , PigaA , AlbertiD , RouanMC , BiglerH , SechaudR . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron‐chelating agent in patients with transfusion‐dependent iron overload due to beta‐thalassemia. Journal of Clinical Pharmacology2003;43(6):565‐72. PigaA , GalanelloR , DessiC , SedaroM , LoehrerF , SchaudR , et al. A novel oral iron chelator (ICL670A): results of a phase I single‐dose safety study. Blood1999;10(Suppl 1 Pt 2):35b. ">Galanello 1999</a>; <a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>). </p> <p><b>7. Other additional outcomes</b> </p> <p>No other additional outcomes were reported.</p> </section> </section> </section> <section id="CD007476-sec-0089"> <h4 class="title">2. Transfusion‐dependent thalassaemia: deferasirox compared to deferoxamine</h4> <p>Seven studies compared deferasirox to deferoxamine (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>; <a href="./references#CD007476-bbs2-0006" title="HabibianN . Comparison of therapeutic effect of osveral &amp; desferal in patients with thalassemia (bahonar hospital in karaj 2012‐13). Iranian Journal of Pediatrics2014;24(Suppl 2):S27. ">Habibian 2014</a>; <a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>; <a href="./references#CD007476-bbs2-0009" title="MolaviMA , DoozandehH , NazemiA , EvaziR , MansooriF . Comparison of therapeutic response and complications of oral Osveral and injection Desfereal chelating agent in patient with thalassemia major. Asian Journal of Medical and Pharmaceutical Researches2013;3(3):93‐7. ">Molavi 2013</a>; <a href="./references#CD007476-bbs2-0012" title="PengP , LongLL , HuangZK , ZhangL , LiXH , FengX , et al. Comparison of deferasirox and deferoxamine treatment in iron‐overloaded patients: Liver iron concentration determined by quantitative MRI‐R2*. Chinese Journal of Radiology2013;47(1):55‐9. ">Peng 2013</a>; <a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>; <a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>). Two additional studies compared all three iron chelators (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>; <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). To include data in the comparison of deferasirox and deferoxamine as well as deferasirox and deferiprone, the number of participants in the deferasirox group was split for each comparison. </p> <p>While mainly earlier studies which specified the treatment used lower deferasirox doses (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>: 5 to 30 mg/kg/day, <a href="./references#CD007476-bbs2-0009" title="MolaviMA , DoozandehH , NazemiA , EvaziR , MansooriF . Comparison of therapeutic response and complications of oral Osveral and injection Desfereal chelating agent in patient with thalassemia major. Asian Journal of Medical and Pharmaceutical Researches2013;3(3):93‐7. ">Molavi 2013</a>: 20 mg/kg/day, <a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>: 10 or 20 mg/kg/day, <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>: 25 mg/kg/day), newer studies extended the upper limit of doses to 40 mg/kg/day (<a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>: 20 to 40 mg/kg/day, <a href="./references#CD007476-bbs2-0012" title="PengP , LongLL , HuangZK , ZhangL , LiXH , FengX , et al. Comparison of deferasirox and deferoxamine treatment in iron‐overloaded patients: Liver iron concentration determined by quantitative MRI‐R2*. Chinese Journal of Radiology2013;47(1):55‐9. ">Peng 2013</a>: 40 mg/kg/day, <a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>: 40 mg/kg/day). Higher doses might affect safety and cause higher costs. </p> <p>For the Cappellini study, discrepancies between those who discontinued (n = 29) or those who died (n = 4), who were not included in the primary efficacy population (n = 33) and those who did not complete one year of study (n = 45 according to the primary report and n = 29 according to the report on patient‐reported outcomes) were not clearly addressed (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>). The success rate analysis (<a href="./references#CD007476-fig-0022" title="">Analysis 2.16</a>) was based on the primary efficacy population (n = 553), while changes in ferritin were based on n = 563 (<a href="./references#CD007476-fig-0016" title="">Analysis 2.10</a>), and both changes in LIC and iron excretion to intake ratio were based on those only who compared one year of study (n = 541) (per protocol analysis) (<a href="./references#CD007476-fig-0020" title="">Analysis 2.14</a>; <a href="./references#CD007476-fig-0026" title="">Analysis 2.20</a>). In the Elalfy study, participants were randomised twice: to three iron chelators and to treatment with vitamin C or no treatment with vitamin C, but results are only reported for those who received vitamin C (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). </p> <section id="CD007476-sec-0090"> <h5 class="title">Primary outcomes  </h5> <section id="CD007476-sec-0091"> <h6 class="title">1. Overall mortality measured at any point in time</h6> <p>Mortality was reported in eight studies (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>; <a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>; <a href="./references#CD007476-bbs2-0009" title="MolaviMA , DoozandehH , NazemiA , EvaziR , MansooriF . Comparison of therapeutic response and complications of oral Osveral and injection Desfereal chelating agent in patient with thalassemia major. Asian Journal of Medical and Pharmaceutical Researches2013;3(3):93‐7. ">Molavi 2013</a>; <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>; <a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>; <a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>; <a href="./references#CD007476-bbs2-0012" title="PengP , LongLL , HuangZK , ZhangL , LiXH , FengX , et al. Comparison of deferasirox and deferoxamine treatment in iron‐overloaded patients: Liver iron concentration determined by quantitative MRI‐R2*. Chinese Journal of Radiology2013;47(1):55‐9. ">Peng 2013</a>; <a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>). <a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a> reported mortality for both 10 and 20 mg/kg/day subgroups.There was no significant difference in mortality observed; data were pooled despite range from eight months to two years (1170 participants) (<a href="./references#CD007476-fig-0007" title="">Analysis 2.1</a>). However, the number of participants and in particular the number of events was limited. Cappellini reported that all four deaths were felt to be unrelated to the administration of the study drug by the independent Program Safety Board (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>) (<a href="./references#CD007476-fig-0007" title="">Analysis 2.1</a>). </p> </section> </section> <section id="CD007476-sec-0092"> <h5 class="title">Secondary outcomes  </h5> <section id="CD007476-sec-0093"> <h6 class="title">1. Reduced end‐organ damage due to iron deposition</h6> <p>One study assessed LVEF (%) (172 participants) (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>) (<a href="./references#CD007476-fig-0008" title="">Analysis 2.2</a>). Data for mean change from baseline was extracted from clinicaltrials.gov as least squares mean and SEM, SD was calculated. LVEF remained stable in both groups, showing no significant difference between both groups after one year. No significant difference was also seen in the number of individuals for both subgroups with improvement from abnormal LVEF at baseline to normal range (21 participants) (<a href="./references#CD007476-fig-0009" title="">Analysis 2.3</a>) and from normal LVEF at baseline to below lower limit of normal at end of study (151 participants) (<a href="./references#CD007476-fig-0009" title="">Analysis 2.3</a>). </p> <p>The incidence of thyroid disease was assessed in one study (19 participants) (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>) (<a href="./references#CD007476-fig-0010" title="">Analysis 2.4</a>). No difference was observed after two years of treatment, but the included population was very small. </p> <p>Two studies reported detailed information on ALT levels and creatinine clearance (<a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>; <a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). Overall mean (SD) ALT levels had decreased in both treatment groups after one year (deferasirox: ‐3.5 (80.4) U/L; deferoxamine: ‐18.9 (35.5) U/L) in the Pennell study, but due to missing number of included participants, we were not able to include these data in our meta‐analysis (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). Among participants with abnormal baseline ALT, levels had improved to within the normal range in a similar number of participants in both groups (119 participants) (<a href="./references#CD007476-fig-0011" title="">Analysis 2.5</a>). In the Hassan study, AST (U/L) and ALT (U/L) levels were significantly different at end of study (<a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>), but values were already significant different at baseline. While ALT levels increased (60 participants), AST levels decreased in both treatment groups (60 participants) during the study (<a href="./references#CD007476-fig-0012" title="">Analysis 2.6</a>; <a href="./references#CD007476-fig-0013" title="">Analysis 2.7</a>). Another study reported, that 32% of participants had increased ALT at baseline, but most participants had normal AST at baseline (<a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>). The authors assume liver damage due to chronic viral hepatitis and/or iron overload. No participant had consistent or progressive elevations in transaminase levels during the study. </p> <p>Hassan reported serum creatinine at end of study (<a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>). The difference between both treatment groups was not significantly different (60 participants) (<a href="./references#CD007476-fig-0014" title="">Analysis 2.8</a>). In the Pennell study, mean (SD) creatinine clearance had decreased in both groups after one year of treatment (deferasirox: ‐37.0 (42.9) mL/min; deferoxamine: ‐23.1 (36.6) mL/min), but the number of included participants was not mentioned (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). One study reported, that blood urea was significantly higher in the deferasirox group at end of study (60 participants), MD 7.10 (95% CI 4.01 to 10.19) (<a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>) (<a href="./references#CD007476-fig-0015" title="">Analysis 2.9</a>). </p> </section> <section id="CD007476-sec-0094"> <h6 class="title">2. Measures of iron overload</h6> <section id="CD007476-sec-0095"> <p><b>a. Serum ferritin concentration</b></p> <p>In the Cappellini study the mean ratio of deferasirox to deferoxamine varied between the predefined subgroups according to iron overload measures at baseline and different effects were seen in the different subgroups accordingly (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>). Data from Cappellini showed a clear dose‐response effect for serum ferritin levels (<a href="./references#CD007476-fig-0016" title="">Analysis 2.10</a>). At a ratio of less than 1:2.2 of deferasirox to deferoxamine, the latter was statistically more effective; similar efficacy was achieved only in the highly iron‐overloaded subgroup at a mean ratio of 1:1.8. </p> <p>One study reported serum ferritin as mean change from baseline (<a href="./references#CD007476-bbs2-0009" title="MolaviMA , DoozandehH , NazemiA , EvaziR , MansooriF . Comparison of therapeutic response and complications of oral Osveral and injection Desfereal chelating agent in patient with thalassemia major. Asian Journal of Medical and Pharmaceutical Researches2013;3(3):93‐7. ">Molavi 2013</a>). For the following studies we used the methods as described by Wan to calculate the means and SDs for our analysis (<a href="./references#CD007476-bbs2-0131" title="WanX , WangW , LiuJ , TongT . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology2014;19(14):135. ">Wan 2014</a>). One study reported median change and range (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). The Peng study reported median and range at end of the study; additionally Z values for change from baseline were given for both treatment groups, so we were able to calculate change from baseline values (<a href="./references#CD007476-bbs2-0012" title="PengP , LongLL , HuangZK , ZhangL , LiXH , FengX , et al. Comparison of deferasirox and deferoxamine treatment in iron‐overloaded patients: Liver iron concentration determined by quantitative MRI‐R2*. Chinese Journal of Radiology2013;47(1):55‐9. ">Peng 2013</a>). A further study reported median and interquartile ranges at end of study (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). A sixth study reported median and range at end of study; due to a given P value for change from baseline (P &lt; 0.001), SD for change from baseline could be calculated (<a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>). </p> <p>Combined evidence from the meta‐analysis of all six studies showed a significant difference between treatment arms, favouring deferoxamine, MD 454.42 (95% CI 337.13 to 571.71) (1002 participants) (<a href="./references#CD007476-fig-0016" title="">Analysis 2.10</a>). Heterogeneity was very high (I² = 92%), likely due to different baseline iron overload and different chelation doses. Using the random‐effects model, results remained statistically significant, MD 743.14 (95% CI 263.18 to 1223.09). </p> <p>A sensitivity analysis was undertaken for serum ferritin without all values which were calculated according to Wan (<a href="./references#CD007476-bbs2-0131" title="WanX , WangW , LiuJ , TongT . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology2014;19(14):135. ">Wan 2014</a>) (701 participants) (<a href="./references#CD007476-fig-0017" title="">Analysis 2.11</a>). The results of the Cappellini and Molavi studies were pooled and remained statistically significant, favouring deferoxamine, MD 418.94 (95% CI 297.23 to 540.65) (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>; <a href="./references#CD007476-bbs2-0009" title="MolaviMA , DoozandehH , NazemiA , EvaziR , MansooriF . Comparison of therapeutic response and complications of oral Osveral and injection Desfereal chelating agent in patient with thalassemia major. Asian Journal of Medical and Pharmaceutical Researches2013;3(3):93‐7. ">Molavi 2013</a>). </p> <p>In the Piga study, data for serum ferritin are presented only in a figure giving means and SDs at various time points; since no information was given with regard to change in mean serum ferritin with respective SDs, we were unable to extract data on ferritin (<a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>). In the Chirico study, data on serum ferritin could not be extracted as it was unclear if mean or median, range or interquartile range were reported (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>). The authors stated, that they did not find statistical differences between serum ferritin changes in all treatment groups after therapy. Although Habibian measured serum ferritin, no data were presented that would allow for inclusion in our meta‐analysis (<a href="./references#CD007476-bbs2-0006" title="HabibianN . Comparison of therapeutic effect of osveral &amp; desferal in patients with thalassemia (bahonar hospital in karaj 2012‐13). Iranian Journal of Pediatrics2014;24(Suppl 2):S27. ">Habibian 2014</a>). The authors reported that "mean ferritin level was alike between two groups except for third month follow up that was significantly higher in Osveral<sup>®</sup> group (P &lt; 0.03)." Data from Elalfy were only available for half of the participants receiving adjuvant vitamin C, but data on participants without vitamin C supplementation was missing and could not be included in our meta‐analysis (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). The author only describes that serum ferritin was significant improved in iron chelation subgroups receiving vitamin C compared to those receiving no vitamin C. </p> </section> <section id="CD007476-sec-0096"> <p><b>b. Liver iron concentration (LIC)</b></p> <p>LIC was measured in one study (<a href="./references#CD007476-bbs2-0012" title="PengP , LongLL , HuangZK , ZhangL , LiXH , FengX , et al. Comparison of deferasirox and deferoxamine treatment in iron‐overloaded patients: Liver iron concentration determined by quantitative MRI‐R2*. Chinese Journal of Radiology2013;47(1):55‐9. ">Peng 2013</a>) by R2* after 12 months of treatment (24 participants) (<a href="./references#CD007476-fig-0018" title="">Analysis 2.12</a>). Based on given median and range at end of study, mean and SD could be calculated as stated in our methods. Due to given Z values for change from baseline, mean change and SDs could be calculated. No significant difference was observed, but the study included only a small population of 24 participants. </p> <p>Change in LIC measured by MRI (R2) was significantly different favouring deferoxamine in one study (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). Elalfy also presented MRI R2* measurements at end of study for those participants receiving vitamin C, (SDs for change could be calculated from P values (both given as &lt; 0.001)), but no difference in LIC was observed between both groups (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). When data from the two studies were pooled, the change in LIC was not significantly different between the two groups, but heterogeneity was very high (I² = 79%) (217 participants) (<a href="./references#CD007476-fig-0019" title="">Analysis 2.13</a>). No significant difference was observed when the analysis was repeated using the random effects model. In the Elalfy study, data for the iron chelation subgroups not receiving vitamin C were not given, but the author describes that LIC was significantly improved compared to those who didn't receive vitamin C (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). </p> <p>In most participants in the Cappellini study, the LIC was measured by biopsy (n = 454) and only in a minority by SQUID (n = 87) (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>). According to the authors, SQUID measurement underestimated LIC; however, since this applies to both groups and data were not completely given for all relevant outcomes, we did not examine these data for the subgroups separately, but rather decided to extract the data on LIC for the combined group measured by either biopsy or SQUID (<a href="./references#CD007476-fig-0020" title="">Analysis 2.14</a>). At a ratio of 1:1.8 deferasirox showed a significantly better efficacy than deferoxamine in the subgroup of highly iron‐overloaded people, while deferoxamine showed higher efficacy in the other three subgroups at ratios of 1:2.2, 1:3.6 and 1:5.5 (541 participants), MD 2.37 (95% CI 1.68 to 3.07) (<a href="./references#CD007476-fig-0020" title="">Analysis 2.14</a>). For both drugs a clear dose‐effect relation was shown. The primary objective of the Cappellini study was to investigate if deferasirox is non‐inferior to deferoxamine regarding success rate in LIC (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>). Across all dose groups, non‐inferiority was not achieved, because the lower limit of the 95% CI was less than ‐15% (predefined by authors, less conservative than our definition of non‐inferiority). </p> <p>Two studies also did special responder analysis (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>; <a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>). Responder‐definition varied between the studies (decrease in LIC more than 10% in the Piga study (67 participants) (non‐significant result) (<a href="./references#CD007476-fig-0021" title="">Analysis 2.15</a>). The Cappellini study (553 participants) used a definition of LIC ranging from 1 to less than 7 mg Fe/g dry weight after one year, significantly favouring deferoxamine, RR 0.80 (95% CI 0.69 to 0.92) (<a href="./references#CD007476-fig-0022" title="">Analysis 2.16</a>). </p> <p>Results for mean change in LIC could not be included in the analysis from the Piga study due to missing SDs (<a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>). However, results for mean change in LIC were reported: ‐0.4 mg Fe/g dry weight for the 10 mg/kg/day deferasirox dose group, ‐2.1 mg Fe/g dry weight for the 20 mg/kg/day dose group and ‐2.0 mg Fe/g dry weight for the 40 mg/kg/day deferoxamine group. </p> </section> <section id="CD007476-sec-0097"> <p><b>c. Myocardial iron concentration</b></p> <p>Two studies measured cardiac T2* (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>; <a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). </p> <p>One study measured myocardial T2* after one year of treatment (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). Results are presented as geometric means and coefficients of variance (%) for both groups in the journal publication, so it was not possible to calculate means and SDs for inclusion in our meta‐analysis. Efficacy is reported as ratio of the Gmeans of deferasirox versus deferoxamine. For the ITT‐population, which only included 180 of 197 randomised participants, the ratio was 1.055 (repeated 95% CI, 0.999 to 1.129). Analysing the per protocol population, a ratio of 1.056 (repeated 95% CI, 0.998 to 1.133) was calculated. Both analyses showed no significant difference between the two treatment arms. The Pennell study was designed as a non‐inferiority study regarding myocardial iron removal (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). The authors defined a non‐inferiority margin of 90% (as we did in our review). The results for myocardial T2* revealed that the lower bound of the 95% CI was greater than prespecified margin of 0.9, which demonstrated non‐inferiority of deferasirox compared to deferoxamine. </p> <p>The second study reported myocardial T2* for participants receiving vitamin C also after one year (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). We were able to calculate the change from baseline due to given P values for change from baseline. Meta‐analysis revealed no significant difference between the two groups (<a href="./references#CD007476-fig-0023" title="">Analysis 2.17</a>, 45 participants). In the Elalfy study, data are not given for participants not receiving vitamin C, but the author describes that cardiac MRI T2* was increased compared to groups not receiving vitamin C (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). </p> <p>The Pennell study authors derived myocardial iron concentration from myocardial T2* values based on a formula described by Carpenter (<a href="./references#CD007476-bbs2-0063" title="Carpenter , John‐Paul , et al. On T2* magnetic resonance and cardiac iron. Circulation2011;123:1519‐1528. ">Carpenter 2011</a>) (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). No significant difference was seen for all participants and for the subgroups of participants with myocardial T2* &lt; 10 ms and ≥ 10 ms at baseline (<a href="./references#CD007476-fig-0024" title="">Analysis 2.18</a>, 172 participants). Improvement in myocardial T2* was defined as increase from a range of 6 to &lt; 10 milliseconds at baseline to 10 to 20 ms at end of study. Worsening of myocardial iron was defined as decrease from a range of 10 ms to ≤ 20 ms at baseline to 6 to &lt; 10 ms. Significantly more participants treated with deferasirox reached normalized myocardial T2* than participants with deferoxamine, RR 2.85 (95% CI 1.09 to 7.43) (<a href="./references#CD007476-fig-0025" title="">Analysis 2.19</a>, 172 participants). No significant difference was found for improvement and worsening between the two groups (<a href="./references#CD007476-fig-0025" title="">Analysis 2.19</a>). </p> </section> <section id="CD007476-sec-0098"> <p><b>d. Other measures of iron overload</b></p> <p>One study evaluated the iron excretion‐intake ratio (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>). The results reflect the dose‐response and ratio effect seen for ferritin, MD ‐0.18 (95% CI ‐0.24 to ‐0.12) (<a href="./references#CD007476-fig-0026" title="">Analysis 2.20</a>, 541 participants). Deferoxamine showed higher efficacy at ratios of 1:2.2, 1:3.6 and 1:5.5, while deferasirox at a ratio of 1:1.8 showed significantly higher efficacy in the subgroup of highly iron‐overloaded people. </p> </section> </section> <section id="CD007476-sec-0099"> <h6 class="title">3. Measures of iron excretion (urine and faeces) over 24 hours (mg/kg/day)</h6> <p>No data on iron excretion were available from any study.</p> </section> <section id="CD007476-sec-0100"> <h6 class="title">4. Adverse events</h6> <p>Five studies reported in a detailed manner on AEs (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>; <a href="./references#CD007476-bbs2-0009" title="MolaviMA , DoozandehH , NazemiA , EvaziR , MansooriF . Comparison of therapeutic response and complications of oral Osveral and injection Desfereal chelating agent in patient with thalassemia major. Asian Journal of Medical and Pharmaceutical Researches2013;3(3):93‐7. ">Molavi 2013</a>; <a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>; <a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>; <a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>). In the Cappellini study, it is not clearly stated whether all 586 participants were included in this analysis; however, since discontinuations are reported, we assume that all 586 participants were included (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>). From the Piga phase II study reports, some safety data were reported by dose group. Our intention was to pool the data with the results of other studies, so we summed the number of AEs of both dose subgroups. Only common (observed in ≥ 5% of participants) adverse events of the Pennell study were reported in the journal publication. On clinicaltrials.gov more adverse events were reported, but due to unexplained differences between journal publication and register entry in the numbers of some adverse events, we extracted the data from the peer‐reviewed journal publication. </p> <p>Two studies reported the number of participants affected by SAEs (773 participants) (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>; <a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>) (<a href="./references#CD007476-fig-0027" title="">Analysis 2.21</a>). The pooled results revealed no significant difference between both treatment groups. One study reported SAEs in detail (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). No significant differences were seen in all SAE between the two groups (187 participants) (<a href="./references#CD007476-fig-0028" title="">Analysis 2.22</a>). </p> <p>No statistically significant difference was found between deferasirox and deferoxamine with regard to the number of participants experiencing "any adverse events" (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>; <a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>, 258 participants); heterogeneity was high (I² = 74%) (<a href="./references#CD007476-fig-0029" title="">Analysis 2.23</a>). No significant difference was observed using random‐effects model. Different types of AEs were reported, but only isolated increases of creatinine occurred significantly more often while on deferasirox treatment compared to deferoxamine (657 participants) (<a href="./references#CD007476-fig-0030" title="">Analysis 2.24</a>). However, likelihood for a false‐positive finding is high due to the large number of AEs reported and compared. All other reported AEs such as thrombocytopenia, agranulocytosis, neutropenia, leukopenia, cardiac AEs, hearing loss, lens and retinal abnormalities, different gastrointestinal disorders, asthenia, influenza‐like illness, pyrexia, allergic conjunctivitis, bronchitis, upper respiratory tract infection, urinary tract infection, increased ALT, elevated ALT (&gt; 2 x ULN), increased AST, increased blood creatinine, increased platelet count, arthralgia, back pain, osteoporosis, headache, vertigo, proteinuria, cough, influenza, nasopharyngitis, oropharyngeal and pharyngolaryngeal pain, pharyngitis, rhinitis and rash were either not observed at all or at frequencies that were not statistically different between both treatments (<a href="./references#CD007476-fig-0030" title="">Analysis 2.24</a>). Heterogeneity regarding the pooled data for diarrhoea was high (I² = 53%), but results remained not statistically significant using a random‐effects model. </p> <p>Cappellini describes mild, dose‐dependent increases in serum creatinine in 38% deferasirox participants, mostly in the 20 and 30 mg/kg/day groups in those participants with the highest decreases in LIC and serum ferritin (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>). Increases were sometimes transient and generally within the normal range. The increases never exceeded 2x ULN. 14% of participants in the deferoxamine group experienced similar increases. Eight participants in the deferasirox and seven participants in the deferoxamine group experienced deafness, neurosensory deafness or hypoacusis. For two participants in the deferasirox group and five participants in the deferoxamine group, cataracts or lenticular opacities were reported. Electrocardiograms were performed for 258 participants in the deferasirox group and 245 participants in the deferoxamine group. The authors reported that no cardiac safety concerns regarding deferasirox were identified and a similar percentage of participants receiving deferasirox (5.1%) and deferoxamine (6.9%) experienced cardiac AEs. </p> <p>Pennell assessed drug‐related AEs and reported the ones affecting ≥ two participants (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). Hassan also reported different kinds of drug‐related AEs, but not in a systematic way (<a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>). As far as possible, these were included in the analyses; no significant differences were observed regarding the number of participants experiencing drug‐related AEs (<a href="./references#CD007476-fig-0031" title="">Analysis 2.25</a>, 187 participants) or the different kinds of drug‐related AEs (<a href="./references#CD007476-fig-0032" title="">Analysis 2.26</a>, 247 participants). In the Cappellini study, the authors describe the most common AEs with an apparent relationship to deferasirox were transient gastrointestinal events (15.2% of participants) and skin rash (10.8%) (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>). Median duration of the gastrointestinal events were eight days or less, therefore dose adjustment or discontinuation of deferasirox was rarely required. Two participants receiving deferasirox developed ALT levels &gt; 2x ULN, which was felt by the investigator to be drug‐related. Of the participants experiencing deafness, neurosensory deafness or hypoacusis, these symptoms were considered drug‐related in one participant receiving deferasirox and five participants receiving deferoxamine. Cataracts or lenticular opacities were reported in one participant receiving deferasirox and four participants receiving deferoxamine. There was no drug‐related agranulocytosis reported in this study. </p> </section> <section id="CD007476-sec-0101"> <h6 class="title">5. Participant satisfaction and adherence</h6> <p>Satisfaction with, convenience of and willingness to continue treatment was significantly higher in the group receiving deferasirox who had previously been treated with deferoxamine, although differences were not as marked in the small group of deferoxamine‐naive participants (<a href="./references#CD007476-fig-0033" title="">Analysis 2.27</a>; <a href="./references#CD007476-fig-0034" title="">Analysis 2.28</a>; <a href="./references#CD007476-fig-0035" title="">Analysis 2.29</a>) (even when those who did not respond to the questionnaire were counted as not satisfied or unwilling to continue treatment). Time lost from normal activities due to treatment was significantly less with deferasirox (<a href="./references#CD007476-fig-0036" title="">Analysis 2.30</a>, 187 participants). For the outcomes "willingness to continue" (<a href="./references#CD007476-fig-0035" title="">Analysis 2.29</a>) and "time lost from normal activities" (<a href="./references#CD007476-fig-0036" title="">Analysis 2.30</a>), the number of participants who responded at end of study were not given; however, to incorporate these data, we assumed that all participants provided this information. </p> <p>Adherence was evaluated in one study and defined as percentage of the planned dose taken by participants (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). No significant difference was seen between both groups (<a href="./references#CD007476-fig-0037" title="">Analysis 2.31</a>, 187 participants). </p> <p>Another study measured adherence by either pill or vial count, but no results were reported (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). Five participants in the deferoxamine subgroup did not continue till the end of study because of poor adherence, but it was unclear if participants actively discontinued the study or were excluded by the investigators. </p> <p>One study reported, that all participants were adherent, but adherence was not defined (<a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>). </p> <p>The number of participants who discontinued the study was not statistically significant different between both groups in eight studies (<a href="./references#CD007476-fig-0038" title="">Analysis 2.32</a>, 1211 participants). In the Piga study, two participants each in the deferasirox 20 mg/kg/day and deferoxamine groups were withdrawn prematurely from the study (<a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>). One participant in the deferasirox 20 mg/kg/day group was excluded due to unsatisfactory therapeutic effect and QTc prolongation. The other three participants were excluded due to adverse events. The AEs of one participant in the deferoxamine group (arthralgia, headache and fever) were considered to be study drug‐related by the investigator. In the Elalfy study, five participants in the deferoxamine treatment group discontinued because of poor compliance (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). It remains unclear if participants left the study deliberate or were excluded by investigators. </p> <p>One study reported the number of participants with dose adjustments or dose interruptions, but no significantly difference between both treatments was observed (586 participants) (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>) (<a href="./references#CD007476-fig-0039" title="">Analysis 2.33</a>); approximately 5% of people discontinued, while dose adjustments were required in approximately one third of people. </p> <p>Another study evaluated number of participants with at least one dose interruption (187 participants) (<a href="./references#CD007476-fig-0040" title="">Analysis 2.34</a>) or dose reduction (187 participants) (<a href="./references#CD007476-fig-0041" title="">Analysis 2.35</a>) separately (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>). No significant differences between both groups were observed.The main reason for interruption (deferasirox: 21/96; deferoxamine: 19/91) and dose reduction (deferasirox: 24/96; deferoxamine: 21/91) was an AE. One study reported the number of participants with dose adjustments (71 participants) (<a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>); there were significantly more participants with dose adjustments in the deferasirox group, RR 3.23 (95% CI 1.28 to 8.16) (<a href="./references#CD007476-fig-0042" title="">Analysis 2.36</a>). However, there was no significant difference in the number of participants with dose interruptions due to an AE in this study (71 participants) (<a href="./references#CD007476-fig-0043" title="">Analysis 2.37</a>). </p> </section> <section id="CD007476-sec-0102"> <h6 class="title">6. Cost of intervention per year</h6> <p>No data on costs of intervention were available from any study.</p> <p><b>7. Other reported outcomes not predefined</b> </p> <p>In the Elalfy study, also transfusion index, haemoglobin, iron, total iron binding capacity, transferrin saturation and vitamin C at baseline and end of study are reported (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). We included transfusion index, haemoglobin and transferrin saturation in our analysis. Due to missing P values, we were not able to calculate the SD for change from baseline. Haemoglobin at end of study was significant higher in the deferoxamine group, MD ‐0.70 (95% CI ‐1.33 to ‐0.07) (<a href="./references#CD007476-fig-0044" title="">Analysis 2.38</a>). In the Molavi study, change in haemoglobin levels from beginning to end of study were significant, MD ‐0.46 (95% CI ‐0.81 to ‐0.11) (<a href="./references#CD007476-bbs2-0009" title="MolaviMA , DoozandehH , NazemiA , EvaziR , MansooriF . Comparison of therapeutic response and complications of oral Osveral and injection Desfereal chelating agent in patient with thalassemia major. Asian Journal of Medical and Pharmaceutical Researches2013;3(3):93‐7. ">Molavi 2013</a>). Pooled results of both studies showed a significant lower hemoglobin in the deferasirox group, MD ‐0.52 (95% CI ‐0.82 to ‐0.21) (180 participants) (<a href="./references#CD007476-fig-0044" title="">Analysis 2.38</a>). No significant difference was observed for either transfusion index or transferrin saturation at end of the Elalfy study (42 participants) (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>) (<a href="./references#CD007476-fig-0045" title="">Analysis 2.39</a>; <a href="./references#CD007476-fig-0046" title="">Analysis 2.40</a>). This study provides only data on participants receiving vitamin C, but the author describes, that improvement in transfusion index, serum iron, Tsat and hemoglobin was significant improved in those receiving vitamin C compared to those not receiving vitamin C. </p> <p>Hassan reports no significant difference regarding platelet count (x10³/mm³) and absolute neutrophilic count (/mm³) (<a href="./references#CD007476-bbs2-0007" title="HassanMA , TolbaOA . Iron chelation monotherapy in transfusion‐dependent beta‐thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electronic Physician2016;8(5):2425‐31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454] ">Hassan 2016</a>) (<a href="./references#CD007476-fig-0047" title="">Analysis 2.41</a>; <a href="./references#CD007476-fig-0048" title="">Analysis 2.42</a>). </p> <p>In the Piga study, all treatment groups had transient and low grade (&lt; 10‐fold above the ULN) elevations of urinary b‐2 microglobulin, but the elevations were more frequent in those receiving deferasirox 20 mg/kg/day (<a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>). The elevations tended to normalize, although the study drug was continued in most cases. In three participants in the deferasirox group, treatment was discontinued and values normalized within seven to 10 days. Two participants in the deferasirox 20 mg/kg/day group had the highest evaluations, the dose was reduced to 10 mg/kg/day which resulted in a normalization of the b‐2 microglobulin levels. Moreover, Piga reported that there were no consistent changes in urinary N‐acetyl‐beta‐glucosaminidase levels (<a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>). </p> <p>Serum copper and zinc levels fluctuated in participants in the Piga study, but no progressive decreases occurred (<a href="./references#CD007476-bbs2-0014" title="CappelliniM , GalanelloR , PigaA , ForniGL , ZanaboniL , MuroniP , et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6‐9; Florence, Italy Florence, Italy, 6‐9 June, 2002. 2002:184. CappelliniMD , GalanelloR , PigaA , ForniGL , OpitzH , FordJM , et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12‐15; Lyon, France. Lyon, 2003. PigaA , GalanelloR , CappelliniM , ForniGL , OpitzH , FordJM , et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood2002;100(11 Pt 1):5a. PigaA , GalanelloR , CappelliniMD , ForniGL , LupoG , FordJM , et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood2003;102(11). [Abstract no: 412] PigaA , GalanelloR , ForniGL , CappelliniMD , OrigaR , ZappuA , et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once‐daily, orally‐administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica2006;91(7):873‐80. ">Piga 2002</a>). In the Cappellini study, the authors describe that zinc and copper levels at the end of the study were comparable in both treatment groups (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>). </p> <p>Growth and development was described as normally within children who were receiving deferasirox (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>). </p> </section> </section> </section> <section id="CD007476-sec-0103"> <h4 class="title">3. Transfusion‐dependent thalassaemia: deferasirox compared to deferiprone</h4> <p>One study compared deferasirox to deferiprone (<a href="./references#CD007476-bbs2-0015" title="MattiM . Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013. SanjeevaGN , NijagunaN , MattiM , ChebbiPG . Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. Journal of of Evolution of Medical and Dental Sciences2015;4(24):4178‐85. [DOI: 10.14260/jemds/2015/601] ">Sanjeeva 2015</a>). Two additional studies compared all three iron chelation monotherapies (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>; <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). A further study compared deferasirox to deferiprone monotherapy and combination of both (<a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). To include data from these multi‐armed studies into meta‐analysis, deferasirox groups were split. </p> <section id="CD007476-sec-0104"> <h5 class="title">Primary outcomes</h5> <section id="CD007476-sec-0105"> <h6 class="title">1. Overall mortality measured at any point in time</h6> <p>No deaths were observed (146 participants) (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>; <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>; <a href="./references#CD007476-bbs2-0015" title="MattiM . Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013. SanjeevaGN , NijagunaN , MattiM , ChebbiPG . Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. Journal of of Evolution of Medical and Dental Sciences2015;4(24):4178‐85. [DOI: 10.14260/jemds/2015/601] ">Sanjeeva 2015</a>) (<a href="./references#CD007476-fig-0049" title="">Analysis 3.1</a>). </p> </section> </section> <section id="CD007476-sec-0106"> <h5 class="title">Secondary outcomes</h5> <section id="CD007476-sec-0107"> <h6 class="title">1. Reduced end‐organ damage due to iron deposition</h6> <p>One study evaluated the incidence of thyroid disease after two years of treatment (18 participants) (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>) (<a href="./references#CD007476-fig-0050" title="">Analysis 3.2</a>). No significant difference was seen between both groups, but the population (n = 18) was very small. </p> <p>One study reported AST, ALT, urea and creatinine levels and neutrophil count at nine months (38 participants) (<a href="./references#CD007476-bbs2-0015" title="MattiM . Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013. SanjeevaGN , NijagunaN , MattiM , ChebbiPG . Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. Journal of of Evolution of Medical and Dental Sciences2015;4(24):4178‐85. [DOI: 10.14260/jemds/2015/601] ">Sanjeeva 2015</a>) (<a href="./references#CD007476-fig-0051" title="">Analysis 3.3</a>; <a href="./references#CD007476-fig-0052" title="">Analysis 3.4</a>; <a href="./references#CD007476-fig-0053" title="">Analysis 3.5</a>; <a href="./references#CD007476-fig-0054" title="">Analysis 3.6</a><a href="./references#CD007476-fig-0055" title="">Analysis 3.7</a>). P values for change from baseline were given, so we were able to calculate the SD for change from baseline. No significant differences between both groups were observed. </p> <p>Although Kakkar reported the performance of monthly renal function tests and measurements of liver enzymes, no results were presented (<a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). </p> <p><b>2. Measures of iron overload</b> </p> <p><b>a. Serum ferritin</b> </p> <p>Two studies measured serum ferritin concentration at end of study (<a href="./references#CD007476-bbs2-0015" title="MattiM . Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013. SanjeevaGN , NijagunaN , MattiM , ChebbiPG . Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. Journal of of Evolution of Medical and Dental Sciences2015;4(24):4178‐85. [DOI: 10.14260/jemds/2015/601] ">Sanjeeva 2015</a>; <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). Mean change from baseline was calculated from P values (baseline to end‐value) for the Sanjeeva study (<a href="./references#CD007476-bbs2-0015" title="MattiM . Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013. SanjeevaGN , NijagunaN , MattiM , ChebbiPG . Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. Journal of of Evolution of Medical and Dental Sciences2015;4(24):4178‐85. [DOI: 10.14260/jemds/2015/601] ">Sanjeeva 2015</a>). The thesis document additionally reported serum ferritin in different subgroups which were categorized according to their baseline serum ferritin. The second study reported median and interquartile ranges, so we calculated mean and SD at end of study (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). No significant difference between both treatment groups was observed for all participants and for subgroups split according to baseline ferritin values (83 participants) (<a href="./references#CD007476-fig-0056" title="">Analysis 3.8</a>). </p> <p>Two other studies measured serum ferritin every three months, but data could not be extracted (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>; <a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). In the Chirico study, data on serum ferritin could not be extracted due to insufficient information on the data (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>): it was unclear if mean or median, range or interquartile range were given. The authors described, that they did not find statistical differences between serum ferritin changes in all treatment groups after therapy. In the Kakkar study, the authors describe that "serum ferritin reduced significantly in group I [DFP] and II [DFX] [...]" (<a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). </p> <p><b>b. Liver iron concentration (LIC)</b> </p> <p>One study measured LIC by MRI R2* at end of study (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). We calculated the SD for change from baseline from P values. No significant difference was seen between both treatment groups (45 participants) (<a href="./references#CD007476-fig-0057" title="">Analysis 3.9</a>). </p> <p>A further study measured liver MRI T2* but no data could be extracted (<a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). Mean values for liver MRI T2* were reported, but it remains unclear if these values represent baseline or end of study data. </p> <p><b>c. Myocardial iron concentration</b> </p> <p>One study measured cardiac T2* at end of study (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). We calculated the SD for change from baseline from P values. No significant difference was seen between both treatment groups (45 participants) (<a href="./references#CD007476-fig-0058" title="">Analysis 3.10</a>). </p> <p>Data from the Kakkar study measuring cardiac T2* could not be extracted (<a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). The authors describe, that cardiac MRI T2* at the end of the study were slightly better in [deferiprone] group as compared to [deferiprone and deferasirox] group, although this was not statistical significant (P = 0.07). </p> <p><b>3. Measures of iron excretion (urine and faeces) over 24 hours (mg/kg/day)</b> </p> <p>No data on iron excretion were available from any study.</p> <p><b>4. Adverse events</b> </p> <p>Three studies provided information on AEs (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>; <a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>; <a href="./references#CD007476-bbs2-0015" title="MattiM . Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013. SanjeevaGN , NijagunaN , MattiM , ChebbiPG . Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. Journal of of Evolution of Medical and Dental Sciences2015;4(24):4178‐85. [DOI: 10.14260/jemds/2015/601] ">Sanjeeva 2015</a>). </p> <p>In the Sanjeeva study, AEs were very common in the deferiprone (15 out of 22, 68.2%) and deferasirox group (seven out of 19, 36.8%), but overall no significant difference was observed (41 participants) (<a href="./references#CD007476-bbs2-0015" title="MattiM . Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013. SanjeevaGN , NijagunaN , MattiM , ChebbiPG . Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. Journal of of Evolution of Medical and Dental Sciences2015;4(24):4178‐85. [DOI: 10.14260/jemds/2015/601] ">Sanjeeva 2015</a>) (<a href="./references#CD007476-fig-0059" title="">Analysis 3.11</a>). Significantly more participants experienced arthralgia in the deferiprone group compared to the deferasirox group, RR 0.13 (95% CI 0.02 to 0.93) (41 participants) (<a href="./references#CD007476-fig-0060" title="">Analysis 3.12</a>), resulting in three participants discontinuing deferiprone treatment. Due to the high number of different types of AEs reported and compared, likelihood for a false‐positive result is increased. Nausea and vomiting appeared frequently in both groups: deferasirox 31.5% (six out of 19), deferiprone 27.2% (six out of 22), respectively, with no significant differences between both groups (41 participants) (<a href="./references#CD007476-fig-0060" title="">Analysis 3.12</a>). One participant in the deferiprone group had abdominal pain (<a href="./references#CD007476-fig-0060" title="">Analysis 3.12</a>, 41 participants). None of the participants experienced rashes or diarrhoea (41 participants) (<a href="./references#CD007476-fig-0060" title="">Analysis 3.12</a>). One participant in the deferiprone group experienced neutropenia, however, agranulocytosis was not observed in any of the groups (38 participants) (<a href="./references#CD007476-fig-0060" title="">Analysis 3.12</a>). The number of participants with ALT or AST levels of 2x above ULN was equal in both treatment groups (38 participants) (<a href="./references#CD007476-fig-0060" title="">Analysis 3.12</a>). One participant in the deferasirox group had 50% increase in serum creatinine levels from baseline (<a href="./references#CD007476-fig-0060" title="">Analysis 3.12</a>, 38 participants). Renal failure was not observed in any of the groups (38 participants) (<a href="./references#CD007476-fig-0060" title="">Analysis 3.12</a>). </p> <p>Elalfy only states that "no serious adverse reaction to iron chelators nor to vitamin C administration have been reported" (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). No data on adverse events could be extracted from the Kakkar study (<a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). </p> <p><b>5. Participant satisfaction and adherence</b> </p> <p>No data on participant satisfaction and adherence could be extracted from any study.</p> <p>One study measured adherence by either pill or vial count, but no results were reported (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). </p> <p>No significant difference was observed in the number of participants discontinuing the study overall (<a href="./references#CD007476-bbs2-0002" title="ChiricoV , AntonioL , VincenzoS , LucaN , ValeriaF , BasiliaP , et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. European Journal of Endocrinology2013;169(6):785‐93. ChiricoV , RigoliL , PirainoB , LaRosaM , SalpietroC , ArrigoT . Endocrinopathies in beta‐thalassemia major: Evidences from ten years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics2013;80:318. ">Chirico 2013</a>; <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>; <a href="./references#CD007476-bbs2-0015" title="MattiM . Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013. SanjeevaGN , NijagunaN , MattiM , ChebbiPG . Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. Journal of of Evolution of Medical and Dental Sciences2015;4(24):4178‐85. [DOI: 10.14260/jemds/2015/601] ">Sanjeeva 2015</a>) (<a href="./references#CD007476-fig-0061" title="">Analysis 3.13</a>, 179 participants) or discontinuing the study due to AEs (41 participants) (<a href="./references#CD007476-fig-0062" title="">Analysis 3.14</a>). </p> <p><b>6. Cost of intervention per year</b> </p> <p>No data on cost of intervention were available from any study.</p> <p><b>7. Other additional outcomes</b> </p> <p>Comparing deferasirox to deferiprone in the identified studies, other, in this review not a priori defined outcomes were measured. A significant higher transferrin saturation was seen in the deferiprone group at end of one study (45 participants), MD ‐7.40 (95% CI ‐13.28 to ‐1.52) (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>) (<a href="./references#CD007476-fig-0063" title="">Analysis 3.15</a>). No significant differences were observed regarding haemoglobin or transfusion index in this study (45 participants) (<a href="./references#CD007476-fig-0064" title="">Analysis 3.16</a>, <a href="./references#CD007476-fig-0065" title="">Analysis 3.17</a>). Additionally, ALP levels were reported at nine months in one study (<a href="./references#CD007476-bbs2-0015" title="MattiM . Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013. SanjeevaGN , NijagunaN , MattiM , ChebbiPG . Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. Journal of of Evolution of Medical and Dental Sciences2015;4(24):4178‐85. [DOI: 10.14260/jemds/2015/601] ">Sanjeeva 2015</a>). Due to P values for change from baseline given, we were able to calculate the SD for change from baseline. No significant difference was observed (38 participants) (<a href="./references#CD007476-fig-0066" title="">Analysis 3.18</a>). Moreover, the thesis document reporting the Sanjeeva study also reported phosphorous and calcium levels, which we did not include in our review (<a href="./references#CD007476-bbs2-0015" title="MattiM . Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013. SanjeevaGN , NijagunaN , MattiM , ChebbiPG . Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. Journal of of Evolution of Medical and Dental Sciences2015;4(24):4178‐85. [DOI: 10.14260/jemds/2015/601] ">Sanjeeva 2015</a>). In the Elalfy study, also iron, total iron binding capacity and vitamin C at end of study are reported (<a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a>). </p> </section> </section> </section> <section id="CD007476-sec-0108"> <h4 class="title"><i>4. Transfusion‐dependent thalassaemia: deferasirox compared to deferasirox in combination with deferiprone</i> </h4> <p>One study with 40 participants reported in one abstract included the comparison of deferasirox versus deferasirox and deferiprone administered sequentially (<a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). </p> <p>Cardiac and liver MRI, serum ferritin, CBC, liver enzymes and renal function tests were assessed during the study. Results for liver MRI, serum ferritin and adverse events were only reported narratively and no data could be extracted: </p> <p>"Liver MRI T2* was not significantly different before and after the study. Serum ferritin reduced significantly in group I [DFP] and II [DFX] but not in group III [DFX+DFP]. Group receiving combination therapy did not show any untoward side effects as compared to single drug regimen." </p> <p>No results regarding cardiac MRI, CBC, liver enzymes and renal function tests were reported. </p> </section> <section id="CD007476-sec-0109"> <h4 class="title">5. Transfusion‐dependent thalassaemia: deferasirox in combination with deferiprone compared to deferiprone alone </h4> <p>One study with 40 participants reported in one abstract included the comparison of deferiprone versus deferasirox and deferiprone administered sequentially (<a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). </p> <p>Cardiac and liver MRI, serum ferritin, CBC, liver enzymes and renal function tests were assessed during the study. Results for cardiac and liver MRI, serum ferritin and adverse events were only reported narratively and no data could be extracted: </p> <p>"Cardiac MRI T2* at the end of the study was slightly better in group I [DFP] as compared to group III [DFP + DFX] although was not statistical significant (p=0.07). [...] Liver MRI T2* was not significantly different before and after the study. Serum ferritin reduced significantly in group I [DFP] and II [DFX] but not in group III [DFP+DFX]. Group receiving combination therapy did not show any untoward side effects as compared to single drug regimen." </p> <p>No results regarding CBC, liver enzymes and renal function tests were reported.</p> </section> <section id="CD007476-sec-0110"> <h4 class="title">6. Transfusion‐dependent thalassaemia: deferasirox in combination with deferoxamine compared to deferoxamine alone </h4> <p>One study compared deferasirox in combination with deferoxamine to deferoxamine alone (<a href="./references#CD007476-bbs2-0010" title="MolaviMA , PoorST , MalesksabetM . Combined Desferrioxamine (Desferal) and Deferasirox in children. Advances in Biological Research2014;8(4):171‐5. ">Molavi 2014</a>). </p> <section id="CD007476-sec-0111"> <h5 class="title">Primary outcomes</h5> <section id="CD007476-sec-0112"> <h6 class="title">1. Overall mortality measured at any point in time</h6> <p>No loss‐to‐follow‐up was reported in the study (94 participants) (<a href="./references#CD007476-bbs2-0010" title="MolaviMA , PoorST , MalesksabetM . Combined Desferrioxamine (Desferal) and Deferasirox in children. Advances in Biological Research2014;8(4):171‐5. ">Molavi 2014</a>) (<a href="./references#CD007476-fig-0067" title="">Analysis 6.1</a>). Therefore, we assumed no deaths occurred in any of the groups. </p> </section> </section> <section id="CD007476-sec-0113"> <h5 class="title">Secondary outcomes</h5> <section id="CD007476-sec-0114"> <h6 class="title">1. Reduced end‐organ damage due to iron deposition</h6> <p>Molavi measured neutrophils, ALT, AST at baseline and at 12 months (<a href="./references#CD007476-bbs2-0010" title="MolaviMA , PoorST , MalesksabetM . Combined Desferrioxamine (Desferal) and Deferasirox in children. Advances in Biological Research2014;8(4):171‐5. ">Molavi 2014</a>). Due to missing P values for change from baseline, no SDs for change from baseline could be calculated. No significant differences were observed in neutrophils, ALT, and AST levels (94 participants) between the two groups at 12 months (<a href="./references#CD007476-fig-0068" title="">Analysis 6.2</a>; <a href="./references#CD007476-fig-0069" title="">Analysis 6.3</a>; <a href="./references#CD007476-fig-0070" title="">Analysis 6.4</a>). </p> <p>No other data on end‐organ damage were available from this study.</p> <p><b>2. Measures of iron overload</b> </p> <p><b>a. Serum ferritin</b> </p> <p>The Molavi study measured serum ferritin at 12 months (<a href="./references#CD007476-bbs2-0010" title="MolaviMA , PoorST , MalesksabetM . Combined Desferrioxamine (Desferal) and Deferasirox in children. Advances in Biological Research2014;8(4):171‐5. ">Molavi 2014</a>). Due to missing P values (baseline to end of study), SD for change from baseline couldn't be calculated. No significant difference was observed between both groups at end of study (94 participants) (<a href="./references#CD007476-fig-0071" title="">Analysis 6.5</a>). </p> <p><b>3. Measures of iron excretion (urine and faeces) over 24 hours (mg/kg/day)</b> </p> <p>No data on iron excretion were available from the study.</p> <p><b>4. Adverse events</b> </p> <p>No AEs were reported.</p> <p><b>5. Participant satisfaction and adherence</b> </p> <p>No data on this outcome were available from the Molavi study; however, no participant discontinued the study (94 participants) (<a href="./references#CD007476-fig-0072" title="">Analysis 6.6</a>). </p> <p><b>6. Cost of intervention per year</b> </p> <p>No data on cost of intervention was available from the study.</p> <p><b>7. Other additional outcomes</b> </p> <p>Haemoglobin at 12 months was slightly higher in participants treated with deferoxamine alone (94 participants) (<a href="./references#CD007476-fig-0073" title="">Analysis 6.7</a>). ALP was significantly higher in participants treated with both deferasirox and deferoxamine (94 participants) (<a href="./references#CD007476-bbs2-0010" title="MolaviMA , PoorST , MalesksabetM . Combined Desferrioxamine (Desferal) and Deferasirox in children. Advances in Biological Research2014;8(4):171‐5. ">Molavi 2014</a>) (<a href="./references#CD007476-fig-0074" title="">Analysis 6.8</a>). </p> </section> </section> </section> <section id="CD007476-sec-0115"> <h4 class="title">7. Transfusion‐dependent thalassaemia: deferasirox in combination with deferiprone compared to deferiprone + deferoxamine </h4> <p>One study compared deferasirox and deferiprone to deferiprone and deferoxamine (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>). </p> <section id="CD007476-sec-0116"> <h5 class="title">Primary outcomes</h5> <section id="CD007476-sec-0117"> <h6 class="title">1. Overall mortality measured at any point in time</h6> <p>No deaths were observed during the study (96 participants) (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>) (<a href="./references#CD007476-fig-0075" title="">Analysis 7.1</a>). </p> </section> </section> <section id="CD007476-sec-0118"> <h5 class="title">Secondary outcomes</h5> <section id="CD007476-sec-0119"> <h6 class="title">1. Reduced end‐organ damage due to iron deposition</h6> <p>The authors reported that "change in mean LVEF after one year was not different between the two treatment groups (data not shown)." (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>). No quantitative data were available. </p> <p><b>2. Measures of iron overload</b> </p> <p><b>a. Serum ferritin</b> </p> <p>One study measured serum ferritin at 12 months and reported mean and SD values (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>). Although not directly stated, we considered the given P value to describe change from baseline so we were able to calculate the mean change and SD. Serum ferritin decreased in both groups, but no significant difference was observed (96 participants) (<a href="./references#CD007476-fig-0076" title="">Analysis 7.2</a>). </p> <p><b>b. Liver iron concentration (LIC)</b> </p> <p>LIC was measured by MRI R2* in the included study and mean and SD values at end of study were reported (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>). Although not directly stated, we considered the given P value to describe change from baseline, so we calculated the mean change and SD. No significant difference was seen between both groups (96 participants) (<a href="./references#CD007476-fig-0077" title="">Analysis 7.3</a>). </p> <p><b>c. Myocardial iron concentration</b> </p> <p>Myocardial iron concentration was measured by T2* in the included study and mean and SD values at end of study were reported (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>). Although not directly stated, we considered the given P value to describe change from baseline, so we were able to calculate the mean change and SD. No significant difference was seen between the groups (96 participants) (<a href="./references#CD007476-fig-0078" title="">Analysis 7.4</a>). </p> <p><b>3. Measures of iron excretion (urine and faeces) over 24 hours (mg/kg/day)</b> </p> <p>No data on iron excretion were available from the included study (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>). </p> <p><b>4. Adverse events</b> </p> <p>The number of participants with a SAE was equal in both groups (96 participants) (<a href="./references#CD007476-fig-0079" title="">Analysis 7.5</a>). An acute cholecystitis was assessed as a drug‐related SAE in a participant receiving deferasirox and deferiprone (96 participants) (<a href="./references#CD007476-fig-0080" title="">Analysis 7.6</a>). A SAE, classified as unrelated to the drugs and which did not lead to death, was reported in one participant who developed appendicitis while receiving deferiprone and deferoxamine (96 participants) (<a href="./references#CD007476-fig-0081" title="">Analysis 7.7)</a>. </p> <p>Mild‐moderate neutropenia was observed in both groups, which resolved with decreasing deferiprone dose (96 participants) (<a href="./references#CD007476-fig-0082" title="">Analysis 7.8</a>). No cases of agranulocytosis were observed (96 participants) (<a href="./references#CD007476-fig-0082" title="">Analysis 7.8</a>). Overall, drug‐related AEs "were mostly of mild to moderate severity" and common in both groups (96 participants) (<a href="./references#CD007476-fig-0083" title="">Analysis 7.9</a>). In the Elalfy study, agranulocytosis, neutropenia, arthralgia, gastrointestinal problems, ALT (at least a three‐fold increase), serum creatinine (an increase of at least 33%) above baseline on two consecutive occasions and skin rash were assessed as drug‐related with similar frequencies in both groups (96 participants) (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>) (<a href="./references#CD007476-fig-0084" title="">Analysis 7.10</a>). </p> <p>Non‐drug‐related AEs were reported by 17 of 48 (35.41%) participants in the deferasirox and deferiprone group versus 18 of 48 (37.5%) in the deferiprone and deferoxamine group (96 participants) (<a href="./references#CD007476-fig-0085" title="">Analysis 7.11</a>). Only the three most common non‐drug‐related AEs were reported (infections, gastrointestinal disorders, skin and subcutaneous tissue disorders) and no significant differences were observed (96 participants) (<a href="./references#CD007476-fig-0086" title="">Analysis 7.12</a>). Mild elevation of hepatic transaminases at the start of therapy were observed in both groups, which returned to normal within the first two months (96 participants) (<a href="./references#CD007476-fig-0087" title="">Analysis 7.13</a>). Initial gastrointestinal manifestations also occurred in both groups and "were in form of nausea and mild abdominal pain" (96 participants) (<a href="./references#CD007476-fig-0088" title="">Analysis 7.14</a>). </p> <p><b>5. Participant satisfaction and adherence</b> </p> <p>Quality of life was measured by SF‐36 in one study (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>). Data were not given, therefore mean and SD at end of study were obtained through estimation from a figure, and SD for change from baseline was calculated from given P values. No significant differences were observed between both groups (96 participants) (<a href="./references#CD007476-fig-0089" title="">Analysis 7.15</a>). </p> <p>The definition of adherence in the Elalfy study was the actual dose divided by the total prescribed dose (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>). We calculated missing SD from given P value. Adherence was significantly higher in the deferasirox and deferiprone group, MD 0.15 (95% CI 0.06 to 0.24) (96 participants) (<a href="./references#CD007476-fig-0090" title="">Analysis 7.16</a>). </p> <p>Overall, no participant discontinued the study (96 participants) (<a href="./references#CD007476-fig-0091" title="">Analysis 7.17</a>) and there were no SAEs necessitating discontinuation or interruption of therapy in any of the groups (96 participants) (<a href="./references#CD007476-fig-0092" title="">Analysis 7.18</a>). </p> <p><b>6. Cost of intervention per year</b> </p> <p>No data on cost of intervention were available from any study.</p> <p><b>7. Other additional outcomes</b> </p> <p>No other additional outcomes were reported.</p> </section> </section> </section> <section id="CD007476-sec-0120"> <h4 class="title">8. Non‐transfusion‐dependent thalassaemia: deferasirox compared to placebo</h4> <p>One study evaluated people with non‐transfusion‐dependent thalassaemia and compared deferasirox 5 mg/kg/day and deferasirox 10 mg/kg/day starting doses to matching placebos (<a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>). </p> <section id="CD007476-sec-0121"> <h5 class="title">Primary outcomes</h5> <section id="CD007476-sec-0122"> <h6 class="title">1. Overall mortality measured at any point in time</h6> <p>No deaths occurred during the study in any treatment group during one year of treatment (148 participants) (<a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>) (<a href="./references#CD007476-fig-0093" title="">Analysis 8.1</a>). </p> </section> </section> <section id="CD007476-sec-0123"> <h5 class="title">Secondary outcomes</h5> <section id="CD007476-sec-0124"> <h6 class="title">1. Reduced end‐organ damage due to iron deposition</h6> <p>No data on end‐organ damage were available from the study.</p> </section> <section id="CD007476-sec-0125"> <h6 class="title">2. Measures of iron overload</h6> <section id="CD007476-sec-0126"> <p><b>a. Serum ferritin</b></p> <p>Different types of data on change in serum ferritin were reported in the journal publication and on <a href="http://www.clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>. The journal publication reports least squares mean (LSM), median and 95% CI; the mean and SD are reported on clinicaltrials.gov. In the journal publication, a LSM of ‐121 ng/mL (95% CI ‐203 to ‐38; median ‐99 ng/mL) and a LSM of ‐222 ng/mL (95% CI ‐304 to ‐140; median ‐190 ng/mL) are given in the 5 and 10 mg/kg/day subgroups, respectively. In the placebo group a LSM of 115 ng/mL (median 78 ng/mL) is reported, but due to missing SD or 95% CI we were not able to include these data in our meta‐analysis. </p> <p>The change in serum ferritin reported on <a href="http://www.clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> was significant in both the 5 and 10 mg/kg/day deferasirox subgroups compared to placebo, with a MD of ‐259.10 (95% CI ‐377.35 to ‐140.85) and ‐377.79 (95% CI ‐522.21 to ‐233.37) in the 5 and 10 mg/kg/day subgroups respectively (154 participants) (<a href="./references#CD007476-fig-0094" title="">Analysis 8.2</a>). The overall result was also significant, MD ‐306.74 (95% CI ‐398.23 to ‐215.24). Only participants with both baseline and post‐baseline values were included in the analyses of the study. </p> </section> <section id="CD007476-sec-0127"> <p><b>b. Liver iron concentration (LIC)</b></p> <p>In the Taher study, the primary efficacy end point was change in LIC from baseline to 52 weeks (159 participants) (<a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>). The authors used LSM and SEM when reporting data, so we calculated SD to include the results in our meta‐analysis. Regarding both starting dose subgroups, decrease in LIC was significant in both groups. For the 5 mg/kg/day group, MD ‐2.33 (95% CI ‐4.00 to ‐0.66); for the 10 mg/kg/day group the decrease was larger, MD ‐4.18 (95% CI ‐5.83 to ‐2.53) (<a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>) (<a href="./references#CD007476-fig-0095" title="">Analysis 8.3</a>). Regarding the different types of thalassaemia, results, reported as mean (SD), were only significant in favour of deferasirox in the β‐thalassaemia subgroups, with a larger decrease in the 10 mg/kg/day group. Results for α‐thalassaemia and HbE/β‐thalassaemia participants were not significant, but included participant populations were smaller than for the β‐thalassemia subgroup. Comparing LIC regarding age of the participants, LIC decrease in the subgroup of participants under 18 years of age with a deferasirox starting dose of 5 mg/kg/day was the only of the four subgroups without significant LIC decrease, but only 10 out of the 159 participants were included (<a href="./references#CD007476-fig-0096" title="">Analysis 8.4</a>). </p> <p>In the 5 mg/kg/day group, neither the decrease of ≥ 3 mg Fe/g dry weight in LIC, nor the reduction in Fe/g dry weight ≥ 30% were significant compared to placebo. However, in the 10 mg/kg/day group, significantly more participants had a LIC decrease of ≥ 3 mg Fe/g dry weight, RR 5.26 (95% CI 1.76 to 15.71) (83 participants) (<a href="./references#CD007476-fig-0097" title="">Analysis 8.5</a>) and a reduction in Fe/g dry weight ≥ 30%, RR 13.75 (95% CI 1.97 to 95.97) (83 participants) (<a href="./references#CD007476-fig-0098" title="">Analysis 8.6</a>). When combined, both of these results were significant across dose groups (<a href="./references#CD007476-fig-0097" title="">Analysis 8.5</a>; <a href="./references#CD007476-fig-0098" title="">Analysis 8.6</a>). Significantly more participants in both dose groups combined moved to a lower iron burden range (166 participants), RR 3.35 (95% CI 1.62 to 6.91); for the 5 mg/kg/day group, RR 3.39 (95% CI 1.10 to 10.45) and for the 10 mg/kg/day group, RR 3.31 (95% CI 1.28 to 8.55) (<a href="./references#CD007476-fig-0099" title="">Analysis 8.7</a>). No significant difference was observed in the number of participants in the 5 and 10 mg/kg/day subgroups who had LIC &lt; 5 mg Fe/g dry weight (166 participants) (<a href="./references#CD007476-fig-0100" title="">Analysis 8.8</a>); however, when these data were combined the result was significant, RR 5.35 (95% CI 1.30 to 21.99) (<a href="./references#CD007476-fig-0100" title="">Analysis 8.8</a>). </p> </section> <section id="CD007476-sec-0128"> <p><b>c. Myocardial iron concentration</b></p> <p>No data on myocardial iron concentration were available from the study.</p> </section> </section> <section id="CD007476-sec-0129"> <h6 class="title">3. Measures of iron excretion (urine and faeces) over 24 hours (mg/kg/day)</h6> <p>No data on iron excretion were available from the study.</p> </section> <section id="CD007476-sec-0130"> <h6 class="title">4. Adverse events</h6> <p>An extensive data on SAEs and other AEs are available on <a href="http://www.clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>. We were not able to include these data in our meta‐analysis, because the data were not reported separately for the core trial. </p> <p>Six investigator‐assessed drug‐related SAEs were reported in four participants receiving deferasirox (abdominal, pyrexia, hepatotoxicity, cellulitis, pruritus, rash), no drug‐related SAEs were reported with placebo (166 participants), these results were not significant (<a href="./references#CD007476-fig-0101" title="">Analysis 8.9</a>; <a href="./references#CD007476-fig-0102" title="">Analysis 8.10</a>). </p> <p>No significant difference was found in the number of participants experiencing at least one AE (166 participants) (<a href="./references#CD007476-fig-0103" title="">Analysis 8.11</a>) and in the number of participants with mild, moderate or severe AEs (166 participants) (<a href="./references#CD007476-fig-0104" title="">Analysis 8.12</a>; <a href="./references#CD007476-fig-0105" title="">Analysis 8.13</a>; <a href="./references#CD007476-fig-0106" title="">Analysis 8.14</a>). Neurosensory deafness was reported in a participant receiving placebo 10 mg/kg/day and proteinuria was reported in one participant receiving deferasirox 5 mg/kg/day (166 participants) (<a href="./references#CD007476-fig-0107" title="">Analysis 8.15</a>). No numbers are given, but the authors report that "the overall number of AEs and SAEs reported before and after dose increases was comparable within each treatment group." Comparisons of the number of participants with notable abnormal post‐baseline laboratory results extracted from clinicaltrials.gov (platelet count, neutrophil count, ALT, AST, serum creatinine, creatinine clearance, urinary protein/creatinine ratio, low/high blood pressure, low/high pulse rate), showed no significant differences between both groups (166 participants) (<a href="./references#CD007476-fig-0107" title="">Analysis 8.15</a>). </p> <p>Investigator‐assessed drug‐related AEs "were reported in 40 (24.1%) patients", but no values for each treatment group separately were given. Most common (at least three participants in total) investigator‐assessed drug‐related AEs were reported (nausea, skin rash, diarrhoea, headache, upper abdominal pain, abdomina pain), but no difference was seen between treatment groups (166 participants) (<a href="./references#CD007476-fig-0108" title="">Analysis 8.16</a>). </p> </section> <section id="CD007476-sec-0131"> <h6 class="title">5. Participant satisfaction and adherence</h6> <p>No data on participant satisfaction were available from the study.</p> <p>Adherence was defined as number of participants taking the planned study dose in Taher study (<a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>). Adherence was high, showing no difference between treatment groups (166 participants) (<a href="./references#CD007476-fig-0109" title="">Analysis 8.17</a>). </p> <p>Overall, no significant difference was observed in participants discontinuing the study (166 participants) (<a href="./references#CD007476-fig-0110" title="">Analysis 8.18</a>) </p> <p>No significant difference was observed in the number of participants who discontinued overall due to AEs (166 participants) (<a href="./references#CD007476-fig-0111" title="">Analysis 8.19</a>): three participants discontinued in the deferasirox 5 mg/kg/day cohort (fractured pelvis, anaemia, increased urine protein level), three participants in the deferasirox 10 mg/kg/day subgroup (pregnancy (n = 2), rash and pruritus) and two participants in the placebo group (optic neuritis and severe anaemia). </p> <p>No significant differences were observed in the number of participants with dose increase (166 participants) (<a href="./references#CD007476-fig-0112" title="">Analysis 8.20</a>), dose interruption (166 participants) (<a href="./references#CD007476-fig-0113" title="">Analysis 8.21</a>), dose reduction (166 participants) (<a href="./references#CD007476-fig-0114" title="">Analysis 8.22</a>) and dose reduction due to AE (166 participants) (<a href="./references#CD007476-fig-0115" title="">Analysis 8.23</a>). </p> <p>A total of 46.4% of participants had a dose doubling after 24 weeks.</p> </section> <section id="CD007476-sec-0132"> <h6 class="title">6. Cost of intervention per year</h6> <p>No data on cost of intervention were available from the study.</p> </section> <section id="CD007476-sec-0133"> <h6 class="title">7. Other additional outcomes</h6> <p>Taher also reported no significant difference in change in haemoglobin (144 participants) (<a href="./references#CD007476-fig-0116" title="">Analysis 8.24</a>). However, the study reported a significant difference in transferrin saturation in the 5 mg/kg/day subgroup only, MD ‐7.16 (95% CI ‐12.15 to ‐1.37) (70 participants) (<a href="./references#CD007476-fig-0117" title="">Analysis 8.25</a>) (<a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>). When dose groups were combined, the difference was also significant, MD ‐7.10 (95% CI ‐11.71 to ‐2.50) (141 participants) (<a href="./references#CD007476-fig-0117" title="">Analysis 8.25</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007476-sec-0134" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007476-sec-0134"></div> <section id="CD007476-sec-0135"> <h3 class="title" id="CD007476-sec-0135">Summary of main results</h3> <p>In the two pharmacokinetic, dose‐finding studies iron eliminating efficacy could be shown. In conclusion, in our opinion efficacy measures in these early studies were of limited value. However, since they fulfilled the review's inclusion criteria and were relevant in particular for safety issues, we included them. They showed a dose‐response effect as expected, but conclusions regarding efficacy when taken continuously were not really appropriate. In conclusion, pharmacodynamic efficacy and acceptable safety could be confirmed justifying further clinical testing in phase II and phase III studies based on an estimated equivalence ratio of deferasirox to deferoxamine of approximately 1 mg: 2 mg. </p> <p>A phase III study showed that depending on the actual dose of deferasirox, sufficient efficacy could be achieved to lower both serum ferritin level and liver iron concentration (LIC) (measured by biopsy or superconducting quantum interference device (SQUID)) in people with iron‐overloaded thalassaemia (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>). In comparison to deferoxamine, at a ratio of more than 2:1, deferoxamine showed a higher efficacy compared to deferasirox; however, similar efficacy of deferasirox could be achieved at a mean ratio of 1.8:1 of deferoxamine to deferasirox. Also, of five smaller studies which didn't consider the actual dose in particular, two showed significantly reduced serum ferritin in participants who received deferoxamine compared with deferasirox. Pooling of all six studies showed a significant reduction in serum ferritin favouring deferoxamine, mean difference (MD) 454.42 (95% confidence interval (CI) 337.13 to 571.71). One study showed a significantly greater change in LIC measured by magnetic resonance imaging (MRI) in favour of deferoxamine, but no significant difference was seen when pooled with a smaller study. </p> <p>Adverse effects, particularly rare adverse effects, are difficult to investigate in randomised clinical studies with a limited number of participants and incomplete or inconsistent reporting. Accordingly, with the exception of "increase in creatinine" (which may also be a false‐positive result due to the large number of different types of adverse events reported and compared) no significant differences in frequencies were observed between deferasirox and deferoxamine. However, from the data it seems that gastrointestinal problems are more common with deferasirox. Due to the low number of included participants who were investigated for adverse events, estimation of rare adverse events (1 to 10 of 10,000 participants) is not possible. Also, data on patient‐relevant outcomes such as mortality or end‐organ damage are either sparse (low number of events for mortality) or too limited to adequately evaluate the efficacy of deferasirox. Due to study duration of maximum two years, long‐term effects of deferasirox can not be judged. </p> <p>Satisfaction with, and convenience of, deferasirox among those who had previously received deferoxamine treatment was judged significantly better resulting in higher willingness to continue treatment; time lost from normal activities was also reported to be less with deferasirox. The proportion of people who discontinued treatment for any reason or who required dose interruptions or adjustments was similar for both drugs. </p> <p>Comparing deferasirox to deferiprone, only two small studies reported markers of iron overload. Given the limited patient population, no difference was seen between either treatment. In one study, significantly more participants experienced arthralgia in the deferiprone group, but the validity of the data are limited because the patient population was very small. </p> <p>Four studies were identified including deferasirox as monotherapy compared to combination therapy or as part of a combination therapy. There was only one study for every comparison and a patient population of 100 or less per study, so the data are very limited. No significant differences were observed in any outcome, except for adherence comparing deferasirox and deferiprone to deferiprone and deferoxamine, which favoured the combination of oral iron chelators, MD 0.15 (95% CI 0.06 to 0.24). </p> <p>Treatment with deferasirox appears to reduce serum ferritin and LIC significantly in people with non‐transfusion‐dependent thalassaemia as reported in one study including 166 participants. From the available safety data regarding overall number of participants with AEs, similar frequencies were observed, but more detailed and complete information on safety is needed. Results should be confirmed in further studies of longer duration, where patient‐relevant outcomes, such as mortality or satisfaction, are also considered. A total of 46.4% of participants had a dose doubling after 24 weeks due to LIC being more than 7 mg Fe/g dry weight and a LIC reduction less than 15% from baseline, which reflects the importance of dose adjustments. </p> </section> <section id="CD007476-sec-0136"> <h3 class="title" id="CD007476-sec-0136">Overall completeness and applicability of evidence</h3> <p>Given our comprehensive search strategy and contact with Novartis, we are confident that we have identified all relevant randomised studies of deferasirox. However, evidence on deferasirox for treatment of iron overload in people with thalassaemia is still limited due to the limited number of randomised participants included in studies comparing deferasirox to other iron chelators (n = 1594) and the methodological limitations of most of the studies. </p> <p>Also, pooling of data from different studies was only feasible for a few outcomes, so that for most outcomes data from only one or very few studies were available. Results from ongoing studies and studies which have not been published in full so far will hopefully add information regarding some of these outcomes in the near future. </p> <p>The applicability of our results is hampered by the use of surrogate endpoints and the short duration of studies. Long‐term studies comparing deferasirox to placebo would be ethically unjustifiable, given that the benefit and therefore also the necessity of iron chelation therapy in people with thalassaemia requiring regular transfusion, has been shown. Since the value of iron chelation therapy with deferoxamine in people with thalassaemia is well‐established (<a href="./references#CD007476-bbs2-0080" title="FisherSA , BrunskillS , DoreeC , GoodingS , ChowdhuryO , RobertsDJ . Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion‐dependent thalassaemia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD004450.pub2] ">Fisher 2013a</a>), change in surrogate parameters such as serum ferritin or LIC would be acceptable to deduce changes in patient‐relevant endpoints such as mortality or end‐organ damage for studies comparing deferasirox to placebo. However, to adequately compare the efficacy of two iron chelating drugs such as deferasirox and deferoxamine, information on patient‐relevant endpoints such as mortality or end‐organ damage should be available. In particular, there is a lack of data from randomised studies regarding the removal of cardiac iron and the prevention of cardiac complications. </p> <p>Although long‐term studies investigating these patient‐important endpoints would be important to adequately weigh benefits and AEs of deferasirox compared to standard treatment with deferoxamine, it must acknowledged that such studies take a long time to conduct and are very cost‐intensive. Therefore, it is not surprising that the producers of deferasirox have no particular interest in undertaking these types of studies after treatment has been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). However, such studies are necessary for a comprehensive evaluation of the effects of deferasirox as compared to deferoxamine. </p> <p>Furthermore, it has to be acknowledged that six included studies were supported by the manufacturer of deferasirox. </p> <p>Finally, the oral mode of application of deferasirox offers an important advantage of deferasirox over deferoxamine, which is of high relevance to those with the disease (<a href="./references#CD007476-bbs2-0127" title="TaherA , Al JefriA , ElalfyMS , Al ZirK , DaarS , RofailD , et al. Improved treatment satisfaction and convenience with deferasirox in iron‐overloaded patients with beta‐Thalassemia: Results from the ESCALATOR Trial. Acta Haematologica2010;123(4):220‐5. [PUBMED: 20424435] ">Taher 2010</a>). Comparing the two oral iron chelators (deferasirox and deferiprone), deferasirox allows for an easier application ‐ once‐daily compared to three‐times daily. Therefore, physicians prefer to prescribe deferasirox. Nevertheless, data on adherence from randomised controlled studies are still limited. One such study comparing deferasirox to deferoxamine showed no difference in adherence (<a href="./references#CD007476-bbs2-0013" title="AydinokY , PorterJB , PigaA , ElalfyM , El‐BeshlawyA , KilincY , et al. Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study. European Journal of Haematology2014;95(3):244‐53. PennellD , PorterJ , PigaA , El‐AlfyM , El‐BeshlawyA , KilincY , et al. Prevalence of cardiac iron overload in patients with transfusion‐dependent anemias: data from the randomized, active‐controlled deferasirox CORDELIA trial. Haematologica2012;97 Suppl 1:384. [CENTRAL: 977599; CRS: 5500100000011087; Abstract no: 0928] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulK , et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta‐thalassemia major: 2‐Year data from the Cordelia extension. Blood2013;122(21):1018. PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BelhoulKM , et al. A 1‐year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta‐thalassemia major (CORDELIA). Blood2014;123(10):1447‐54. [CENTRAL: 977602; CRS: 5500125000000573; PUBMED: 24385534] PennellDJ , PorterJB , PigaA , LaiY , El‐BeshlawyA , BeloulK , et al. A multicenter, randomized, open‐label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β‐thalassemia major and iron overload (CORDELIA). Blood2012;121(21). [CENTRAL: 977601; CRS: 5500125000000570; Abstract no: 2124] PennellDJ , PorterJB , PigaA , LaiYR , El‐BeshlawyA , ElalfyM , et al. Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology2015;90(2):91‐6. ">Pennell 2014</a>), while a study comparing deferasirox and deferiprone to deferiprone and deferoxamine showed a significant higher adherence favouring the combination of oral iron chelators (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>). Whether this advantage will translate into better long‐term adherence and improved patient‐relevant outcomes is still to be shown (<a href="./references#CD007476-bbs2-0129" title="TrachtenbergF , VichinskyE , HainesD , PakbazZ , MednickL , SobotaA , et al. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American Journal of Hematology2011;86(5):433‐6. ">Trachtenberg 2011</a>). Recently, the FDA and the EMA have approved a new formulation of deferasirox (<a href="./references#CD007476-bbs2-0065" title="ChalmersAW , ShammoJM . Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long‐term blood transfusions. Ther Clin Risk Manag.2016;12:201‐8. ">Chalmers 2016</a>; <a href="./references#CD007476-bbs2-0074" title="European Medicines Agency (EMA). Exjade: EPAR. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/000670/WC500033925.pdf (accessed 2 January 2017). ">EMA 2016</a>; <a href="./references#CD007476-bbs2-0110" title="Novartis . Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overload. https://www.novartis.com/news/media‐releases/novartis‐announces‐fda‐approval‐jadenutm‐simplify‐treatment‐administration. ">Novartis 2015</a>). These tablets can be swallowed with some water in a single step without dispersing in water, which could further increase adherence. Results of studies investigating this new formulation are not yet available, but may influence future updates of this review, in particular regarding adherence and safety compared to other iron chelators. </p> </section> <section id="CD007476-sec-0137"> <h3 class="title" id="CD007476-sec-0137">Quality of the evidence</h3> <p>The evidence on deferasirox for treating iron overload in thalassaemia is still limited.</p> <p>The quality of included studies comparing deferasirox to deferoxamine in people with transfusion‐dependent thalassaemia was moderate to low, mainly due to a lack of blinding and selective reporting, the use of a surrogate marker instead of patient‐important outcomes and imprecision. For the comparison of deferasirox to placebo in people with non‐transfusion‐dependent thalassaemia, the quality of the evidence was moderate to very low based on only one small study. For the other comparisons, quality of evidence was low to very low, mainly due to the inclusion of even fewer participants. </p> </section> <section id="CD007476-sec-0138"> <h3 class="title" id="CD007476-sec-0138">Potential biases in the review process</h3> <p>A very comprehensive search strategy was applied to identify all potential studies and their reports. However, information on several relevant outcome data prespecified in our protocol were not reported. Several of these outcome measures are, however, important to make an informed and balanced decision on which chelator to choose. Some of these outcome measures were most likely not ascertained during the study, however, others could have well been collected but not reported. Unfortunately, even after contacting the primary investigators, to date we have not been able to obtain any additional data. </p> <p>We followed the rigorous methodology for systematic reviews outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007476-bbs2-0090" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), e.g. extracting data independently in duplicate to minimize errors and reduce bias in the process of doing this systematic review. </p> </section> <section id="CD007476-sec-0139"> <h3 class="title" id="CD007476-sec-0139">Agreements and disagreements with other studies or reviews</h3> <p>Vanorden and Hagemann published the first review on deferasirox based on a systematic literature search in 2006 (<a href="./references#CD007476-bbs2-0130" title="VanordenHE , HagemannTM . Deferasirox‐‐an oral agent for chronic iron overload. Annals of Pharmacotherapy2006;40(6):1110‐7. ">Vanorden 2006</a>). Besides data from the phase III study (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>), this review includes evidence from phase I and phase II as well as pharmacokinetic studies in both humans and non‐humans. The authors made no attempt to pool the data; so findings are presented narratively (including observational data). The authors concluded that their findings suggest that deferasirox is as safe and effective as deferoxamine. </p> <p>Lindsey and co‐authors summarized the available data from five phase I/II and the one phase III study in their systematic review published in 2007 (<a href="./references#CD007476-bbs2-0101" title="LindseyWT , OlinBR . Deferasirox for transfusion‐related iron overload: a clinical review. Clinical Therapeutics2007;29(10):2154‐66. [PUBMED: 18042472] ">Lindsey 2007</a>). All six studies are critically discussed, but no pooling of data was performed and data are synthesized qualitatively. Based on the only study looking at efficacy as a primary endpoint (<a href="./references#CD007476-bbs2-0059" title="CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. ">Cappellini 2006</a>), the authors come to the conclusion that the two agents have similar efficacy, although overall the non‐inferiority of deferasirox could not be shown by the primary phase III study investigators. Tolerability is assessed as good, even though deferasirox is associated with a higher incidence of adverse effects. The authors conclude that long‐term efficacy and safety remain to be established. </p> <p>In 2009, McLeod and co‐authors published a comprehensive health technology assessment on deferasirox for secondary iron overload in individuals with chronic anaemia, such as thalassaemia and sickle cell disease (<a href="./references#CD007476-bbs2-0104" title="McLeodC , FleemanN , KirkhamJ , BagustA , BolandA , ChuP , et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technology Assessment (Winchester, England)2009;13(1):iii‐iv, ix‐xi, 1‐121. [PUBMED: 19068191] ">McLeod 2009</a>). They identified 14 randomised studies looking at various iron chelation regimens with a high degree of heterogeneity between studies in terms of study design and outcome reporting. Only three of these compared deferasirox to deferoxamine, but data were not included in a meta‐analysis. Furthermore, eight economic evaluations were included in their report. The authors conclude that it appears that there is little difference between agents in terms of reducing serum ferritin. The economic evaluations appear to demonstrate the cost‐effectiveness of deferasirox compared to deferoxamine. However, the authors state that both their clinical and economic analyses were restricted by the available evidence and should only be considered exploratory. </p> <p>Cochrane Reviews on the effects of deferasirox in people with sickle cell disease (<a href="./references#CD007476-bbs2-0106" title="Meerpohl JoergJ , Schell LisaK , RückerG , MotschallE , FleemanN , Niemeyer CharlotteM , et al. Deferasirox for managing transfusional iron overload in people with sickle cell disease. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2014, issue 5. [DOI: 10.1002/14651858.CD007477.pub3; CD007477] ">Meerpohl 2014a</a>) and myelodysplastic syndrome (<a href="./references#CD007476-bbs2-0105" title="Meerpohl JoergJ , Schell LisaK , RückerG , FleemanN , MotschallE , Niemeyer CharlotteM , et al. Deferasirox for managing iron overload in people with myelodysplastic syndrome. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2014, issue 10. [DOI: 10.1002/14651858.CD007461.pub3; CD007461] ">Meerpohl 2014</a>) have been published; both conclude that data on deferasirox in these groups of people are still limited and therefore evidence is insufficient to recommend first‐line use of deferasirox in sickle cell disease or myelodysplastic syndrome. Several narrative reviews on deferasirox have also been published of late. These have usually concluded that efficacy is given and the profile of adverse events manageable and therefore acceptable (<a href="./references#CD007476-bbs2-0061" title="CappelliniMD . Long‐term efficacy and safety of deferasirox. Blood Reviews2008;22 Suppl 2:S35‐41. [PUBMED: 19059055] ">Cappellini 2008</a>; <a href="./references#CD007476-bbs2-0062" title="CappelliniMD , PattoneriP . Oral iron chelators. Annual Review of Medicine2009;60:25‐38. [PUBMED: 19630568] ">Cappellini 2009</a>; <a href="./references#CD007476-bbs2-0119" title="PorterJB . Deferasirox: an update. Hemoglobin2009;33 Suppl 1:S70‐5. [PUBMED: 20001635] ">Porter 2009</a>). </p> <p>A clinical practice guideline by the Italian Society of Hematology for the management of iron overload in thalassaemia major and related disorders supports our findings and conclusions by recommending deferoxamine for children who start iron chelation therapy before six years of age and in whom the goal of chelation therapy is the prophylactic maintenance of iron balance; while oral chelators (such as deferasirox) should be considered investigational and be used primarily within clinical trials or registries or for patients with poor adherence to, or experiencing AEs from deferoxamine (<a href="./references#CD007476-bbs2-0054" title="AngelucciE , BarosiG , CamaschellaC , CappelliniMD , CazzolaM , GalanelloR , et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica2008;93(5):741‐52. [PUBMED: 18413891] ">Angelucci 2008</a>). Due to the limited evidence, these recommendations were given a level D according to the Scottish Intercollegiate Guidelines Network (SIGN) grading system reflecting consensus of the experts (<a href="./references#CD007476-bbs2-0124" title="Scottish Intercollegiate Guidelines Network. A guideline developer's handbook. Guideline No. 50. http://www.sign.ac.uk/guidelines/fulltext/50/index.html (accessed 02 September 2011). ">SIGN 2008</a>). This recommendation is in line with the approval by the EMA as first‐line only in people with thalassemia major from six years of age (<a href="./references#CD007476-bbs2-0074" title="European Medicines Agency (EMA). Exjade: EPAR. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/000670/WC500033925.pdf (accessed 2 January 2017). ">EMA 2016</a>). In contrast, the FDA have already approved deferasirox in individuals with thalassemia major aged two years of age and older and in non‐transfusion‐dependent thalassemia individuals aged 10 years and older with a LIC of at least 5 mg Fe/g dry weight and serum ferritin over 300 µg/L (<a href="./references#CD007476-bbs2-0078" title="Food , Drug Administration(FDA) . USA . Exjade (deferasirox) Prescribing Information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021882s019lbl.pdf (accessed 02 January 2017). ">FDA 2013</a>). </p> <p>A systematic review published by Maggio in 2011 reviewed randomised controlled studies for all three iron chelators used in people with thalassaemia major (<a href="./references#CD007476-bbs2-0103" title="MaggioA , FilosaA , VitranoA , AlojG , KattamisA , CeciA , et al. Iron chelation therapy in thalassemia major: a systematic review with meta‐analyses of 1520 patients included on randomized clinical trials. Blood Cells, Molecules &amp; Diseases2011;47(3):166‐75. ">Maggio 2011</a>). The authors included two studies considering deferasirox (<a href="./references#CD007476-bbs2-0001" title="AngelucciE , TurlinB , CanatanD , MangiagliA , DeSanctisV , MeddebB , et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood2005;106(11 Pt 1). [Abstract no: 2696] AydinokY , AgaogluL , BejaouiM , CanatanD , DrelichmanG , EconomouM , et al. Growth and development of paediatric patients with beta‐thalassaemia treated with deferasirox for up to 5 years. Haematologica2010;95:429. AydinokY , ArikanC , KarakasZ , SasmazI , CanatanD , AgaogluL , KilincY , CanatarA , OcakO , AlnigenisE . A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. Haematologica2010;95:718. BrissotP , TurlinB , ForniGL , AlimenaG , QuartaG , SelleslagD , et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion‐dependent anemia. Blood2005;106(11). [Abstract no: 823] CappelliniM , BejaouiM , PerrottaS , AgaogluL , KattamisA , GiardinaP , et al. Phase III evaluation of once‐daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta‐thalassemia and transfusional hemosiderosis. Blood2004;104(11 Pt 1). [Abstract no: 3619] CappelliniMD , BejaouiM , AgaogluL , CanatanD , CapraM , CohenA , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow‐up. Blood2011;118(4):884‐93. CappelliniMD , BejaouiM , AgaogluL , LaiME , MangiagliA , StraussG , et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood2005;106(11). [Abstract no: 2704] CappelliniMD , BejaouiM , AgaogluL , PorterJ , CoatesT , JengM , et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics2007;29(5):909‐17. CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once‐daily oral iron chelator, in patients with beta‐thalassemia. Blood2006;107(9):3455‐62. CappelliniMD , GiardinaP , PorterJ , CoatesT , Della PortaMG , SiegalJ , et al. Long‐term safety and tolerability of the once‐daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood2006;108(11). [Abstract no: 1768] ChristoforidisA , TsatraI , KarasmanisK , ZevgaridouE , KoussiA , TsitouridesI , et al. Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. Haematologica2006;91(S1):209. CohenA , MaseraG , ZoumbosN , UysalZ , BouletD , WatmanN , et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670). Blood2005;106(11 Pt 1). [Abstract no: 822] CohenAR , GlimmE , PorterJB . Effect of transfusional iron intake on response to chelation therapy in beta‐thalassemia major. Blood2008;111(2):583‐7. DeugnierY , TurlinB , DongV , GiannoneV , ZhangY , GriffelL , et al. Deferasirox improves liver pathology in beta‐Thalassemia patients with transfusional iron overload. Blood2010;116(21):1734‐5. DeugnierY , TurlinB , RopertM , BejaouiM , Athanassiou‐MetaxaM , CarioH , et al. Semi‐quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion‐dependent anemia. Blood2005;106(11 Pt 1):761A. DeugnierY , TurlinB , RopertM , CappelliniMD , PorterJB , GiannoneV , et al. Improvement in liver pathology of patients with beta‐thalassemia treated with deferasirox for at least 3 years. Gastroenterology2011;141(4):1202‐11. DeugnierY , TurlinB , Ropert‐BouchetM , RabaultB , BrissotP . Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion‐dependent anemia. Journal of Hepatology2008;48(Suppl 2):S79‐80. FischerR , HarmatzP , NielsenP . Does liver biopsy overestimate liver iron concentration?. Blood2006; Vol. 108, issue 5:1775‐6; author reply 1776. [PUBMED: 16926297] GalanelloR . Evaluation of ICL670, a once‐daily oral iron chelator in a phase III clinical trial of beta‐thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences2005;1054:183‐5. GrosseR , JanssenG , EngelhardtR , GroegerM , LeismannO , NielsenP , et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. Blood2006;108(11). [Abstract no: 1779] KarnonJ , AkehurstRL , JewittK , OssaD . Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. Haematologica2007;92 Suppl 1:222. KattamisA , PaleyC , Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients‐treated with deferasirox(Exjade (R), ICL670). Pediatric Blood &amp; Cancer2007;48(6):609. KattamisC , KilincY , FattoumS , FersterA , GallisaiD , MaggioA , et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood2005;106(11 Pt 1):756A. [Abstract no: 2692] KattamisC , MeddebB , Ressayre‐DjafferC , AlbertiD , Parsing Using SmartSource . Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. Haematologica2006;91(Suppl 1):415. KleinertDA , JonesE , SisonCP , MarksP , GiardinaPJ . Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5‐40mg/kg/day and deferoxamine 20‐60 mg/kg/day in beta‐thalassemia patients with transfusional hemosideosis. Blood2005;106(11 Pt 2):44B. [Abstract no: 3853] MartinMG , ArcasoyMO . Deferasirox versus deferoxamine. Blood2006;108(2):774‐5; author reply 775‐6. [PUBMED: 16822908] PigaA , FischerR , HarmatzP , StPierreTG , LongoF , FungE , et al. Comparison of LIC obtained from biopsy, BLS and R‐2‐MRI in iron overloaded patients with beta‐thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood2005;106(11 Pt 1):755A. WalterP , MacklinE , PorterJ , EvansP , CoatesT , OlivieriNF , et al. Control of oxidant‐stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta‐thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. Blood2005;106(11). [Abstract no: 3598] WalterPB , MacklinEA , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , et al. Inflammation and oxidant‐stress in beta‐thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica2008;93(6):817‐25. WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Increased leucocyte apoptosis in transfused beta‐thalassaemia patients. British journal of haematology2013;160(3):399‐403. [PUBMED: 23216540] WalterPB , PorterJ , EvansP , KwiatkowskiJL , NeufeldEJ , CoatesT , et al. Leukocyte apoptosis and mitochondrial dysfunction in beta‐thalassemia patients treated with deferasirox or deferoxamine. Blood2007;110(11 Pt 1):815A. [Abstract no: 2773] ">Cappellini 2005b</a>; <a href="./references#CD007476-bbs2-0011" title="GiardinaP , OlivieriNF , Nisbet‐BrownE , GradyRW , SizerKC , SechaudR , et al. ICL670, a tridentate orally‐active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6‐9; Florence, Italy. 2002. [Abstract no: 0236] Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , NeufeldEJ , SechaudR , et al. Effectiveness and safety of ICL670 in iron‐loaded patients with thalassaemia: a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2003;361(9369):1597‐602. Nisbet‐BrownE , OlivieriNF , GiardinaPJ , GradyRW , SizerK , SechaudR , et al. ICL670A, a tridentate orally‐active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron‐overloaded patients with thalassemia. Blood2001;98(11 Pt 1):747a. ">Nisbet‐Brown 2001</a>). They did not pool data from the different dosing subgroups, but analysed the comparisons separately and found significantly lower increases in serum ferritin favouring deferoxamine compared to deferasirox 5 mg/day and 10 mg/day, significantly higher decreases in the deferoxamine group compared to deferasirox 20 mg/day and no significant difference in decrease in the deferasirox 30 mg group versus deferoxamine. </p> <p>Some additional data, including longer‐term effects on deferasirox, were available from observational studies. However, these studies were not systematically searched for nor critically evaluated within this review. Also, due to a higher risk of bias and potential confounding, these types of data are not as well‐suited for comparison of two interventions as are data from high quality randomised studies. </p> <p>It is important to note, however, that other more severe AEs have been reported, such as: cytopenias; Fanconi syndrome and renal failure (<a href="./references#CD007476-bbs2-0087" title="GrangeS , BertrandDM , GuerrotD , EasF , GodinM . Acute renal failure and Fanconi syndrome due to deferasirox. Nephrology, dialysis, transplantation2010;25(7):2376‐8. [PUBMED: 20466673] ">Grange 2010</a>; <a href="./references#CD007476-bbs2-0120" title="RafatC , FakhouriF , RibeilJA , DelarueR , LeQuintrecM . Fanconi syndrome due to deferasirox. American Journal of Kidney Diseases2009;54(5):931‐4. [PUBMED: 19493602] ">Rafat 2009</a>; <a href="./references#CD007476-bbs2-0138" title="YewCT , TalaulikarGS , FalkMC , ClaytonP , D'RozarioJ , BrownM . Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short‐term dialysis. Nephrology (Carlton, Vic.)2010;15(3):377. [PUBMED: 20470310] ">Yew 2010</a>); liver failure; and gastrointestinal bleeding, which resulted in a boxed warning by the FDA (<a href="./references#CD007476-bbs2-0079" title="USFood , DrugAdministraton . Exjade (Deferasirox): Boxed Warning. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm200850.htm (accessed 02 September 2011). ">FDA Boxed Warning 2010</a>). These potential severe AEs must be taken into consideration when prescribing or using deferasirox. </p> <p>Also, some studies have shown that higher doses of deferasirox than those evaluated in the early included studies are often needed to achieve adequate reduction of iron overload or prevent further iron accumulation in heavily‐transfused individuals (<a href="./references#CD007476-bbs2-0066" title="ChirnomasD , SmithAL , BraunsteinJ , FinkelsteinY , PereiraL , BergmannAK , et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood2009;114(19):4009‐13. [PUBMED: 19724055] ">Chirnomas 2009</a>; <a href="./references#CD007476-bbs2-0126" title="TaherA , CappelliniMD , VichinskyE , GalanelloR , PigaA , LawniczekT , et al. Efficacy and safety of deferasirox doses of &gt;30 mg/kg per d in patients with transfusion‐dependent anaemia and iron overload. British Journal of Haematology2009;147(5):752‐9. ">Taher 2009</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007476-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007476-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007476-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007476-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 1 Mortality at any time point." data-id="CD007476-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 1 Mortality at any time point. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 2 AEs." data-id="CD007476-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 2 AEs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 3 Discontinuations due to serious AEs." data-id="CD007476-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 3 Discontinuations due to serious AEs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 1 Mortality at any time point." data-id="CD007476-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 1 Mortality at any time point. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 2 LVEF (%): least squares mean change from baseline." data-id="CD007476-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 2 LVEF (%): least squares mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 3 LVEF (# participants affected)." data-id="CD007476-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 3 LVEF (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 4 Incidence of thyroid disease at end of study." data-id="CD007476-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 4 Incidence of thyroid disease at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 5 ALT (# participants affected): improvement from abnormal to normal range." data-id="CD007476-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 5 ALT (# participants affected): improvement from abnormal to normal range. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 6 ALT (U/L) at end of study." data-id="CD007476-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 6 ALT (U/L) at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 7 AST (U/L) at end of study." data-id="CD007476-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 7 AST (U/L) at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 8 Serum creatinine (mg/dL) at end of study." data-id="CD007476-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 8 Serum creatinine (mg/dL) at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 9 Blood urea (mg/dL): mean at end of study." data-id="CD007476-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 9 Blood urea (mg/dL): mean at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 10 Serum ferritin (ng/mL): mean change from baseline and at end of study." data-id="CD007476-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 10 Serum ferritin (ng/mL): mean change from baseline and at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 11 Sensitivity analysis: serum ferritin (ng/mL): mean change from baseline." data-id="CD007476-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 11 Sensitivity analysis: serum ferritin (ng/mL): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 12 Liver R2* (Hz): mean change from baseline." data-id="CD007476-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 12 Liver R2* (Hz): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 13 LIC (mg/g) evaluated by MRI (R2/R2*): mean change from baseline." data-id="CD007476-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 13 LIC (mg/g) evaluated by MRI (R2/R2*): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 14 LIC (mg Fe/g dw) evaluated by biopsy or SQUID: mean change from baseline." data-id="CD007476-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 14 LIC (mg Fe/g dw) evaluated by biopsy or SQUID: mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 15 Responder analysis I (responder: fall in LIC &gt; 10%)." data-id="CD007476-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 15 Responder analysis I (responder: fall in LIC &gt; 10%). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 16 Responder analysis II (responder: LIC 1 to &lt; 7 mg Fe/g dw)." data-id="CD007476-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 16 Responder analysis II (responder: LIC 1 to &lt; 7 mg Fe/g dw). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 17 Myocardial T2* (ms): mean change from baseline." data-id="CD007476-fig-0023" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 17 Myocardial T2* (ms): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 18 Myocardial iron concentration derived from T2* value (mg Fe/g dw): change from baseline." data-id="CD007476-fig-0024" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 18 Myocardial iron concentration derived from T2* value (mg Fe/g dw): change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 19 Myocardial T2* (# participants affected)." data-id="CD007476-fig-0025" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 19 Myocardial T2* (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 20 Iron excretion‐intake ratio." data-id="CD007476-fig-0026" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 20 Iron excretion‐intake ratio. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 21 Any serious AEs (# participants affected)." data-id="CD007476-fig-0027" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 21 Any serious AEs (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 22 Serious AEs." data-id="CD007476-fig-0028" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 22 Serious AEs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 23 Any AE (# participants affected)." data-id="CD007476-fig-0029" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 23 Any AE (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 24 AEs." data-id="CD007476-fig-0030" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 24 AEs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 25 Any drug‐related AE (# participants affected)." data-id="CD007476-fig-0031" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 25 Any drug‐related AE (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 26 Drug‐related AEs." data-id="CD007476-fig-0032" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 26 Drug‐related AEs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 27 Satisfaction with treatment (very satisfied or satisfied)." data-id="CD007476-fig-0033" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 27 Satisfaction with treatment (very satisfied or satisfied). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 28 Convenience (good or very good)." data-id="CD007476-fig-0034" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.28</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 28 Convenience (good or very good). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 29 Willingness to continue treatment." data-id="CD007476-fig-0035" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.29</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 29 Willingness to continue treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 30 Time lost from normal activities due to treatment (hours/month): participants treated previously with DFO." data-id="CD007476-fig-0036" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.30</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 30 Time lost from normal activities due to treatment (hours/month): participants treated previously with DFO. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 31 Adherence (% of planned dose)." data-id="CD007476-fig-0037" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.31</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 31 Adherence (% of planned dose). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 32 Discontinuations." data-id="CD007476-fig-0038" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.32</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 32 Discontinuations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 33 Dose adjustments and dose interruptions." data-id="CD007476-fig-0039" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.33</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 33 Dose adjustments and dose interruptions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 34 Dose interruptions (interrupted at least once)." data-id="CD007476-fig-0040" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.34</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 34 Dose interruptions (interrupted at least once). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 35 Dose reduction (at least once)." data-id="CD007476-fig-0041" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.35</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 35 Dose reduction (at least once). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 36 Dose adjustments (# participants affected)." data-id="CD007476-fig-0042" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.36</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 36 Dose adjustments (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 37 Dose interruptions due to an AE (# participants affected)." data-id="CD007476-fig-0043" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.37</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 37 Dose interruptions due to an AE (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 38 Haemoglobin (g/dL): mean change from baseline and at end of study." data-id="CD007476-fig-0044" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.38</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 38 Haemoglobin (g/dL): mean change from baseline and at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 39 Transfusion index (mL/kg/year): mean at end of study." data-id="CD007476-fig-0045" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.39</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 39 Transfusion index (mL/kg/year): mean at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 40 Transferrin saturation (%): mean at end of study." data-id="CD007476-fig-0046" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.40</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 40 Transferrin saturation (%): mean at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 41 Platelet count (x10³/mm³): mean at end of study." data-id="CD007476-fig-0047" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.41</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 41 Platelet count (x10³/mm³): mean at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-002-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-002-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 42 Absolute neutrophilic count (/mm³): mean at end of study." data-id="CD007476-fig-0048" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.42</div> <div class="figure-caption"> <p>Comparison 2 Transfusion‐dependent thalassemia: deferasirox vs deferoxamine, Outcome 42 Absolute neutrophilic count (/mm³): mean at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-002-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 1 Mortality at any time point." data-id="CD007476-fig-0049" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 1 Mortality at any time point. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 2 Incidence of thyroid disease at end of study." data-id="CD007476-fig-0050" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 2 Incidence of thyroid disease at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 3 ALT (U/L): mean change from baseline." data-id="CD007476-fig-0051" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 3 ALT (U/L): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 4 AST (U/L): mean change from baseline." data-id="CD007476-fig-0052" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 4 AST (U/L): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 5 Urea (mg/dL): mean change from baseline." data-id="CD007476-fig-0053" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 5 Urea (mg/dL): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 6 Creatinine (mg/dL): mean change from baseline." data-id="CD007476-fig-0054" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 6 Creatinine (mg/dL): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 7 Neutrophil (count per mm³): mean change from baseline." data-id="CD007476-fig-0055" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 7 Neutrophil (count per mm³): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 8 Serum ferritin (ng/mL): mean change from baseline and at end of study." data-id="CD007476-fig-0056" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 8 Serum ferritin (ng/mL): mean change from baseline and at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 9 LIC (mg/g) evaluated by MRI (R2*): mean change from baseline." data-id="CD007476-fig-0057" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 9 LIC (mg/g) evaluated by MRI (R2*): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 10 Myocardial T2* (ms): mean change from baseline." data-id="CD007476-fig-0058" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 10 Myocardial T2* (ms): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 11 Any AE (# participants affected)." data-id="CD007476-fig-0059" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 11 Any AE (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 12 AEs." data-id="CD007476-fig-0060" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 12 AEs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 13 Discontinuations (# participants affected)." data-id="CD007476-fig-0061" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 13 Discontinuations (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 14 Discontinuation due to an AE (# participants affected)." data-id="CD007476-fig-0062" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 14 Discontinuation due to an AE (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 15 Transferrin saturation (%): mean at end of study." data-id="CD007476-fig-0063" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 15 Transferrin saturation (%): mean at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 16 Haemoglobin (g/dL): mean at end of study." data-id="CD007476-fig-0064" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 16 Haemoglobin (g/dL): mean at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 17 Transfusion index (mL/kg/year): mean at end of study." data-id="CD007476-fig-0065" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 17 Transfusion index (mL/kg/year): mean at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 18 ALP (U/L): mean change from baseline." data-id="CD007476-fig-0066" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 Transfusion‐dependent thalassemia: deferasirox vs deferiprone, Outcome 18 ALP (U/L): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 1 Mortality at any time point." data-id="CD007476-fig-0067" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 1 Mortality at any time point. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 2 Neutrophil (µg/L): mean at end of study." data-id="CD007476-fig-0068" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 2 Neutrophil (µg/L): mean at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 3 ALT (g/dL): mean at end of study." data-id="CD007476-fig-0069" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 3 ALT (g/dL): mean at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 4 AST (g/dL): mean at end of study." data-id="CD007476-fig-0070" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 4 AST (g/dL): mean at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 5 Serum ferritin: mean at end of study (ng/mL)." data-id="CD007476-fig-0071" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 5 Serum ferritin: mean at end of study (ng/mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 6 Discontinuations." data-id="CD007476-fig-0072" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 6 Discontinuations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 7 Haemoglobin (g/dL): mean at end of study." data-id="CD007476-fig-0073" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 7 Haemoglobin (g/dL): mean at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 8 ALP (g/dL): mean at end of study." data-id="CD007476-fig-0074" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 8 ALP (g/dL): mean at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 1 Mortality at any time point." data-id="CD007476-fig-0075" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 1 Mortality at any time point. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 2 Serum ferritin (ng/mL): mean change from baseline." data-id="CD007476-fig-0076" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 2 Serum ferritin (ng/mL): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 3 LIC (mg/g) evaluated by MRI (R2*): mean change from baseline." data-id="CD007476-fig-0077" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 3 LIC (mg/g) evaluated by MRI (R2*): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 4 Myocardial T2* (ms): mean change from baseline." data-id="CD007476-fig-0078" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 4 Myocardial T2* (ms): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 5 Serious AE (# participants affected)." data-id="CD007476-fig-0079" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 5 Serious AE (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 6 Serious drug‐related AE (# participants affected)." data-id="CD007476-fig-0080" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 6 Serious drug‐related AE (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 7 Serious non‐related drug AE." data-id="CD007476-fig-0081" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 7 Serious non‐related drug AE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 8 AEs." data-id="CD007476-fig-0082" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 8 AEs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 9 Drug‐related AEs (# participants affected)." data-id="CD007476-fig-0083" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 9 Drug‐related AEs (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 10 Drug‐related AEs." data-id="CD007476-fig-0084" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 10 Drug‐related AEs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 11 Non‐related drug AEs (# participants affected)." data-id="CD007476-fig-0085" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.11</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 11 Non‐related drug AEs (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 12 Non‐related drug AEs." data-id="CD007476-fig-0086" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.12</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 12 Non‐related drug AEs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 13 Mild elevation of hepatic transaminases at start of therapy (# participants affected)." data-id="CD007476-fig-0087" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.13</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 13 Mild elevation of hepatic transaminases at start of therapy (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 14 Initial gastrointestinal manifestations (# participants affected)." data-id="CD007476-fig-0088" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.14</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 14 Initial gastrointestinal manifestations (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 15 Quality of life (%) (measured by SF‐36): mean change from baseline." data-id="CD007476-fig-0089" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.15</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 15 Quality of life (%) (measured by SF‐36): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 16 Adherence: actual dose/total prescribed dose." data-id="CD007476-fig-0090" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.16</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 16 Adherence: actual dose/total prescribed dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 17 Discontinuations." data-id="CD007476-fig-0091" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.17</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 17 Discontinuations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-007-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-007-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 18 Serious AE resulting in study discontinuation or interruption." data-id="CD007476-fig-0092" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.18</div> <div class="figure-caption"> <p>Comparison 7 Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 18 Serious AE resulting in study discontinuation or interruption. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-007-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 1 Mortality at any time point." data-id="CD007476-fig-0093" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 1 Mortality at any time point. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 2 Serum ferritin (ng/mL): mean change from baseline." data-id="CD007476-fig-0094" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 2 Serum ferritin (ng/mL): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 3 LIC (mg Fe/g dw) evaluated by MRI R2: least squares mean change from baseline." data-id="CD007476-fig-0095" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 3 LIC (mg Fe/g dw) evaluated by MRI R2: least squares mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 4 LIC (mg Fe/g dw) evaluated by MRI R2: mean change from baseline." data-id="CD007476-fig-0096" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 4 LIC (mg Fe/g dw) evaluated by MRI R2: mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 5 LIC: decrease of ≥ 3 mg Fe/g dw (# participants affected)." data-id="CD007476-fig-0097" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 5 LIC: decrease of ≥ 3 mg Fe/g dw (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 6 LIC: ≥ 30% reduction Fe/g dw (# participants affected)." data-id="CD007476-fig-0098" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 6 LIC: ≥ 30% reduction Fe/g dw (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 7 LIC: shift to lower iron burden range (# participants affected)." data-id="CD007476-fig-0099" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 7 LIC: shift to lower iron burden range (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 8 LIC: achieve LIC &lt; 5 mg Fe/g dw (# participants affected)." data-id="CD007476-fig-0100" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 8 LIC: achieve LIC &lt; 5 mg Fe/g dw (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 9 Drug‐related serious AEs (# participants affected)." data-id="CD007476-fig-0101" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 9 Drug‐related serious AEs (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 10 Drug‐related serious AEs (# participants affected)." data-id="CD007476-fig-0102" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 10 Drug‐related serious AEs (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 11 Any AE (# participants affected)." data-id="CD007476-fig-0103" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.11</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 11 Any AE (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 12 Mild AE (# participants affected)." data-id="CD007476-fig-0104" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.12</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 12 Mild AE (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 13 Moderate AE (# participants affected)." data-id="CD007476-fig-0105" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.13</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 13 Moderate AE (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 14 Severe AE (# participants affected)." data-id="CD007476-fig-0106" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.14</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 14 Severe AE (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 15 AEs." data-id="CD007476-fig-0107" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.15</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 15 AEs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 16 Drug‐related AEs." data-id="CD007476-fig-0108" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.16</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 16 Drug‐related AEs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 17 Adherence (# participants taking the planned study dose)." data-id="CD007476-fig-0109" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.17</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 17 Adherence (# participants taking the planned study dose). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 18 Discontinuations." data-id="CD007476-fig-0110" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.18</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 18 Discontinuations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 19 Discontinuing study due to AE (# participants affected)." data-id="CD007476-fig-0111" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.19</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 19 Discontinuing study due to AE (# participants affected). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 20 Dose increase." data-id="CD007476-fig-0112" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.20</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 20 Dose increase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 21 Dose interruption (at least once)." data-id="CD007476-fig-0113" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.21</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 21 Dose interruption (at least once). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 22 Dose reduction." data-id="CD007476-fig-0114" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.22</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 22 Dose reduction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 23 Dose reduction due to AE." data-id="CD007476-fig-0115" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.23</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 23 Dose reduction due to AE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 24 Haemoglobin (g/L): mean change from baseline." data-id="CD007476-fig-0116" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.24</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 24 Haemoglobin (g/L): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007476-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/urn:x-wiley:14651858:media:CD007476:CD007476-CMP-008-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_t/tCD007476-CMP-008-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 25 Transferrin saturation (%): mean change from baseline." data-id="CD007476-fig-0117" src="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.25</div> <div class="figure-caption"> <p>Comparison 8 Non‐transfusion‐dependent thalassemia: deferasirox vs placebo, Outcome 25 Transferrin saturation (%): mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/media/CDSR/CD007476/image_n/nCD007476-CMP-008-25.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007476-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Deferasirox compared to deferoxamine in people with transfusion‐dependent thalassemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Deferasirox compared to deferoxamine in people with transfusion‐dependent thalassemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : people with transfusion‐dependent thalassemia<br/> <b>Setting</b> : outpatient care<br/> <b>Intervention</b> : deferasirox<br/> <b>Comparison</b>: deferoxamine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferoxamine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality at any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.48<br/> (0.09 to 2.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1170<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1.000<br/> (1 to 18) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Responder analysis II (responder: LIC 1 to less than 7 mg Fe/g dw)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/> (0.69 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>553<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>664 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>531 per 1.000<br/> (458 to 611) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum ferritin (ng/mL): mean change from baseline and at end of study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 454.42 higher<br/> (337.13 higher to 571.71 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1002<br/> (6 RCTs) <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LIC (mg Fe/g dw) evaluated by biopsy or SQUID: mean change from baseline</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.37 higher<br/> (1.68 higher to 3.07 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>541<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Satisfaction with treatment (very satisfied or satisfied): participants previously treated with DFO<br/> assessed with: questionnaire<br/> follow up: mean 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.20<br/> (1.89 to 2.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>571<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.330 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1.000<br/> (1.000 to 1.000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adherence: discontinuations</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.95<br/> (0.60 to 1.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1211<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1.000<br/> (33 to 82) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AE: investigations ‐ isolated serum creatinine increase above ULN</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.57<br/> (1.88 to 3.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>657<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>137 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>353 per 1.000<br/> (258 to 482) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE</b> : adverse events; <b>CI</b> : confidence interval; <b>DFO</b> :deferiprone; <b>dw</b> : dry weight; <b>FE</b> : iron <b>LIC</b> : liver iron concentration; <b>MD</b> : mean difference; <b>RR</b> : risk ratio; <b>SQUID</b> : superconducting quantum interference device; <b>ULN</b>: upper limit of normal. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Serious risk of bias: studies that carry large weight for the overall effect estimate rated as high risk of bias due to lack of blinding and selective reporting.<br/> <sup>2</sup> Serious imprecision: wide confidence interval including both clinically relevant benefit as well as harm.<br/> <sup>3</sup> Serious inconsistency: differing ratio of drugs between subgroups of one study.<br/> <sup>4</sup> Upgrade due to dose‐response gradient: observed for both drugs. Effects therefore depending on ratio of drugs used in comparisons.<br/> <sup>5</sup> A sensitivity analysis without the results from four studies which were calculated according to <a href="./references#CD007476-bbs2-0131" title="WanX , WangW , LiuJ , TongT . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology2014;19(14):135. ">Wan 2014</a> showed similar results.<br/> <sup>6</sup> Serious imprecision: Wide confidence interval, including less discontinuations with deferoxamine treatment.<br/> <sup>7</sup> Serious indirectness: Surrogate of creatinine used for patient‐important outcome of kidney failure. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Deferasirox compared to deferoxamine in people with transfusion‐dependent thalassemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007476-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Deferasirox compared to deferiprone in people with transfusion‐dependent thalassemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Deferasirox compared to deferiprone in people with transfusion‐dependent thalassemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> :people with transfusion‐dependent thalassemia<br/> <b>Setting</b> : outpatient care<br/> <b>Intervention</b> : deferasirox<br/> <b>Comparison</b>: deferiprone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferiprone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality at any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>146<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Responder analysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum ferritin (ng/mL): mean change from baseline and at end of study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 229.99 ng/mL higher<br/> (403.14 lower to 863.11 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LIC (mg/g) evaluated by MRI R2*: mean change from baseline</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.8 mg/g lower<br/> (2.75 lower to 1.15 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Satisfaction</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adherence: discontinuations</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.16<br/> (0.01 to 2.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>179<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1.000<br/> (0 to 95) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>38<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>LIC</b> : liver iron concentration; <b>MD</b> : mean difference; <b>MRI</b> : magnetic resonance imaging; <b>NA</b> : not applicable <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Very serious imprecision: only very few number of included participants.<br/> <sup>2</sup> Serious risk of bias: selective reporting: Results from <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a> for 60 participants not reported.<br/> <sup>3</sup> Serious risk of bias: no blinding assumed, selective reporting: Results from <a href="./references#CD007476-bbs2-0003" title="ElalfyM , AdlyAA , IsmailE , ElalfyO . Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b‐thalassemia major: a randomized prospective trial [abstract]. Haematologica2015;100 Suppl 1:131. ElalfyMS , SaberM , AdlyA , IsmailE , TarifM , IbrahimF , et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta‐thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. Blood2014;124(21):4046. ElalfyMS , SaberMM , AdlyAA , IsmailEA , TarifM , IbrahimF , et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta‐thalassemia major patients: efficacy and safety in relation to tissue iron overload. European Journal of Haematology2016;96(3):318‐26. [DOI: 10.1111/ejh.12594] ">Elalfy 2015a</a> for 60 participants not reported.<br/> <sup>4</sup> Very serious imprecision: very wide confidence interval including both relevant benefit as well as harm.<br/> <sup>5</sup> Serious imprecision: wide CIs including both benefit as well as harm.<br/> <sup>6</sup> Serious risk of bias: no blinding assumed. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Deferasirox compared to deferiprone in people with transfusion‐dependent thalassemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007476-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Deferasirox alone compared to combined deferasirox and deferiprone in people with transfusion‐dependent thalassemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Deferasirox alone compared to combined deferasirox and deferiprone in people with transfusion‐dependent thalassaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : people with transfusion‐dependent thalassaemia<br/> <b>Setting</b> : outpatient care<br/> <b>Intervention</b> : deferasirox<br/> <b>Comparison</b>: deferasirox and deferiprone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox and deferiprone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality at any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Responder analysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum ferritin (ng/mL)</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LIC (mg Fe/g dry weight)</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Satisfaction with treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adherence</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: serum creatinine increase</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE</b> : adverse events; <b>CI</b> : confidence interval; <b>LIC</b> : liver iron concentration; <b>MD</b> : mean difference; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> One RCT (40 participants) contributed to this comparison, but no relevant outcome data to this table are available (<a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Deferasirox alone compared to combined deferasirox and deferiprone in people with transfusion‐dependent thalassemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007476-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Combined deferasirox and deferiprone compared to deferiprone alone in people with transfusion‐dependent thalassemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Combined deferasirox and deferiprone com</b> p<b>ared to deferiprone alone in people with transfusion‐dependent thalassaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : people with transfusion‐dependent thalassemia<br/> <b>Setting</b> : outpatient care<br/> <b>Intervention</b> : deferasirox and deferiprone<br/> <b>Comparison</b>: deferiprone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox and deferiprone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality at any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Responder analysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum ferritin (ng/mL)</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LIC (mg Fe/g dry weight)</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Satisfaction with treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adherence</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: Serum creatinine increase</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE</b> : adverse events; <b>CI</b> : confidence interval; <b>LIC</b> : liver iron concentration; <b>MD</b> : mean difference; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> One RCT (40 participants) contributed to this comparison, but no relevant outcome data to this table are available (<a href="./references#CD007476-bbs2-0008" title="KakkarS , SobtiPC , Jhinger , PK . Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. Haematologica2014;99 Suppl 1:735. [Abstract no: PB1923] ">Kakkar 2014</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Combined deferasirox and deferiprone compared to deferiprone alone in people with transfusion‐dependent thalassemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007476-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Deferasirox and deferoxamine compared to deferoxamine in people with transfusion‐dependent thalassemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Deferasirox and deferoxamine compared to deferoxamine in people with transfusion‐dependent thalassemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : people with transfusion‐dependent thalassemia<br/> <b>Setting</b> :outpatient care<br/> <b>Intervention</b> : deferasirox and deferoxamine<br/> <b>Comparison</b>: deferoxamine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferoxamine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox and deferoxamine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality at any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>94<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Responder analysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum ferritin (ng/mL) ‐ mean at end of study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 87.84 ng/mL higher<br/> (612.23 lower to 787.91 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LIC</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Satisfaction with treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adherence: Discontinuations</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>94<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: serum creatinine increased</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum creatinine was measured in Molavi 2014, but no results were reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE</b> : adverse events; <b>CI</b> : confidence interval; <b>LIC</b> : liver iron concentration; <b>MD</b> : mean difference; <b>NA</b> : not applicable; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Very serious imprecision: only very few participants included.<br/> <sup>2</sup> Serious risk of bias: assumed lack of blinding.<br/> <sup>3</sup> Very serious imprecision: very wide confidence interval including both benefit as well as harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Deferasirox and deferoxamine compared to deferoxamine in people with transfusion‐dependent thalassemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007476-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Deferasirox and deferiprone compared to deferiprone and deferoxamine in people with transfusion‐dependent thalassemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Deferasirox and deferiprone compared to deferiprone and deferoxamine in people with transfusion‐dependent thalassemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : people with transfusion‐dependent thalassemia<br/> <b>Setting</b> : outpatient care<br/> <b>Intervention</b> : deferasirox and deferiprone<br/> <b>Comparison</b>: deferiprone and deferoxamine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferiprone and deferoxamine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox and deferiprone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality at any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"All the included patients continued till the end of study with no patients were lost follow‐up." (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Responder analysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum ferritin (ng/mL): mean change from baseline</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 315.9 ng/mL lower<br/> (1046.26 lower to 414.46 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LIC evaluated by MRI R2*: mean change from baseline</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.62 mg/g lower<br/> (2.25 lower to 1.01 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Satisfaction</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Compared to baseline, patient‐reported satisfaction associated with ICT was significantly higher in group B [DFX and DFP] compared to group A [DFP and DFO] (p&lt;0.01)" (<a href="./references#CD007476-bbs2-0004" title="ElalfyM , WalliY , AdlyA , HenawyY . 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B‐thalassemia major. Haematologica2014;99:443‐4. [Abstract no: ABSSUB‐5856] ElalfyMS , AdlyAM , WaliY , TonyS , SamirA , ElhenawyYI . Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology2015;95(5):411‐20. ElalfyMS , WaliY , TonyS , SamirA , AdlyA . Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β‐thalassemia major. Blood2013;122(21):559. ">Elalfy 2015b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adherence: Discontinuations</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Drug‐related AE: serum creatinine increased (≥ 33%) above baseline in 2 consecutive occasions </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.00<br/> (0.32 to 27.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1.000<br/> (7 to 580) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE</b> : adverse events; <b>CI</b> : confidence interval; <b>LIC</b> : liver iron concentration; <b>MD</b> : mean difference; <b>MRI</b> : magnetic resonance imaging; <b>NA</b> : not applicable; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Very serious imprecision: very few participants included.<br/> <sup>2</sup> Serious risk of bias: no blinding, selective reporting: no data for 18 months follow‐up.<br/> <sup>3</sup> Very serious imprecision: very wide confidence interval including both benefit as well as harm.<br/> <sup>4</sup> Serious imprecision: wide confidence interval including both benefit as well as harm.<br/> <sup>5</sup> Serious indirectness: surrogate of creatinine used for patient‐important outcome of kidney failure. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Deferasirox and deferiprone compared to deferiprone and deferoxamine in people with transfusion‐dependent thalassemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007476-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Deferasirox compared to placebo in people with non‐transfusion‐dependent thalassemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Deferasirox compared to placebo in people with non‐transfusion‐dependent thalassemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : people with non‐transfusion‐dependent thalassemia<br/> <b>Setting</b> : outpatient care<br/> <b>Intervention</b> : deferasirox<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with deferasirox</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality at any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>148<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"No deaths occurred during the study in any group" (<a href="./references#CD007476-bbs2-0016" title='PorterJ , CappelliniM , KattamisA , ViprakasitV , LawniczekT , RosJ , et al. Relationships between plasma non‐transferrin‐bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non‐transfusion‐dependent thalassaemia syndromes. Haematologica2011;96 Suppl:228‐9. PorterJB , CappelliniMD , KattamisA , ViprakasitV , MusallamKM , ZhuZ , et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non‐transfusion‐dependent thalassemia: A longitudinal analysis from the thalassa study. Haematologica2014;99 Suppl:441‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Estimation of liver iron concentration by serum ferritin measurement in non‐transfusion‐dependent thalassemia patients: Analysis from the 1‐year thalassa study. Haematologica2012;97 Suppl:383. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Reduction in liver iron concentration is consistent across subgroups of non‐transfusion‐dependent thalassemia patients treated with deferasirox: Results from the 1‐year thalassa study. Haematologica2012;97 Suppl:381‐2. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion‐dependent thalassemia treated with deferasirox: Thalassa study extension analysis. Haematologica2013;98 Suppl:486. TaherA , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. The safety profile of deferasirox remains consistent as non‐transfusion‐dependent thalassemia patients approach the target liver iron concentration of &lt;3 mg fe/g dw for interrupting chelation. Haematologica2013;98 Suppl 1:165‐6. TaherA , PorterJB , KattamisA , ViprakasitV , LawniczekT , PerenoR , et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non‐transfusion‐dependent thalassemia patients with iron overload [abstract]. Blood2009;114(Issue 22). [Abstract no: 5111] TaherA , ViprakasitV , PorterJ , KattamisA , LawniczekT , PerenoR , et al. Factors associated with iron accumulation in non‐transfusion‐dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). Haematologica2010;95 Suppl:707. TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study. Blood2012;120(5):970‐7. [CRS: 5500125000000556; PUBMED: 22589472] TaherAT , PorterJ , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion‐dependent thalassemia: 1‐year results from a prospective, randomized, double‐blind, placebo‐controlled study.". Blood2012;120(5):970‐7. [CENTRAL: 842274; CRS: 5500125000000551; PUBMED: 22589472] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: The safety profile of deferasirox. European Journal of Haematology2014;92(6):521‐6. [CENTRAL: 977521; CRS: 5500125000000555; PUBMED: 24460655] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox continues to reduce iron overload in non‐transfusion‐dependent thalassemia: a one‐year, open‐label extension to a one‐year, randomized, double‐blind, placebo‐controlled study (THALASSA). Blood2012;120(21). [CENTRAL: 977519; CRS: 5500125000000550; Abstract no: 3258] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients. American Journal of Hematology2013;88(6):503‐6. [CENTRAL: 964527; CRS: 5500125000000552; PUBMED: 23553596] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox effectively reduces iron overload in non‐transfusion‐dependent thalassemia (NTDT) patients: 1‐year extension results from the THALASSA study. Annals of Hematology2013;92(11):1485‐93. [CENTRAL: 876359; CRS: 5500125000000553; PUBMED: 23775581] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Deferasirox significantly reduces liver iron concentration in non‐transfusion‐dependent thalassemia patients with iron overload: results from the 1‐year randomized, double‐blind, placebo‐controlled phase II THALASSA study. Blood2011;118(21):412‐3. [CENTRAL: 977518; CRS: 5500125000000549] TaherAT , PorterJB , ViprakasitV , KattamisA , ChuncharuneeS , SutcharitchanP , et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia. British Journal of Haematology2015;168(2):284‐90. TaherAT , TemrazS , CappelliniMD . Deferasirox for the treatment of iron overload in non‐transfusion‐dependent thalassemia. Expert Review of Hematology2013;6(5):495‐509. [CENTRAL: 977520; CRS: 5500125000000554; PUBMED: 24083402] '>Taher 2012</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Responder analysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum ferritin (ng/mL): mean change from baseline</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 306.74 ng/mL lower<br/> (398.23 lower to 215.24 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LIC (mg Fe/g dry weight) evaluated by MRI R2: least squares mean change from baseline</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.27 mg Fe/g dry weight lower<br/> (4.44 lower to 2.09 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Satisfaction with treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adherence: Discontinuations</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.32<br/> (0.50 to 3.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>166<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1.000<br/> (45 to 314) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AE: abnormal serum creatinine (post‐baseline)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.59<br/> (0.19 to 68.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>166<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AE</b> : adverse events; <b>CI</b> : confidence interval; <b>LIC</b> : liver iron concentration; <b>MD</b> : mean difference; <b>NA</b> : not applicable; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Serious imprecision: only few patients included.<br/> <sup>2</sup> Very serious imprecision: very wide confidence interval, including both benefit as well as harm.<br/> <sup>3</sup> Serious indirectness: surrogate of creatinine used for patient‐important outcome of kidney failure. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Deferasirox compared to placebo in people with non‐transfusion‐dependent thalassemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/full#CD007476-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007476-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Transfusion‐dependent thalassemia: deferasirox vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at any time point <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Eye disorders ‐ retinal infarct</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 GI disorders ‐ abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 GI disorders ‐ diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 GI disorders ‐ nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Investigations ‐ extended QT interval, hypocalcaemia, hypoparathyroidism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Skin and subcutaneous tissue disorders ‐ rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Discontinuations due to serious AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Transfusion‐dependent thalassemia: deferasirox vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007476-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Transfusion‐dependent thalassemia: deferasirox vs deferoxamine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at any time point <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.09, 2.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 8 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 48 weeks (deferasirox 10 mg/kg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 At 48 weeks (deferasirox 20 mg/kg/day )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 At 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.09, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 At 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 LVEF (%): least squares mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 LVEF (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Improvement from abnormal LVEF to normal range</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Decrease from normal LVEF to below LLN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Incidence of thyroid disease at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 ALT (# participants affected): improvement from abnormal to normal range <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 ALT (U/L) at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 AST (U/L) at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serum creatinine (mg/dL) at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Blood urea (mg/dL): mean at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Serum ferritin (ng/mL): mean change from baseline and at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>454.42 [337.13, 571.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Less than 3 mg Fe/g dw (median 5 mg deferasirox / 30mg deferoxamine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>978.0 [544.71, 1411.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 More than 3 to 7 mg Fe/g dw (10/35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>801.0 [572.53, 1029.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 More than 7 mg Fe/g dw (20/41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>328.0 [124.94, 531.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 More than 14 mg Fe/g dw (30/51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>77.0 [‐303.18, 457.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Any iron overload</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>234.25 [‐8.02, 476.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Sensitivity analysis: serum ferritin (ng/mL): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>418.94 [297.23, 540.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Less than 3 mg Fe/g dw (median 5 mg deferasirox / 30 mg deferoxamine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>978.0 [544.71, 1411.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 More than 3 to 7 mg Fe/g dw (10/35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>801.0 [572.53, 1029.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 More than 7 mg Fe/g dw (20/41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>328.0 [124.94, 531.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 More than 14 mg Fe/g dw (30/51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>77.0 [‐303.18, 457.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 Any iron overload</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐64.16 [‐354.62, 226.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Liver R2* (Hz): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 LIC (mg/g) evaluated by MRI (R2/R2*): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [‐1.01, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 LIC (mg Fe/g dw) evaluated by biopsy or SQUID: mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [1.68, 3.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 LIC 3 mg Fe/g dw or less (5/30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.3 [2.30, 6.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 LIC more than 3 mg to 7 mg (10/35) Fe/g dw</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [2.74, 4.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 LIC more than 7 mg to 14 mg Fe/g dw (20/41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.28, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 LIC more than 14 mg Fe/g dw (30/51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.5 [‐4.55, ‐0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Responder analysis I (responder: fall in LIC &gt; 10%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Response at 48 weeks (deferasirox 10 mg/kg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Response at 48 weeks (deferasirox 20 mg/kg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Responder analysis II (responder: LIC 1 to &lt; 7 mg Fe/g dw) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.69, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Response at 1 year (LIC below 7 mg Fe/g dw)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.37, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Response at 1 year (LIC at least 7 mg Fe/g dw)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.84, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Myocardial T2* (ms): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Myocardial iron concentration derived from T2* value (mg Fe/g dw): change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Participants with T2* &lt;10 ms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Participants with T2* ≥10 ms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Myocardial T2* (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Normalization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Improvement (from 6 ‐ &lt; 10 ms to 10 ‐ ≤ 20 ms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 Worsening (from 10‐ ≤ 20 ms to 6 ‐ &lt; 10 ms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Iron excretion‐intake ratio <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.24, ‐0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Less than 3 mg Fe/g dw (median 5 mg deferasirox / 30 mg deferoxamine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐0.54, ‐0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 More than 3 to 7 mg Fe/g dw (10/35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.41, ‐0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 More than 7 mg Fe/g dw (20/41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.21, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.4 More than 14 mg Fe/g dw (30/51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.05, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Any serious AEs (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.42, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Serious AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Cardiac disorders ‐ arrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 Endocrine disorders ‐ hypogonadism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 GI disorders abdominal abscess</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.4 GI disorders amoebiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5 GI disorders ‐ appendicitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.6 GI disorders ‐ colitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.7 GI disorders ‐ diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.8 GI disorders ‐ gastric haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.9 GI disorders ‐ gastroenteritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.10 GI disorders ‐ ileus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.11 GI disorders ‐ upper abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.12 GI disorders ‐ vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.13 GI disorders ‐ GI infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.14 General disorders and administration site conditions ‐ pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.15 General disorders and administration site conditions ‐ local swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.16 Hepatobiliary disorders ‐ liver abscess</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.17 Hepatobiliary disorders ‐ cholelithiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.18 Immune system disorders ‐ face oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.19 Infections and infestations ‐ herpes zoster</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.20 Infections and infestations ‐ tooth infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.21 Infections and infestations ‐ urinary tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.22 Injury, poisoning and procedural complications ‐ oesophageal rupture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.23 Injury, poisoning and procedural complications ‐ haemosiderosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.24 Injury, poisoning and procedural complications ‐ iron overload</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.25 Metabolism and nutrition disorders ‐ hyperglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.26 Musculoskeletal and connective tissue disorders ‐ back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.27 Musculoskeletal and connective tissue disorders ‐ pain in jaw</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.28 Nervous system disorders ‐ grand mal convulsion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.29 Nervous system disorders ‐ meningitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.30 Respiratory, thoracic and mediastinal disorders ‐ acute tonsilitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Any AE (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Blood and lymphatic system disorder ‐ agranulocytosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Blood and lymphatic system disorder ‐ leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.37, 133.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 Blood and lymphatic system disorder ‐ neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.4 Blood and lymphatic system disorder ‐ thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [0.46, 34.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.5 Cardiac disorders ‐ cardiac AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.38, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.6 Ear and labyrinth disorders ‐ hearing loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.41, 3.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.7 Eye disorder ‐ lens abnormality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.08, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.8 Eye disorder ‐ retinal abnormality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.9 GI disorders ‐ abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.93, 3.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.10 GI disorders ‐ abdominal pain upper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.36, 3.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.11 GI disorders ‐ diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.86, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.12 GI disorders ‐ dyspepsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.25, 5.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.13 GI disorders ‐ GIT upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.66, 13.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.14 GI disorders ‐ nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [0.90, 7.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.15 GI disorders ‐ vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [0.91, 9.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.16 General disorders and administration site conditions ‐ asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.42, 3.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.17 General disorders and administration site conditions ‐ influenza‐like illness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.42, 3.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.18 General disorders and administration site conditions ‐ pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.66, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.19 Immune system disorders ‐ allergic conjunctivitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.41 [0.25, 78.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.20 Infections and infestations ‐ bronchitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [0.30, 19.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.21 Infections and infestations ‐ upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.37, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.22 Infections and infestations ‐ urinary tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [0.30, 19.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.23 Investigations ‐ ALT increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.59, 4.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.24 Investigations ‐ elevated ALT (&gt;2 UNL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.90 [0.24, 101.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.25 Investigations ‐ AST increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.59, 8.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.26 Investigations ‐ blood creatinine increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.79 [0.83, 17.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.27 Investigations ‐ isolated serum creatinine increase above upper limit of normal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [1.88, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.28 Investigations ‐ platelet count increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.08, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.29 Musculoskeletal and connective tissue disorders ‐ arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.55, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.30 Musculoskeletal and connective tissue disorders ‐ back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.73, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.31 Musculoskeletal and connective tissue disorders ‐ osteoporosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [0.47, 11.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.32 Nervous system disorders ‐ headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.68, 3.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.33 Nervous system disorders ‐ vertigo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.32, 3.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.34 Renal and urinary disorders ‐ proteinuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.50, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.35 Respiratory, thoracic and mediastinal disorders ‐ cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.67, 4.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.36 Respiratory, thoracic and mediastinal disorders ‐ influenza</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.52, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.37 Respiratory, thoracic and mediastinal disorders ‐ nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.59, 6.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.38 Respiratory, thoracic and mediastinal disorders ‐ oropharyngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [0.59, 13.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.39 Respiratory, thoracic and mediastinal disorders ‐ pharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.52, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.40 Respiratory, thoracic and mediastinal disorders ‐ pharyngolaryngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.37, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.41 Respiratory, thoracic and mediastinal disorders ‐ rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.58, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.42 Skin and subcutaneous tissue disorders ‐ Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [0.78, 9.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Any drug‐related AE (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Drug‐related AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 Blood and lymphatic system disorder ‐ neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 Injury, poisoning and procedural complications ‐ infusion site haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.3 Injury, poisoning and procedural complications ‐ infusion site pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.4 Injury, poisoning and procedural complications ‐ infusion site swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.5 Injury, poisoning and procedural complications ‐ injection site pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.6 Injury, poisoning and procedural complications ‐ injection site reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.7 Investigations ‐ blood creatinine increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.8 Investigations ‐ ALT increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.9 Investigations ‐ AST increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.10 GI disorders ‐ abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.11 GI disorders ‐ abdominal pain upper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.12 GI disorders ‐ diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.13 GI disorders ‐ nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.14 GI disorders ‐ vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.15 Immune system disorders ‐ hypersensitivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.16 Immune system disorders ‐ urticaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.17 Musculoskeletal and connective tissue disorders ‐ arthropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.18 Renal and urinary disorders ‐ proteinuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.19 Skin and subcutaneous tissue disorders ‐ alopecia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.20 Skin and subcutaneous tissue disorders ‐ rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.21 Injury, poisoning and procedural complications ‐ pulmonary toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.22 Eye disorders ‐ Ophthalmological toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.23 Ear and labyrinth disorders ‐ Audiological toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Satisfaction with treatment (very satisfied or satisfied) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 Week 4 ‐ participants previously treated with DFO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 Week 24 ‐ participants previously treated with DFO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.3 End of study (1 year) ‐ participants previously treated with DFO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.4 Week 4 ‐ DFO‐naive participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.5 Week 24 ‐ DFO‐naive participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.6 End of study (1 year) ‐ DFO‐naive participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Convenience (good or very good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 Week 4 ‐ participants previously treated with DFO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 Week 24 ‐ participants previously treated with DFO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.3 End of study (1 year) ‐ participants previously treated with DFO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.4 Week 4 ‐ DFO‐naive participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.5 Week 24 ‐ DFO‐naive participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.6 End of study (1 year) ‐ DFO‐naive participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Willingness to continue treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 Participants treated previously with DFO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 DFO‐naive participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Time lost from normal activities due to treatment (hours/month): participants treated previously with DFO <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 week 4 ‐ patients treated previously with DFO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 week 24 ‐ patients treated previously with DFO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.3 end of study (1 year) ‐ patients treated previously with DFO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.4 week 4 ‐ DFO‐naive patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.5 week 24 ‐ DFO‐naive patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.6 end of study (1 year) ‐ DFO‐naive patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Adherence (% of planned dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Discontinuations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.60, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 Deferasirox 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 3.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2 Deferasirox 20 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.10, 9.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.3 Deferasirox 25 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.4 Deferasirox 40 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.51, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.5 Deferasirox ‐ variable dosage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.67, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.6 Deferasirox dosing unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Dose adjustments and dose interruptions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Dose interruptions (interrupted at least once) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Dose reduction (at least once) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Dose adjustments (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Dose interruptions due to an AE (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Haemoglobin (g/dL): mean change from baseline and at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.82, ‐0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1 At 8 months (change from baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.81, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.2 At 1 year (at end of study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐1.33, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 Transfusion index (mL/kg/year): mean at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 Transferrin saturation (%): mean at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 Platelet count (x10³/mm³): mean at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 Absolute neutrophilic count (/mm³): mean at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Transfusion‐dependent thalassemia: deferasirox vs deferoxamine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007476-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Transfusion‐dependent thalassemia: deferasirox vs deferiprone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at any time point <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of thyroid disease at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 ALT (U/L): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 AST (U/L): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Urea (mg/dL): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Creatinine (mg/dL): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Neutrophil (count per mm³): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serum ferritin (ng/mL): mean change from baseline and at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>229.99 [‐403.14, 863.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Ferritin &gt; 4000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1129.0 [‐2226.18, 4484.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Ferritin 2000 ‐ 4000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐151.0 [‐743.80, 441.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Ferritin &lt; 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>388.0 [‐255.71, 1031.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 LIC (mg/g) evaluated by MRI (R2*): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Myocardial T2* (ms): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Any AE (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 GI disorders ‐ diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 GI disorders ‐ nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 GI disorders ‐ pain abdomen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 GI disorders ‐ vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 Musculoskeletal and connective tissue disorders ‐ arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6 Skin and subcutaneous tissue disorders ‐ rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.7 Blood and lymphatic system disorder ‐ agranulocytosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.8 Blood and lymphatic system disorder ‐ neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.9 Investigations ‐ AST levels &gt; 2x UNL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.10 Investigations ‐ ALT levels &gt; 2x UNL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.11 Investigations ‐ serum creatinine 50% increase from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.12 Renal and urinary disorders ‐ renal failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Discontinuations (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 2.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Discontinuation due to an AE (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Transferrin saturation (%): mean at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Haemoglobin (g/dL): mean at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Transfusion index (mL/kg/year): mean at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 ALP (U/L): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Transfusion‐dependent thalassemia: deferasirox vs deferiprone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007476-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at any time point <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Neutrophil (µg/L): mean at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 ALT (g/dL): mean at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 AST (g/dL): mean at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum ferritin: mean at end of study (ng/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Discontinuations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Haemoglobin (g/dL): mean at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 ALP (g/dL): mean at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007476-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at any time point <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serum ferritin (ng/mL): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 LIC (mg/g) evaluated by MRI (R2*): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Myocardial T2* (ms): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious AE (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serious drug‐related AE (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Cholecystitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Serious non‐related drug AE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Appendicitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Blood and lymphatic system disorder ‐ agranulocytosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Blood and lymphatic system disorder ‐ neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Drug‐related AEs (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Drug‐related AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Blood and lymphatic system disorders ‐ agranulocytosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Blood and lymphatic system disorders ‐ neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 GI disorders ‐ GI problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Investigations ‐ ALT increase ( ≥ 3 folds)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Investigations ‐ serum creatinine ( ≥ 33%) above baseline in 2 consecutive occasions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 Musculoskeletal and connective tissue disorders ‐ arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.7 Skin and subcutaneous tissue disorders ‐ skin rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Non‐related drug AEs (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Non‐related drug AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Infections and infestations ‐ infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 GI disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Skin and subcutaneous tissue disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Mild elevation of hepatic transaminases at start of therapy (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Initial gastrointestinal manifestations (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Quality of life (%) (measured by SF‐36): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adherence: actual dose/total prescribed dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Discontinuations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Serious AE resulting in study discontinuation or interruption <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Transfusion‐dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007476-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Non‐transfusion‐dependent thalassemia: deferasirox vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at any time point <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Deferasirox 5 mg/kg/day: at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Deferasirox 10 mg/kg/day: at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serum ferritin (ng/mL): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐306.74 [‐398.23, ‐215.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Deferasirox 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐259.1 [‐377.35, ‐140.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Deferasirox 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐377.79 [‐522.21, ‐233.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 LIC (mg Fe/g dw) evaluated by MRI R2: least squares mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.27 [‐4.44, ‐2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Deferasirox 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.33 [‐4.00, ‐0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Deferasirox 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.18 [‐5.83, ‐2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 LIC (mg Fe/g dw) evaluated by MRI R2: mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Non‐transfusion‐dependent β‐thalassemia 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Non‐transfusion‐dependent β‐thalassemia 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 α‐thalassemia 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 α‐thalassemia 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 HbE/β‐thalassemia 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 HbE/β‐thalassemia 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 &lt; 18 years 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 &lt; 18 years 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 ≥18 years 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10 ≥18 years 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 LIC: decrease of ≥ 3 mg Fe/g dw (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.16 [1.90, 9.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Deferasirox 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [0.98, 9.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Deferasirox 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.26 [1.76, 15.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 LIC: ≥ 30% reduction Fe/g dw (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.17 [2.88, 69.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Deferasirox 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.02 [0.93, 242.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Deferasirox 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.75 [1.97, 95.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 LIC: shift to lower iron burden range (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.35 [1.62, 6.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Deferasirox 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.39 [1.10, 10.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Deferasirox 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.31 [1.28, 8.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 LIC: achieve LIC &lt; 5 mg Fe/g dw (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.35 [1.30, 21.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 deferasirox 5mg/kg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.07 [0.54, 30.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 deferasirox 10mg/kg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.62 [0.91, 48.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Drug‐related serious AEs (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Drug‐related serious AEs (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 GI disorders ‐ abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Infections and infestations ‐ cellulitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Skin and subcutaneous tissue disorders ‐ pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Skin and subcutaneous tissue disorders ‐ rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 General disorders ‐ pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 Hepatobiliary disorders ‐ hepatotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Any AE (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Mild AE (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Moderate AE (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Severe AE (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Ear and labyrinth disorders ‐ neurosensory deafness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Investigations ‐ abnormal platelet count (post‐baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Investigations ‐ abnormal neutrophils count (post‐baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 Investigations ‐ abnormal ALT (post‐baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5 Investigations ‐ abnormal AST (post‐baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6 Investigations ‐ abnormal serum creatinine (post‐baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.7 Investigations ‐ abnormal creatinine clearance (post‐baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.8 Investigations ‐ urinary protein/creatinine ratio (post‐baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.9 Investigations ‐ abnormal (low) systolic blood pressure (post‐baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.10 Investigations ‐ abnormal (high) systolic blood pressure (post‐baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.11 Investigations ‐ abnormal (low) diastolic blood pressure (post‐baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.12 Investigations ‐ abnormal (high) diastolic blood pressure (post‐baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.13 Investigations ‐ abnormal (low) pulse rate (post‐baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.14 Investigations ‐ abnormal (high) pulse rate (post‐baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.15 Renal and urinary disorders ‐ proteinuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Drug‐related AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 GI disorders ‐ abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 GI disorders ‐ abdominal pain upper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 GI disorders ‐ diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 GI disorders ‐ nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5 Nervous system disorders ‐ headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6 Skin and subcutaneous tissue disorders ‐ skin rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adherence (# participants taking the planned study dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Discontinuations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.50, 3.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Deferasirox 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.33, 4.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Deferasirox 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.33, 7.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Discontinuing study due to AE (# participants affected) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Dose increase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.63, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Deferasirox 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.57, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Deferasirox 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.54, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Dose interruption (at least once) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.88, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Deferasirox 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.73, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 Deferasirox 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.87, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Dose reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.70, 3.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Deferasirox 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.54, 4.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 Deferasirox 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.4 [0.49, 4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Dose reduction due to AE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.69, 3.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Deferasirox 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.63, 6.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 Deferasirox 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.39, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Haemoglobin (g/L): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [‐0.82, 3.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Deferasirox 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐2.31, 4.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Deferasirox 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [‐1.27, 5.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Transferrin saturation (%): mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.10 [‐11.71, ‐2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Deferasirox 5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.16 [‐12.95, ‐1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 Deferasirox 10 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.01 [‐14.59, 0.57]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Non‐transfusion‐dependent thalassemia: deferasirox vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007476.pub3/references#CD007476-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007476.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007476-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007476-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007476-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD007476-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD007476-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007476-note-0017">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007476\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007476\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007476\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007476\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007476\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007476\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007476\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007476\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007476\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007476\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007476\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007476\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007476\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007476\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007476\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007476\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007476\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007476\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007476.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007476.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007476.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007476.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007476.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717134779"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007476.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717134783"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007476.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db0816fce936e',t:'MTc0MDcxNzEzNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 